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Preface
The Occupational Safety and Health Act of 1970 emphasizes the need 
for standards to protect the health and safety of workers exposed to an 
ever-increasing number of potential hazards in their workplace.
Pursuant to the fulfillment of this need, the National Institute for 
Occupational Safety and Health (NIOSH) has developed a strategy of 
disseminating information about adverse health effects of chemical or 
physical agents encountered by workers. This approach is intended to 
assist employers in providing protection for employees from exposure to 
these hazards. The Special Hazard Review serves to support and 
complement the other major standards development or hazards 
documentation activities of the Institute. The purpose of Special 
Hazard Reviews is to analyze and document, from a health standpoint, 
the problems associated with a given industrial chemical, process, or 
physical agent considered to have a special effect or hazard including 
a potential for producing carcinogenic, mutagenic, or teratogenic 
effects, and to recommend the implementation of engineering controls 
and work practices to alleviate these problems. While the Special 
Hazard Review is not intended to supplant the more comprehensive NIOSH 
Criteria Document, nor the brief NIOSH Current Intelligence Bulletin, 
it is nevertheless prepared in such a way as to assist in the 
formulation of regulations.
MichaelJ.  Lane, M.D.
Acting Director, National Institute 
for Occupational Safety and Health
iii
ACKNOWLEDGMENTS
Jimmy L. Perkins, M.S. of the Division of Criteria Documentation and 
Standards Development, Priorities and Research Analysis Branch, had 
program responsibility for this document and served as project officer. 
Clement Associates, Inc. under sub-contract to JRB Associates, Inc. 
developed the basic information for consideration by NIOSH staff and 
consultants under Contract 210-77-0006.
The Division review staff for this document consisted of Jon R, May, 
Ph.D. (Chairman), J. Henry Wills, Ph.D., and Charles C. Hassett, 
Ph.D., consultant.
SUMMARY AND RECOMMENDATIONS
NIOSH, as a World Health Organization (WHO) Collaborating Center 
for Occupational Health, is participating in a continuing WHO program 
which involves the establishment of international recommendations for 
occupational health stan&ards for toxic substances. It is anticipated 
that one group of substances to be considered will be pesticides. At 
the present time, the most economically important pesticides are 
insecticides belonging to the organochlorine, organophosphorus, and 
carbamate classes. NIOSH has previously documented the criteria for 
and recommended to the U.S. Department of Labor a series of 
occupational standards dealing with the widely used insecticides 
parathion, methyl parathion, malathion, and carbaryl. This document on 
Aldrin/Dieldrin and a companion document prepared for DDT serve as 
comprehensive reports on three of the most representative compounds of 
the organochlorine class of insecticides. Together with the NIOSH 
criteria documents on the four insecticides previously mentioned, the 
Aldrin/Dieldrin and DDT reports will form the basis for NIOSH 
recommendations for international occupational health standards.
Although aldrin and dieldrin are no longer produced in the U.S., 
they may still be utilized for certain restricted uses, including 
subsurface ground insertion for termite control, dipping of non-food 
roots and tops, and mothproofing by using closed-system manufacturing 
processes (39 Federal Register 37246, October 18, 1974). Though the 
use of aldrin and dieldrin is banned in many foreign countries, these
insecticides are still manufactured in a number of European countries 
and are used throughout the world for public health purposes.
Although aldrin and dieldrin are more acutely toxic to humans than 
DDT, their acute oral toxicity is nevertheless quite low. The 
estimated human oral LD50 for the two insecticides is approximately 65 
mg/kg. Like DDT, documented chronic toxicity in humans, clearly 
related to aldrin or dieldrin, is non-existent. Results of animal 
experiments, however, do indicate that aldrin and dieldrin have 
considerable potential for carcinogenic effects in humans. Aldrin and 
dieldrin were carcinogenic in mice in 20 experiments, having produced 
increased incidences of tumors, usually in males and females 
independently. Dieldrin, at dietary doses as low as 0.1 and 1 ppm, 
caused significant increases in both lung and liver tumors in mice. In 
6 of 8 experiments with rats, aldrin and dieldrin induced the 
development of significantly more tumors than appeared in control rats 
though the sites of the tumors were inconsistent among the experiments.
Based on the demonstrated potentials for induction of tumors in 
both rats and mice by aldrin and dieldrin, NIOSH recommends that these 
two pesticides be controlled and handled in the workplace as suspected 
occupational carcinogens and that exposure be minimized to the greatest 
extent possible. With regard to airborne exposure, NIOSH recommends 
that workplace environmental limits no higher than 0.15 mg/cu m be 
established for both compounds. The recommended exposure limit is the 
lowest concentration detectable by the current NIOSH validated sampling 
and analytical methods (NIOSH methods S275 and S283). Workers should 
also avoid skin contact with aldrin and dieldrin, as these pesticides
can be absorbed through the skin. Percutaneous absorption is 
substantially increased when aldrin and dieldrin are dissolved 
organic solvents.
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1. Extent of Exposure
1.1 Identity and Nomenclature
"Aldrin" is the common name approved by the International Standards 
Organization for a product containing not less than 95% of 1,2,3,4,10,10- 
hexachloro-1,4,4a,5,8,8a-hexahydro-exo-l,4-endo-5,8-dimethanonaphthalene.
In Canada, aldrin refers to the pure compound, which is known as HHDN in 
Great Britain (IARC 1974). Aldrin can be degraded environmentally and 
metabolically into dieldrin (Jager 1970, IARC 1974) . In 1967, the composition 
of technical aldrin was reported to be: 90.5% HHDN, 3.5% isodrin, 0.5%
chlordene, 0.2% hexachlorocyclopentadiene (HCCPD), 0.6% hexachlorobutadiene, 
0.5% octachlorocyclopentene, less than 0.1% hexachloroethane, 0.1% HHDN 
diadduct, less than 0.1% bicycloheptadiene (BCH), 0.3% toluene, and 3.6% 
other compounds (primarily a complex mixture of compounds formed by 
polymerization of HCCPD and BCH) (IARC 1974).
"Dieldrin“ is the common name approved by the International standards 
Organization for a product containing not less than 85% of 1,2,3,4,10,10- 
hexachloro-6,7-epoxy-1,4,4a,5,6,7,8,8a-octahydro-exo-1,4-endo-5,8-dimethano- 
naphthalene. In Canada, the name dieldrin refers to the pure compound, 
which is known in Great Britain as HEOD (IARC 1974) . Technical dieldrin 
contains some aldrin and endrin, but the precise constitution of technical 
dieldrin does not appear to have been published.
The von Baeyer/IUPAC names for aldrin, dieldrin, and some of their 
major metabolites, together with Chemical Abstracts Service numbers and 
structural formulae, are listed in Table 5.1. The physical and chemical 
properties of aldrin and dieldrin and some of their synonyms and trade names,
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are listed in Tables 5.2 and 5.3, respectively.
In this document, the words aldrin and dieldrin are used for the pure 
compounds (HHDN and HEOD, respectively). Where necessary, the technical 
products will be referred to as such.
1.2 Discovery and Introduction
Aldrin and dieldrin were first synthesized in the laboratory in about 
1948 (Whetstone 1964). Commercial production in the United States was first 
reported in 1950 (U.S. Tariff Commission 1951).
1.3 Changing Use and Production Patterns
Table 1.3.1 summarizes estimates of the quantities of aldrin and dieldrin 
used in the United States for some of their principal end uses from 1954 to
1971. The major use of aldrin in the early 1950's was in protecting cotton 
against boll weevils. In the mid-1950's the superior effectiveness of 
dieldrin on cotton became widely known. By the late 1950's, however, the 
boll weevil had become resistant to all chlorinated insecticides, so only 
minor quantities were sold for this purpose in the 1960's. Nevertheless, 
aldrin, along with toxaphene and DDT, accounted for over half of all 
insecticides used by U.S. farmers in 1966 (USDHEW 1969).
In 1971, the following use pattern was estimated for aldrin in the 
United States: corn soil usage, 80%; termite and pest control operators,
14%; rice seed treatments, 1%; and miscellaneous soil applications including 
on tobacco, vegetables, and strawberries, 1%. The percentages of dieldrin 
consumed for various uses in 1971 were: termite and pest control operators,
44%; fruit (foliage), 20%; seed treatment, 14%; vegetables, 13%; and
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TABLE 1.3.1
ESTIMATED U.S. CONSUMPTION OF ALDRIN AND DIELDRIN 
IN SOME PRINCIPAL END USES 
(in thousands of pounds)
Aldrin
1954
Year
1964 1968 1971
Cotton (foliage) 934
Corn (soil) 804
Grasshoppers 476
Potatoes (soil) 289
Peanuts 81
Citrus (soil)
Sugar beets
Seed treatment (except rice) 6
Rice seed treatment 
Japanese beetle
White-fringed beetle 10
Dieldrin
Cotton (foliage) 757
Public health 62
Government programs 133
Fruit (foliage) (plum curculio) 202
Mothproofing
Small grains (foliage) 175
Small package (home and garden use)
19
10,191 12,089
20
9,410
35
60
80
235
13
20
205
408
320
180
227
200
150
472
104
217
158
34
150
130
286
120
Adapted from Train 1974
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miscellaneous uses including application on tobacco, sweet potatoes, and 
similar crops, 9% (Train 1974).
U.S. domestic sales of aldrin and dieldrin from 1950 through July i, 
1974, including consumer specialty sales but excluding sales to the World 
Health Organization (WHO) and the Agency for International Development (AID) 
are outlined in Table 1.3.2 (Train 1974). Aldrin consumption increased in 
the United States until 1966, when about 19 million pounds were sold. In 
contrast, the overall use of dieldrin dropped from a peak of 3.6 million 
pounds m  1956 to an estimated 600 thousand pounds in 1973.
On June 26, 1972, the U.S. Environmental Protection Agency (EPA) 
proposed cancellation of registrations of all pesticide products containing 
aldrin or dieldrin. During public hearings on the cancellation order, in 
August 1974, EPA suspended most registrations of aldrin and dieldrin, 
prohibiting their production for use within the United States (Train 1974) . 
Production for exempted uses was discontinued in 1975. In November 1976, 
EPA issued Toxic Pollutant Effluent Standards prohibiting direct discharge 
of aldrin and dieldrin into ambient waters (USEPA 1977).
Johnson (1972) estimated that 9.9 million pounds of aldrin and 1 
million pounds of dieldrin were produced in the United States in 1971. 
During the 6 months prior to July 1, 1974, 9.7 million pounds of aldrin 
were reportedly consumed (Train 1974). About 3 million pounds of aldrin 
from existing stocks were used in 1975 (Aspelin 1975) and probably smaller 
quantities were in 1976. Imports for exempted uses (subterranean uses 
against termites) are still permitted, but no information was found that 
indicated dieldrin is now being imported into the United States.
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TABLE 1.3.2
u.s . DOMESTIC SALES OF ALDRIN AND DIELDRIN, 
(in thousands of pounds)
1950-74
1950 1,456 0
1951 3,288 185
1952 814 750
1953 1,234 1,135
1954 2,993 1,777
1955 4,372 2,585
1956 6,495 3,635
1957 2,431 2,673
1958 4,971 3,074
1959 5,566 3,008
1960 8,109 2,650
1961 9,926 2,764
1962 10,886 2,990
1963 12,152 2,685
1964 12,693 2,052
1965 14,278 1,814
1966 19,327 1,908
1967 18,092 1,473
1968 13,690 1,332
1969 9,902 1,206
1970 8,909 749
1971 11,615 705
1972 11,868 740
1973 (estimated) (10,000) (576)
1974 (to July 1) 9,700 -
Adapted from Train 1974
Little information is available on present-day patterns of production 
and use in overseas countries that would indicate the potential for 
exposure to manfactures, formulators, and users. Table 1.3.3 summarizes 
estimates made by the United Nations Food and Agriculture Organization 
(FAO 1977) of the consumption of "aldrin and similar insecticides" in 
reporting countries in 1973, 1974, and 1975. These estimates are of 
limited value in assessing consumption of aldrin and dieldrin, however,
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TABLE 1.3.3
ESTIMATED CONSUMPTION OF ALDRIN AND SIMILAR INSECTICIDES 
IN REPORTING COUNTRIES, 1973-75 
(in thousands of kg, îe, metric tons)
Country
1973
Year
1974 1975
Africa
Burundi 5 1 _*
Chad 27 - -
Congo 3 - -
Egypt 274 1,002 -
Ivory Coast 8 10 -
Madagascar 2 - -
Niger 8 12 1
Nigeria 9 - -
Swaziland 16 — —
North and Central America
Canada 180 - 138
Mexico 170 92 -
USA 40,533 - -
South America
Argentina 243 - -
Bolivia 2 - -
Chile - - 166
Uruguay 26 - -
Asia
Burma 3 1 -
Cyprus - - 1
India 1,200 1,270 652
Iran 123 - -
Israel 1 - -
Japan 1 - -
Korea, Republic of 1,245 1,536 -
Kuwait 1 1 -
Pakistan - 131 -
Europe
Austria 5 2 2
Czechoslovakia - - 7
Germany (FDR) 17 - -
Italy 15,541 4,540 -
Portugal 14 15
that no aldrin was used.
Adapted from FAO 1977
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because the category also includes chlordane, endnn, and other widely 
used cyclodiene insecticides.
The following European countries were reported to be producing 
aldrin or dieldrin in 1972 or 1973 (the number of producing companies is 
given in parentheses): Belgium (1), Federal Republic of Germany (2),
France (2), Italy (2), the Netherlands (1), and the United Kingdom (1).
In 1972, Japan was reported to have had eight suppliers of aldnn/dieldrin 
and their formulations, some of which may also have been producers. The 
reported amounts of aldrin and dieldrin imported into Japan in 1970 were 
143 thousand kg and 42 thousand kg, respectively (IARC 1974) . At this 
time aldrin and dieldrin are being produced m  the Netherlands and Venezuela, 
but no data on quantities produced are available.
The use of aldrin and dieldrin has been banned or severely restricted 
in Japan and in a number of European countries, including Sweden, the 
Federal Republic of Germany, the United Kingdom, and Italy. Aldrin has 
been banned in Norway and the USSR, and dieldrin has been banned in 
Switzerland (IARC 1974).
1.4 Exposure
Exposure of workers in a manufacturing plant in the Netherlands has 
been extimated indirectly by measuring levels of dieldrin in the blood 
(Jager 1970). Dieldrin levels in the blood of aldrin/dieldrin workers 
during the period of exposure were in the range 0.022-0.078 yg/ml. Mean 
levels showed a progressive decrease from 0.069 ug/ml m  1964 to 0.025 yg/ml 
in 1969 as a result of improved safety precautions in the plant. According
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to the empirical storage of Hunter et al (1969), these mean levels would 
correspond to oral intakes of 800 and 290 yg/man/day, respectively 
(Jager 1970). For comparison, mean intakes by the general population in 
the United Kingdom and the United States were estimated to be in the range 
3-22 yg/day (Jager 1970). However, re-analysis of the data from Hunter et 
al suggested that these estimates of intake are too high by a factor of
1.2-1.9 (Moriarty 1974) (see section 1.5.4).
Dieldrin levels in the blood of workers in a manufacturing plant 
in the United States were in the range 0.0012-0.137 yg/ml; the more highly 
exposed workers had estimated intakes in the range 0.7-1.1 mg/man/day 
(Hayes and Curley 1968). Aldrin and dieldrin levels in the blood of six 
workers at a formulating plant were at least as high as this, with at 
least one individual close to the threshold for intoxication of 0.30 yg/ml 
dieldrin (Mick et al 1971). Dieldrin concentrations in the urine of men 
working in a factory where aldrin and dieldrin were made and formulated 
were determined to be in the range 0.0053-0.0514 yg/ml, compared to 
0.0008 yg/ml in persons from the general population (Cueto and Biros 1967).
Estimates of the potential exposure of agricultural workers to 
dieldrin under various conditions are summarized in Table 1.4.1. These 
measurements indicate the potential for very high rates of dermal exposure 
unless protective clothing is worn. Fletcher et al (1959) estimated 
that men spraying dieldrin in a public health program in East Africa came 
into dermal contact with about 1.8 mg of dieldrin/day. Levels of dieldrin 
and its metabolites in the urine of these men were in the range 0.4-1.1 yg/ml
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(Cueto and Hayes 1962). The highest of these figures is more than twice 
that measured in highly exposed factory workers (Cueto and Biros 1967) .
Observations of occupationally exposed workers, summarized in Section 
3.3, show that exposures leading to clinical intoxication are not infrequent 
in certain types of application. According to the storage formula of 
Hunter et al (1969) the threshold level for intoxication of 0.30 yg/ml in 
blood proposed by Jager (1970) corresponds to repeated intakes of about
3.5 mg/man/day or to intermittent intake of correspondingly higher quantities.
1.5 Metabolism and Pharmacokinetics
1.5.1 Metabolism in Mammals
The metabolism of aldrin and dieldrin has been reviewed by FAO/WHO
(1971), by Jager (1970), and in greater detail by Menzie (1969). The
principal metabolic pathways in mammals are summarized in Figure 1.5.1.
In addition to the metabolites shown in Figure 1.5.1, 9-hydroxydieldrin 
(see Table 5.1) has been identified as a major metabolite in mammals 
(Baldwin et al 1972, Mueller et al 1975a,b).
The conversion of aldrin to dieldrin has been demonstrated in a
number of mammalian species. This reaction takes place in liver microsomes 
and requires the presence of NADPH (Nakatsugawa et al 1965, Wong and 
Terriere 1965). The enzyme involved is aldrin epoxidase, the activity of 
which appears to vary greatly depending upon the preparation and the 
temperature of storage (Chan and Terriere 1969). Microsomal epoxidation 
of aldrin to dieldrin is greatly accelerated by inducers of mixed function 
oxidase activity, such as DDT (Gillett et al 1966) and phénobarbital
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TABLE 1.4.1
SUMMARY OF PUBLISHED STUDIES ON POTENTIAL EXPOSURE OF 
WORKERS DIRECTLY APPLYING DIELDRIN
Activity Exposure Reference
Respiratory
(mg/hr)
Dermal
(mg/hr)
Total 
(% toxic dose/hr)
Hand-spraying 
of dwellings 
for disease 
vector control
18.6* >0.33* Fletcher et a'. 
1959
Spraying pear 
orchards
0.03** 14.2 0.24 Wolfe et al 
1963
Operating power 
air blast ma­
chine spraying 
fruit orchards
0.03 15.5 0.25 Wolfe et al 
1967
Power handgun 
spraying fruit 
orchards from 
portable machine
0.03 15.1 0.25 I
* Calculated by Wolfe et al 1967
**0nginal value (0.25 mg/hr) incorrectly derived
Adapted from Wolfe et al 1967
(Ghiasuddin and Menzer 1976) . Aldrin is also converted to dieldrin in 
lung tissues of rabbits; dieldrin was detected within 3 minutes of initial 
exposure to aldrin (Mehendale et al 1974).
After rabbits were fed radiolabeled dieldrin, six different metabol­
ites were identified m  their urine. Of the total urinary excretion, 85%
10
Figure 1.5.1 (from Menzie 1969)
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consisted of one of the two enantiomorphic isomers of trans-6,7-dihydroxy- 
dihydroaldrin ("trans-aldrin-diol" or "trans-dihydro-aldrindiol"; compound 
III) (Jager 1970).
In a comparative study with mice and rats fed radiolabeled dieldrin, 
10 times more radioactivity appeared in the feces than in the urine of both 
species. More unchanged dieldrin occurred in the urine of rats than in 
that of mice, and Klein's metabolite (XI) was identified only in rat urine, 
its proportion increasing from 3% to 67% during the 8 days after admin­
istration. Mice and rats excreted high levels of 9-hydroxydieldrin in 
feces (46% and 26%, respectively) and about one-third of the radio­
activity was excreted as unidentified metabolites by the two species 
(Baldwin et al 1972). One of the fecal metabolites in the rat was identi­
fied as 6,7-trans-dihydroaldrindiol, and one of the urinary metabolites as 
hexachlorohexahydromethanoindene-1,3-dicarboxylic acid ("aldrindicarboxylic 
acid," see Table 5.1). Other major metabolites were listed by Menzie (1969) 
(see Figure 1.5.1).
In detailed studies of the metabolism of dieldrin' by rat liver 
microsomes in vitro, the rate and pathways of metabolism were found to be 
influenced markedly by nutritional, hormonal, and environmental factors.
One group of metabolites was produced in much higher yield by microsomes 
from males than by those from females (Oberholser et al 1977). Pretreatment 
of rats with phenobarbital, DDT, or dieldrin itself influenced not only 
the rate of metabolism of dieldrin but also the metabolic profile. Some 
metabolites increased the rates of their own metabolism, whereas the major
12
metabolite (probably 9-hydroxydieldrin) inhibited formation of all metabolites, 
including itself (Oberholser et al 1977).
Mueller et al (1975a) administered radiolabeled dieldrin to rhesus 
monkeys by the oral and intravenous routes. The main pathway of metabolism 
was direct oxidation resulting in 9-hydroxydieldrin. At high liver 
concentrations the epoxide ring was opened, leading to the production 
of trans-aldrindiol.
Hutson (1976) compared the metabolism of radiolabeled dieldrin in 
CFE rats and two strains of mice. The major metabolic pathways of dieldrin, 
leading to 9-hydroxydieldrin, 6,7-trans-dihydroaldrindiol, aldrindic.arboxylic 
acid, and the pentachloroketone were found to be present in both species.
The main differences between the species were a more rapid metabolism of 
dieldrin in rats, a much greater production of the pentachloroketone by 
rats, and the production of small amounts of polar urinary metabolites by 
mice. The two strains of mice were similar to one another in most but not 
all of the parameters measured.
Mueller et al (1975b) compared the metabolism of dieldrin in mice, 
rats, rabbits, rhesus monkeys, and chimpanzees. In all five species, 
9-hydroxydieldrin and 6,7-trans-dihydroaldrindiol were the major g^tabolites.
The ratio of these two metabolites was similar in rats and rhesus 
monkeys. In the mouse and the rabbit, more of the dieldrin wag metabolized 
to dihydrodiol (see Table 1.5.1). The rate of metabolism was highest in 
mice, with 33-34% excreted as metabolites within 10 days compared to 7-11% 
in rats, 11% in rhesus monkeys, and 3% in chimpanzees. The authors
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TABLE 1.5.1
PERCENTAGE OF RADIOACTIVE MATERIAL EXCRETED WITHIN 10 DAYS 
AFTER SINGLE ORAL ADMINISTRATION OF 14C-DIELDRIN
Mice Rats Rabbits Rhesus Chimpanzee
male female male female male female male female
Dieldrin 5.5 3.2 0.8 2.8 0.3 0.5 9.0 3.2
12-0H-
dieldrin
13.0 7.5 8.8 4.6 - 0.2 9.4 2.0
Aldrin-
tr-diol
20.0 26.0 2.3 2.4 1.5 2.0 2.0 1.1
Total 38.5 36.9 11.9 9.8 1.8 2.7 20.4 6.3
Feces 36.6 35.0 11.3 9.3 0.3 0.5 16.0 5.0
Urine 1.9 1.9 0.6 0.5 1.5 2.2 4.4 1.3
Adapted from Mueller et al 1975b
suggested that the mouse liver would correspondingly be more highly 
exposed to the dihydrodiol. However, mice retained a higher percentage 
of administered dieldrin in their tissues than rats and almost as much as 
rhesus monkeys (see Table 1.5.5).
1.5.2 Metabolism in Humans
The limited data available on the metabolism of aldrin and dieldrin 
in humans have not shown qualitative differences between the metabolic 
pathways in humans and in other mammals. At least two unidentified polar 
metabolities of dieldrin have been isolated from human urine, fat, and 
bile (Cueto and Hayes 1962, Paschal et al 1974). One metabolite isolated
14
*from the fat, bile, and gallstone of a pest control worker was tentatively 
identified as the aldehyde derivatxve, compound XV xn Fxgure 1.5.1 (Paschal 
et al 1974). 9-Hydroxydxeldrin has been identified xn human feces 
(Richardson and Robinson 1971).
1.5.3 Pharmacokinetics in Experimental Anxmals
Data on the pharmacokinetics of aldrxn/dxexdrxn xn mammals were 
summarized by USDHEW (1969) and Jager (1970) and were critxcally reviewed 
by Moriarty (1974, 1975). A number of mathematical models have been 
proposed (Robinson et al 1969; USDHEW 1969; Garrettson and Curley 1969; 
Moriarty 1974, 1975; Lxndstrom et al 1975, 1976).
When radiolabeled aldrin was fed to male rats, the radioactxve 
materxal excreted in feces and urine consxsted of aldrin, diedrin, and 
hydrophilic metabolites. Paper chromatography of extracts of feces and 
urine inxtially showed a high percentage of aldrxn. The percentage of 
unchanged aldrin then decreased, while that of hydrophxlic metabolites 
increased contxnuously for about 12 days. The dxstributxon of excreted 
compounds then remained unchanged as long as aldrin was adminxstered 
daily. After aldrin admxnistration was discontinued, the percentage of 
aldrin decreased and that of dieldrxn xncreased (Ludwig et al 1964). At 
a feeding rate of 4.3 pg/rat/day, a steady state level was reached after 
about 8 weeks; daily excretxon of radioactive material thereafter 
approximated daily intake (Menzie 1969).
When rats were given radiolabeled dieldrin, intestinal absorption 
started almost immediately after oral administration, but the rate and
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extent of the absorption varied with the vehicle used. The absorbed 
dieldrin was mainly transported by the portal vein blood, and only a 
small proportion via the lymph. Initially, dieldrin was distributed 
widely in the body, but redistribution took place rapidly in favor of 
fat. The storage level in the fat was related to the quantity ingested 
and varied according to species. Biliary excretion started shortly after 
absorption, mainly in the form of hydrophilic metabolites. A part of the 
excretion products was reabsorbed from the intestine and again transported 
to the liver. Thus, an enterohepatic circulation occurred. About 90% of 
the total dose was excreted as hydrophilic metabolites in the feces and 
about 10% in the urine (Heath and Vandekar 1964, Ludwig et al 1964) .
Cole et al (1968) injected male rats, with and without bile 
fistulae, with 0.25 mg/kg dieldrin. The urine and feces were collected 
daily. The bile was collected 1, 3, 6, 12, and 24 hours after injection 
and subsequently at daily intervals. After 5-7 days, the animals were 
killed. Over 90% of the excreted dieldrin-denved materials was found in 
the feces from the intact rats or in the bile of the rats with a bile 
fistula. Fifty percent of the dieldrin administered was excreted within 
3 days; 32% had been excreted in the bile after 6 hours.
Moss and Hathway (1964) found that the solubility of dieldrin in 
rabbit serum is 4,000 times greater than its solubility in water. In 
exposed rabbits and rats, dieldrin is primarily located in the erythro­
cytes and the blood plasma but not in the leucocytes, the platelets, 
or the erythrocyte stroma. The distribution between plasma and red cells
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is roughly 2:1. In the red cells, dieldrin is largely associated with 
hemoglobin and an unknown constituent, while in the serum it is associated 
with albumin, alpha^- and alpha2~globulins, and another unidentified 
component. The erythrocyte membrane is freely permeable to dieldrin 
(Jager 1970).
After absorption, dieldrin is circulated through the body in the 
blood and is transferred in and out of other organs throughout the body. 
The rate of transport across membranes is believed to be highly tissue 
specific (Lindstrom et al 1976). Figure 1.5.2 shows a two-compartment 
model for the loss of dieldrin from the body after cessation of exposure. 
In this model, compartment 1 is identified with the blood, and the 
remainder of the body is considered together as compartment 2 (Moriarty 
1975). Such a model has three rate constants, kQ ,^ k^2» and k2 .^
FIGURE 1.5.2 (Moriarty 1975)
If Q is the amount of dieldrin in the blood and Q the amount of
1 2
dieldrin in the other body compartment, the model predicts:
Ql = Xje + X2e'"A2t
Q2 = X3e"Alt + X4e“X2fc
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where X,, X , X , and X are constants, and and are rate constants 
1 2 3 4
that depend in a complicated way on Kl2f an<^  K21 M^or^art^ 1975).
These equations provide a good description of data on uptake (Figure 1.5.3) 
and loss (Figure 1.5.4) of dieldrin from animals. Two-compartment models 
of this kind are usually needed to fit experimental data, although one- 
compartment models have been used where experimental data are limited 
(Richardson et al 1967, Moriarty 1975).
Tables 1.5.2 and 1.5.3 summarize data on the uptake and loss of 
dieldrin from experimental animals, as fitted to one- and two-compartment 
models (Moriarty 1975). Rats take up and excrete dieldrin considerably 
faster than larger mammals. In rats, dogs, and sheep, the three species 
for which data are available, rate constants ( ) for uptake are considerably
larger than rate constants for loss (Moriarty 1975).
The compartmental models of Moriarty (1975) and others assume impli­
citly that the physiologic state of the animals remains constant for times 
much longer than -1. Accordingly they predict an ultimate steady state 
concentration of dieldrin in the tissues of animals constantly exposed. 
However, actual data on experimental animals exposed for long periods at 
constant levels of exposure indicate that a true steady state is not 
reached (see Figure 1.5.3 for sheep, Figure 1.5.5 for rats).
"Quasi-steady" states reached after long-term exposure are referred 
to in the literature, and the potential for storage after exposures of 
more than 1-2 years may be underestimated (Moriarty 1974, 1975).
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FIGURE 1.5.3 (Moriarty 1975)
INCREASE IN DIELDRIN CONCENTRATION (C) IN THE BLOOD OF SHEEP 
INGESTING 2 MG DIELDRIN/KG BODY WEIGHT
fcoo
O'a
ao•H
n)U■Pa
8coo
C = 689-234e"°*itCl0t-47Oe-CI- 00771+t
* • Line derived from equation with
two exponential terms
Line derived from equation with 
one exponential term
40  BO 120 160 2 0 0
Exposure Time (days)
FIGURE 1.5.4 (Moriarty 1975)
DECREASE IN THE CONCENTRATION (C) OF DIELDRIN IN RAT BLOOD 
DURING THE FIRST 71 DAYS AFTER EXPOSURE
(Data fitted to an equation with two exponential terms)
+298e'■0.0529t
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TABLE 1.5.2
INTAKE OF DIELDRIN BY VARIOUS MAMMALS
Species 
(and sex)
Tissue
Exposure
Concentration
Duration of 
Experiment 
(days)
No. of Expo­
nential Terms A
(d"1)
Coo*
ppm
Rat (F) Blood 50 ppm (diet) 183 1 0 . 2 5 0 . 2 5
Rat (F) Liver 50 ppm (diet) 183 1 0 . 1 7 8 . 6
Rat (F) Fat 50 ppm (diet) 183 1 0 . 1 2 184
Sheep Blood 0 .5 mg/kg/d 112 1 0 . 1 2 _*
Sheep Blood 1 . 0  mg/kg/d 224 2 0 . 4 2 ,0 . 0 2 9 0 . 2 1
Sheep Blood 2 . 0  mg/kg/d 224 2 0.40,
0.077
0 . 6 9
Dog (M) Blood 0 . 0 0 5  mg/kg/d 548 1 0.0088 0.011**
Dog (M) Blood 0.05 mg/kg/d 548 1 0.017 0.047**
Dog (F) Blood 0 . 0 0 5  mg/kg/d 548 1 0.031 0.0083**
Dog (F) Blood 0.05 mg/kg/d 548 1 0.013 0.048**
Dog (F) Fat 0.3 mg/kg/d, 
5 d/wk
300 1 0.014 56
* Asymptotic concentration of dieldrm in tissues 
**Steady state questionable (see text)
Adapted from Moriarty 1975
TABLE 1.5.3
LOSS OF DIELDRIN RESIDUES FROM VARIOUS MAMMALS 
AFTER CESSATION OF EXPOSURE
Species 
(and sex)
Tissue
Initial
Level
(ppm)
Duration of 
Experiment 
(days)
No. of Expo- \  
nential Terms (d_1)
Half-
life
(days)
Rat (M) Fat 47.6 19 1 0.13 5.2
Rat (M>- Fat 22.6 52 1 0.069 10.1
Rat (M) Liver 3.5 52 1 0.091 7.6
Rat (M) Brain 0.95 52 1 0.073 9.5
Rat (M) Muscle 0.93 52 1 0.069 10.1
Rat (M) Fat 15.9 84 2 0.43, 1.6,
0.066 10.5
Rat (M) Blood 0.076 71 2 0.54, 1.3,
0.053 13.1
Rat (M) Liver 0.85 59 2 0.54, 1.3,
0.068 10.2
Rat (F) Fat 121 52 1 0.055 12.7
Rat (F) Liver 5.0 52 1 0.052 13.4
Rat (F) Brain 2.5 52 1 0.046 15.1
Rat (F) Muscle 2.4 52 1 0.067 10.3
Dog Fat 56 365 1 0.0055 127
Dog Fat 80 330 1 0.0042 165
Cattle Fat 78 224 1 0.0097 74
Sheep Fat 79 252 1 0.0073 97
Adapted from Moriarty (1975)
FIGURE 1.5.5 (Moriarty 1974)
CHANGES IN THE CONCENTRATION OF DIELDRIN 
IN THE BLOOD, LIVER, AND FAT OF RATS FED 
A DIET CONTAINING DIELDRIN AT 500 PPM
Blood
§ ; Liver
•£ 14 ' k = 0.168 ± 0.043/day
iri
£ ^ ----^  5
cQJ .a Ac 0u o
c•H
I SO  IO O  Ib'O
Exposure Time (days)
(Data fitted to equations with one exponential 
term; horizontal bars indicate the standard 
error of the means)
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CONCENTRATION OF HEOD IN TISSUES OF ANIMALS AND HUMANS
TABLE 1.5.4
Mean (Geometric) Concentration
Species Sex Dietary Exposure* of HEOD in Tissues (ppm)_____  Reference
mg/kg diet mg/Tcg body Blood Fat Liver Brain
(ppm) weight
Mouse M O  0
0.1 0.012
1.0 1.12
10.0 1.2
F 0 0
0.1 0.016
1.0 0.16
10.0 1.6
Rat M 0  0
0.1 0.00475
1.0 0.0475
10.0 0.475
F 0 0
0.1 0.00582
1.0 0.0582
10.0 0.582
Dog M O  0
0.15 0.005
1.5 0.05
F 0 0
0.15 0.005
1.5 0.05
0.00091 0.39 0.020 - Unpublished
0.0039 1.55 0.176 - work
- 12.0 1.58 - (Tunstall
0.426 67.9 4.09 - Laboratory)
- 0.18 0.0175 -
0.0026 1.27 0.0774 -
0.044 10.9 1.05 -
0.52 62.8 5.44 -
0.0009 0.060 0.0059 0.0020 Walker et
0.0021 0.259 0.0159 0.0069 al 1969
0.031 1.49 0.155 0.104
0.147 19.7 1.48 0.432
0.0015 0.31 0.011 0.0077
0.0065 0.90 0.035 0.022
0.086 13.9 0.43 0.29
0.395 57.8 2.97 1.13
0.0045 1.09 0.165 0.038 Walker et
0.0175 4.36 0.778 0.107 al 1969
0.093 18.2 4.9 0.498
0.0040 0.794 0.129 0.062
0.0174 4.9 0.804 0.150
0.095 18.6 4.18 0.536
TABLE 1.5.4 (Continued)
Mean (Geometric) Concentration
Species Sex Dietary Exposure* of HEOD in Tissues (ppm) Reference
mg/kg diet 
(pDTnl
mgAq body 
weight
Blood Fat Liver Brain
Rhesus 0 0 0.0028 0.157 0.147 0.0235 Unpublished
monkey 0.01 0.00026 0.0038 0.386 1.18 0.0245 work
0.1 0.0033 0.0075 1.01 1.20 0.0344 (Tunstall
0.5 0.013 0.022 4.98 3.96 0.142 Laboratory)
1.0 0.028 0.033 8.29 5.24 0.171
1.75 0.041 0.075 19.1 7.55 0.465
Human 0.006 0.00013 (0.0011) ** 0.17 0.03 0.0053 de Vlieger
Workmen, Pernis*** et al 1968
1964 0.535 0.01146 0.069 (10.9) (1.81) (0.34)
Formulators 0.791 0.01694 0.102 (16.1) (2.68) (0.50)
pre-1960 (1.55) (0.03323) (0.2) (31.6) (5.26) (0.99)
*The concentrations (mg HEOD/kg diet) are the nominal added concentrations of HEOD, except for 
the rhesus monkey, which received dieldnn incorporated into the solid diet. The equivalent 
intakes per kg body weight were calculated for the mouse, rat, and dog from observations made 
at Tunstall Laboratory; for the rhesus monkey from data supplied by Kettering Laboratory; and 
for humans from the mean concentration in body fat according to the formula:
concentration of HEOD in body fat 
daily intake = 0.0185
and assuming 70 kg as body weight. (The concentration in the human diet is based on a solid 
food intake of 1.5 kg/day.)
**Estimated from concentration in body fat according to the ratio of 158 for concentration 
in body fat to that in blood
***Concentrations in tissue (in parentheses) derived from the mean concentration in blood; 
pre-1960 values estimated, based on clinical observations of the workmen at Perms
Adapted from USEPA 1974
Data for a number of species, such as that presented in Table 1.5.4 
suggest that residues m  tissues after long-term exposure are proportional 
to the rates of intake (USEPA 1974, USDHEW 1969, Moriarty 1975). Table
1.5.5 summarizes the "storage factors" for dieldrin in blood and fat of 
various species after low-level exposure. The storage factor is defined 
as the concentration of dieldrin in the tissue at "quasi-steady" state di­
vided by the concentration in the diet.
The storage of dieldrin in mammals is affected by interactions with 
other chemicals, especially enzyme inducers. Storage of dieldrin in the 
fat of female rats was markedly reduced and the excretion of polar dieldrin 
metabolites was markedly increased when DDT was fed simultaneously (Street 
1964, Street and Chadwick 1967). A similar reduction in storage of dieldrin 
was produced by treatment with phenobarbital (Cueto and Hayes 1965), amino- 
pyrine, tolbutamide, phenylbutazone, and heptabarbital (Street et al 1966).
Dieldrin has been shown to cross the placenta in a number of experimental 
animals, including rabbits, rats, pigs, and cows (IARC 1974). Dieldrin is 
excreted in the milk of rabbits, cows, and rats (Jager 1970, Harr et al 1970a).
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TABLE 1.5.. 5
STORAGE FACTORS FOR DIELDRIN IN BLOOD AND FAT OF ANIMALS EXPOSED 
FOR LONG PERIODS TO DIELDRIN AT DIETARY LEVELS OF 0.1-0.15 PPM
Species Sex Storage Factor*
In Blood In Fat
Mouse M 0.039 15.5
Mouse F 0.026 12.7
Rat M 0.021 2.6
Rat F 0.065 9.0
Dog M 0.117 29.1
Dog F 0.116 32.7
0.075 10.0
*The concentration of dieldrin in the tissue at "quasi-steady" state 
divided by the concentration in the diet; calculated from data in 
Table 1.5.4
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1.5.4 Pharmacokinetics in Humans
Dieldrin is absorbed into the human body after ingestion (Hunter 
et al 1967, 1969), percutaneous absorption (Feldman and Maibach 1974), 
and presumably after inhalation. When small doses (4 yg/cm^) of radio- 
labeled aldrin and dieldrin in acetone solution were applied to the skin 
of male volunteers, 7.8% and 7.7%, respectively, of the radioactivity 
were excreted in urine within 120 hours. By contrast, when aldrin and 
dieldrin were injected intravenously, only 3.6% and 3.3%, respectively, 
were excreted in the urine (Feldman and Maibach 1974).
After ingestion, aldrin and dieldrin are circulated throughout the 
body in the blood, mainly in the plasma but to a lesser degree in the 
erythrocytes (Mick et al 1971, Morgan et al 1972). Most of the dieldrin 
in the plasma is bound to serum protein, and extremely little is partitioned 
into the cerebrospinal fluid (Garrettson and Curley 1969). Dieldrin is 
found in a wide variety of organs, its distribution generally paralleling 
that of the fat in the tissues (Table 1.5.6).
Dieldrin is excreted slowly in the bile. Samples taken from a pest- 
control operator during surgery contained dieldrin at concentrations of
24.6 ppm in adipose lipid, 165 ppb in blood serum, and 159 ppb in bile.
Two hydrophilic metabolites were also identified in bile (Paschal et al
1974).
Data on the uptake and loss of dieldrin in the human body have been 
fitted to one-compartment models. In a study in which male volunteers 
ingested 50 or 211 yg of dieldrin daily for 2 years, the rate constants for 
uptake were estimated by the original authors to be about 0.007, corresponding 
to a half-time of about 100 days (Hunter et al 1967, 1969).
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TABLE 1.5.6
AVERAGE CONCENTRATIONS. OF DIELDRIN IN VARIOUS TISSUES FROM 
AUTOPSIES OF 44 PEOPLE IN THE GENERAL POPULATION
Tissue
No. of 
Samples
Lipid
Content
(%)
Dieldrin
(ppm)
Perirenal fat 30 55.7 0.0300
Mesenteric fat 29 54.2 0.0630
Panniculus fat 30 60.6 0.0270
Bone marrow 19 20.6 0.0620
Lymph node 11 8.6 0.0190
Adrenal 18 10.5 0.0060
Kidney 38 3.2 0.0056
Liver 42 2.1 0.0037
Brain 32 7.9 0.0031
Gonad 36 1.3 0.0021
Lung 25 0.7 0.0022
Spleen 27 0.6 0.0021
Adapted from Casarett et al 1968
However, analysis by Moriarty (1975) has shown that the rate constants 
were actually considerably lower, corresponding to half-times of 150-200 
days. Estimates for the half-life of dieldrin in the human body after 
exposure ends are 266 days (based on exposed workers: Jager 1970, Moriarty
1975), 50-167 days (based on exposed workers: Kazantzis et al 1964, Brown 
et al 1964), and 50 days (based on a poisoned child: Garrettson and Curley 
1969). The shorter half-lives are based on poisoning victims therapeutically 
treated with drugs such as phénobarbital and diphenylhydantoin.
Hunter et al (1967, 1969) suggested that "steady state" concentrations 
were reached in their experimental subjects after 9-12 months of constant 
exposure. However, Moriarty (1975) has shown that this apparent steady
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state was an artifact of their mathematical procedure. In fact, dieldrin 
concentrations in fat and blood were still rising at the end of the 2-year 
study, and it is not completely clear that a steady state would ever have 
been reached. However, Moriarty was able to fit a one-compartment model 
to data for five of the six men, predicting asymptotic levels in blood
1.2-1.9 times higher than those reported by Hunter et al (Table 1.5.7). 
Accordingly the equations proposed by Hunter et al to describe the 
"steady state" in middle-aged men should be modified to the following:
Concentration of HEOD in blood (ppm) = 1.3 10“  ^amount ingested (yg/day) 
Concentration of HEOD m  fat (ppm) = 2.8 10“  ^amount ingested {yg/day) 
The corresponding storage factors (assuming 1.5 kg/day intake of food) 
are 0.2 for blood and 42 for fat. These are higher than those reported for 
other experimental mammals and 3-10 times greater than those reported in 
mice and rats (Table 1.5.5).
TABLE 1.5.7
ESTIMATES OF ASYMPTOTIC LEVELS OF DIELDRIN IN BLOOD 
OF MEN EXPERIMENTALLY EXPOSED FOR 2 YEARS
Daily Intake Estimate of Level (ppb)
(yg HEOD) By Hunter et al 1969 By Moriarty 1974
50 6.6 + 0.3 8.0 + 0.7
50 7.9 + 1.3 14.3 + 11.3
50 5.0 + 0.3 6.4 + 0.6
211 25.2 + 3.9 - *
211 20.5 + 1.5 26.0 + 3.4
211 16.9 + 1.8 25.6 + 9.3
*Calculation impossible because data did not fit asymptotic model
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In surveys of the general population of the United States, mean 
dieldrin levels in the adipose tissue lipids have been found to be about 
twice as high m  adults (25 years and older) than in children (3-14 years), 
although children are believed to ingest more dieldrin because of their 
higher consumption of milk products (Train 1974). This suggests that storage 
factors increase with age, probably by a factor of 5 or more between child­
hood and middle age.
Storage of dieldrin may be modified by interaction with other chemicals, 
especially enzyme inducers. In a study by Davies et al (1971), volunteers 
given diphenylhydantoin at a rate of 300 mg/man/day for 9 months showed a
reduction in dieldrin residues in fat by 73%.
Dieldrin crosses the placenta into the human fetus and is excreted into 
human milk (USDHEW 1969, Jager 1970). Polishuk et al (1977a) showed that 
dieldrin levels m  lipids of the fetus were two to six times higher than 
those in maternal lipids. The same group showed that dieldrin levels in 
human milk lipids were lower than those in plasma lipids: mean 0.58 versus
2.0 ppm (Polishuk et al 1977b). Data from an EPA Human Monitoring Survey 
showed that, in the United States, mean levels of dieldrin in human adipose 
tissue lipids are about 0.19 ppm and those in human milk lipids are about
0.12 ppm (Train 1974). According to the data given above and if an excretion
of about 25 g/day lipids in milk is assumed, the average lactating woman 
ingests about 7 yg/day and excretes about 4 yg/day in milk. The correspond­
ing intakes per unit body weight are about 0.1 yg/kg/day in the mother and 
0.8 yg/kg/day m  the breast-fed infant.
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2. Toxic Effects in Animals
2.1 General Toxicity
2.1.1 Acute Toxicity
Table 2.1.1 summarizes acute toxicity data for aldrin and dieldrin. 
The LD^q 's vary with the concentration (Barnes and Heath 1964) and the 
vehicle used (Heath and Vandekar 1964). Organic solvents and vegetable oils 
increase the toxicity by enhancing the rate of absorption of toxicant into 
the body (Jager 1970). The toxicity also varies between species, as 
shown in Table 2.1.2 for dieldrin and its photoisomerization product, 
photodieldrin.
The main signs of acute aldrin and dieldrin intoxication are 
increased irritability and tremor, followed by tonic-clonic convulsions, 
with the central nervous system as the principal site of action. Rats 
injected with nonlethal doses were found to recover fully and to show no 
delayed effects (Heath and Vandekar 1964).
2.1.2. Factors Modifying Toxicity
In addition to interspecific differences in susceptibility, the 
toxicities of aldrin and dieldrin vary according to the mode of adminis­
tration: highest toxicity via the intravenous route, lower via the oral
route, and lowest from dermal application. Studies by Treon and Cleveland 
(1955) and Heath and Vandekar (1964) indicated that aldrin and dieldrin are 
slightly more toxic to female than to male rats (see Table 2.1.1 ).
Table 2.1.2 shows this also to be the case for dogs.
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TABLE 2.1.1
ACUTE TOXICITY OF ALDRIN AND DIELDRIN IN EXPERIMENTAL ANIMALS
Species Strain Sex Route Formulation ld50
Aldrin
(mg/kg)
Dieldrin
Rat Wistar F Oral Arachis oil _ 50.8
Rat Wistar M Oral Arachis oil - 63.5
Rat CFE* Oral Peanut oil 45.9 38.3
Rat CFE Oral Arom. solv. 18.8 -
Rat CFE Oral 40% emulsifiable conc. 56.4 -
Rat CFE Oral 40% wettable powder 62.5 -
Rat CFE Oral 75% dust conc. 72.2 -
Rat CFE Oral 2.5% field strength dust 109.0 -
Rat CFE Oral 20% emulsifiable conc. - 55.9
Rat CFE Oral 50% wettable powder - 52.1
Mouse - Oral - 95 75-100
Mouse - Oral - 44 38
Guinea pig - Oral - 33 49-59
Rabbit - Oral - 50-80 45-50
Dog - Oral - 65-95 56-80
Sheep - Oral - - 50-75
Rat CFE Dermal 40% emulsifiable conc. 194.0 -
Rat CFE Dermal 40% wettable powder 274.0 -
Rat CFE Dermal 75% dust conc. 269.0 -
Rat CFE Dermal 2.5% field dust strength<100.0 -
Rat CFE M Dermal 20% emulsifiable conc. - 213.8
Rat CFE F Dermal 20% emulsifiable conc. - 119.9
Rat CFE Dermal 50% wettable powder - 213.4
Rat Wistar F ip Glycerol - 55.9
Rat Wistar F iv Glycerol - 8.9
Mouse
"
iv — 21.5 15.2
*Carworth Farm E strain
Adapted from Jager 1970
THE LD 's OF PHOTODIELDRIN AND DIELDRIN 50
TABLE 2.1.2
Species Approximate LD5Q 
Photodieldrin
(mg/kg)
Dieldrin
Rat 10 47
Mouse 7 77
Guinea pig 3 24
Dog (M) 140 120
Dog (F) 100 90
Chicken 80 48
Pigeon 90 250
Adapted from FAO/WHO 1971
Another factor modifying the toxicity of aldrin/dieldrin is diet.
Heath and Vandekar (1964) found that rats underfed for a prolonged period before 
dosing were considerably more susceptible to toxic doses of aldrin and 
dieldrin than those fed normally, probably because of lower storage 
capacity in adipose tissue and consequently higher dieldrin levels in the 
blood and in the central nervous system.
2.1.3. Mode of Action
The exact mode of action of aldrin and dieldrin on the central nervous 
system is still not fully understood. Hathway and Mallinson (1964) re-
ported that the action of dieldrin leads to liberation of ammonia in the 
brain before convulsions begin and throughout their course. They suggested 
that dieldrin may inhibit glutamine synthesis in the brain.
Studies conducted on cockroaches suggest that a metabolite, probably 
trans-6,7-dihydroxydihydroaldrin, may be the active neurotoxic agent, 
because this metabolite caused an immediate reaction when applied to isolated 
nerve axons, whereas dieldrin elicited a weaker response which occurred 
only after a delay (Wang et al 1971).
2.1.4 Effects Observed in Long-Term Feeding Studies
In a study of slightly more than 15 months duration, dogs fed diets 
containing either aldnn or dieldrin at 1 and 3 ppm survived the entire 
test period. Increased liver weights were observed in the dogs fed the 
diets with dieldrin at 1 and 3 ppm and m  those given aldrin at 3 ppm.
Minor liver cell changes were seen in dogs fed aldrin at 3 ppm, but none 
were seen m  dogs fed dieldrin (Treon and Cleveland 1955).
In a 2-year study conducted by Fitzhugh et al (1964) dogs were fed 
aldrin or dieldrin in the diet at dosages of 0.2, 0.5, 1.0, 2.0, 5.0, 
and 10.0 mg/kg. A "no-effect level" of 0.2 mg/kg (equivalent to about 
6 ppm in the diet) was established for both compounds. Neither clinical 
nor histopathologic abnormalities were reported at this dose level.
At 0.5 mg/kg, the dogs suffered from convulsions; 4/4 dogs fed aldrin 
and 1/4 dogs fed dieldrin died during the 2-year exposure period. At 
higher dose levels, all dogs died within 49 weeks. At autopsy they 
displayed fatty changes in their livers and renal tubules.
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A male and a female dog were exposed to dietary dieldrin at a rate 
of 0.2 mg/kg/day for 5 years. The only effects observed were increased 
serum alkaline phosphatase activity in both animals and increased 
bromosulphthalein clearance in the male. The iatter change was considered 
a sign of stimulation of miscrosomal enzyme activity (Jager 1970).
In a 2-year study, Walker et al (1969) daily gave groups of five 
male and five female beagles capsules containing 0.05 mg/kg doses of 
recrystallized dieldrin in olive oil. Control dogs received capsules 
containing olive oil only. General health, behavior, and body weight 
were unaffected in each group. Electroencephalographic recordings 
showed no difference between the control and the high dose group.
The results of hematologic studies and urinalyses were similar in all 
groups. The serum alkaline phosphatase level in the dogs given 0.05 
mg/kg was higher after the 18th week than in the controls. At autopsy 
the only significant finding was an increase in the liver-to-body 
weight ratio in the high dose group. This increase was not associated 
with any histologic anomaly.
Treon and Cleveland (1955) fed male and female rats diets containing 
either aldrin or dieldrin at 2.5, 12.5, and 25 ppm for up to 2 years. A 
slight increase in the ratio of liver weight to body weight was observed 
in both males and females, even at the lowest dose level. Liver lesions 
were recorded for animals in all of the experimental groups.
In a feeding study conducted by Fitzhugh et al (1964), male and 
female rats received diets containing aldrin or dieldrin at 0.5, 2, 10,
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50, 100, and 150 ppm for 2 years. The rats exposed at 50 ppm and above 
suffered a dose-related reduction in lifespan and a high incidence of 
nephritis and microscopic liver lesions described as characteristic 
results of exposure to chlorinated hydrocarbons. Increased liver 
weight and "minimal" liver cell changes were observed even in the rats fed 
aldrin or dieldrin at 0.5 ppm. However, 0.5 ppm was considered a 
"minimal effect level" and was used as the basis for WHO's Acceptable 
Daily Intake (FAO/WHO 1971). For further evaluation of this experiment 
see Sections 2.2.1, 2.2.2, and 2.5.
Walker et al (1969) fed recrystallized dieldrin (99% purity) at
dietary levels of 0.1, 1.0, or 10 ppm to groups of 25 male and 25 female 
rats for periods up to 2 years. Forty-five males and 45 females 
served as controls, but the control diet contained dieldrin at 0.026 ppm. 
Body weights and food intakes were unaffected by the added dieldrin, but 
at 10 ppm all the animals became irritable after 8-13 weeks; occasional 
convulsions occurred in this group during handling. No adverse effect 
on survival was observed. Liver weights were normal for the first 18 
months, but after 2 years increased liver weights and liver-to-body 
weight ratios were observed in the groups fed 10 ppm. For further
evaluation of this experiment see Section 2.5.
A series of long-term feeding studies with recrystallized dieldrin 
(99% pure) in CFI mice was conducted at Tunstall Laboratory (Walker 
et al 1972; Thorpe and Walker 1973). The most striking effect was a 
dose-related increase of liver tumors in all experiments (for details
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see Section 2.5). Survival was markedly reduced in mice receiving dieldrin 
at 10 and 5 ppm and in female mice at 2.5 ppm, but not in males at 2.5 ppm 
or m  either sex at lower concentrations (Figure 2.1.1).
Murphy and Korschgen (1970) conducted 3-year feeding tests on white- 
tailed deer. Groups of 10 deer and their progeny were given dieldrin at 
5 or 25 ppm. No signs of overt intoxication were observed, and 9 or 
10 adult deer in each group survived the 3 years. Growth was slower and 
remained reduced m  dieldrin-exposed females that were immature when the 
study began. Hematologic values and serum protein concentrations were not 
significantly related to treatment. Liver-to-body weight ratios were 
significantly larger m  deer given dieldrin at 25 ppm, and pituitary 
glands were smaller and thyroids were larger in deer fed dieldrin.
Male rhesus monkeys were fed dieldrin at 0.1, 0.5, 1.0, 1.75, and
5.0 ppm (0.002-0.07 mg/kg/d) in the diet for about 6 years. No signi­
ficant liver changes were observed at dietary levels below 1.0 ppm.
A dose-related increase in microsomal P450 was found at the higher levels, 
and increased microsomal enzyme activity was observed at the 1.0 and 
1.75 ppm levels, but no changes in subcellular structure were found 
(Wright 1974, Jager 1970).
2.2 Organ-Specific Effects
2.2.1 Liver Effects
Histologic changes occur in the livers of rats given repeated doses 
of certain chlorinated hydrocarbon compounds. These changes have been 
studied in rats exposed to DDT or to dieldrin and appear to be similar
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FIGURE 2.1.1 (Walker et al 1972)
CUMULATIVE MORBIDITY OF MICE FED DIELDRIN 
AT LEVELS OF 0 (•), 1.25 (O), 2.5 (a ), 5 (a), 
10 (*), OR 20( 7 ) PPM
Maies
Time (weeks)
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for each compound (USDHEW 1969). The histologic changes m  the parenchymal 
cells of the liver consist of increased deposition of fat, margination of 
cytoplasmic granules, and hypertrophy of cells. The most characteristic 
change is the formation of complex lipoid cytoplasmic inclusion bodies 
termed "lipospheres." In rats fed dieldnn, structural changes m  the 
liver included an increase in the amount of smooth endoplasmic reticulum 
(SER) associated with induction of microsomal enzymes (Wright 1974). 
Fitzhugh et al (1964) reported that the severity of these histopathologic 
changes increased progressively with dosage of both aldrin and dieldrin 
(see Table 2.2.1).
Kimbrough et al (1971) found morphologic changes, including an 
increase in SER and atypical mitochondria, in adult male rats fed technical 
grade dieldrin at 50 or 100 ppm for 8 weeks. Effects were more pronounced 
in rats fed DDT and dieldrin simultaneously.
In comparative studies, single doses of dieldrin caused a marked 
proliferation of SER in the livers of rats given 8 mg/kg and in dogs given 
2 mg/kg but caused less marked effects m  mice given 0.16-7.5 mg/kg. 
Increases m  SER were accompanied by increased microsomal enzyme activity 
(see Section 2.2.2). In mice, an increase in liver DNA content indicated 
cell proliferation, whereas rats and dogs showed cellular hypertrophy 
(Jager 1970; Wright 1974).
Liver lesions induced in mice and rats by aldrin and dieldrin after 
long-term feeding (15-26 months) have been re-evaluated by Reuber (1974, 
1975, 1976). He reported that the lesions spanned all stages of de-
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TABLE 2.2.1
CHARACTERISTIC "CHLORINATED INSECTICIDE" CHANGES IN 
LIVERS OF RATS FED ALDRIN OR DIELDRIN
Dietary Number of Livers
Concentration Degree of Liver Change* Sectioned
(ppm) N T VS S S-M&M >M
Control
None 16 1 0 0 0 0 17
Aldrin
0.5 15 4 0 0 0 0 19
2 10 8 0 1 0 0 19
10 11 3 7 1 0 0 22
50 0 0 0 6 10 2 18
100 0 0 0 0 5 6 11
150 0 0 0 0 2 7 9
Dieldrin
0.5 17 4 0 1 0 0 22
2 12 5 5 1 0 0 23
10 7 7 3 1 0 0 18
50 0 0 3 8 6 3 20
100 0 0 1 1 8 8 18
150 0 0 0 1 5 5 11
*N = none, T = trace or minimal, VS = very slight, S = slight, and
M = moderate; figures based on microscopic sections 
Adapted from Fitzhugh et al 1964
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velopment from hypertrophy, through areas or foci of hyperplasia to hyper­
plastic nodules and well differentiated or moderately well differentiated 
hepatocellular carcinomas. Reuber (1976) described and illustrated stages 
in this progressive development. For further details see Section 2.5.
2.2.2 Liver Microsomal Enzymes
Many compounds, including phénobarbital and chlorianted hydrocarbon 
insecticides such as DDT and dieldrin, stimulate the drug-metabolizing 
enzyme system of the liver and are frequently associated with liver en­
largement (Fouts 1963, Hard and Fouts 1963, Hart et al 1963, Gilbert and 
Goldberg 1967, Conney et al 1967, Remmer 1967, Kupfer 1967, Rubin et al 
1968, Kimbrough et al 1968, Conney 1967, 1969). The increased activity 
of microsomal enzymes leads to enhanced rates of metabolism of steroid 
hormones (see Section 2.3.8) and other chemicals, including dieldrin it­
self (Oberholser et al 1977) . Triolo and Coon (1966a,b) reported that 
a single dose of aldrin and dieldrin at 1 mg/kg body weight administered 
to rats caused a reduction in the toxicity of parathion, paraoxan, and 
several other organophosphates administered 4 days later. This effect 
was attributed to enhance metabolism of the organophosphates.
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Rats fed 200 ppm of dieldrin in the diet showed cellular changes 
observable with electron microscopy within 24 hours. These changes were 
correlated with an increased activity of certain enzymes, such as those 
capable of hydroxylating aniline or catalyzing the o-dealkylation of 
chlorfenviphos, but the activity of other enzymes such as acid phospha­
tase or glucose-6-phosphatase did not change (Jager 1970).
In dogs fed dieldrin at 0.05 mg/kg/day for 2 years, cellular changes 
observable by electron microscopy were similar to those found in rats 
(Jager 1970, Wright 1974) . In the dog, however, unlike in the rat, in­
creased activity of liver and serum alkaline phosphatases was observed at 
the highest dose level (Walker et al 1969). Street et al (1969) reported 
a dietary "threshold" level for hepatic enzyme induction by dieldrin of 1 
ppm after 2 weeks oral administration to rats, compared with 5 ppm for DDT. 
Den Tonkelaar and van Esch (1974) found markedly stimulated aminopyrine 
demethylase activity in male rats fed dieldrin for 2 weeks at 2 ppm, the 
lowest dietary concentration tested.
2.2.3 Kidney Effects
Fitzhugh et al (1964) observed a marked increase in kidney lesions, 
diagnosed as slight or moderate nephritis, in rats given aldrin or dieldrin 
at 50-150 ppm for 2 years (Table 2.2.2). In examining kidney
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TABLE 2.2.2
GROSS AND MICROSCOPIC PATHOLOGY IN THE KIDNEYS OF RATS 
EXPOSED TO ALDRIN OR DIELDRIN FOR 2 YEARS
Dietary No. of Livers
Concentration % Survival Sectioned Nephritis
(ppm) 18 mo 24 mo S or M >M
Control
None 75 50 17 6 1
Aldrin
0.5 75 50 19 4 2
2 83 50 19 4 3
10 67 42 22 8 1
50 63 25 18 1 2
100 42 17 11 4 5
150 17 4 9 3 2
Dieldrin
0.5 79 42 22 5 3
2 88 63 23 6 0
10 79 25 18 6 1
50 67 21 20 6 3
100 50 13 18 2 8
150 21 4 11 7 1
*S = slight and M = moderate; figures based on the microscopic sections, except 
for the inclusion of one markedly damaged kidney, based on gross appearance 
only, in the 100 ppm aldrin group
Adapted from Fitzhugh et al 1964
sections from this study, Reuber (1974) found that chronic nephritis 
occurred more commonly in males than females and was very common at 
high dose levels, particularly of dieldrin; he suggested that the 
figures in Table 2.2.2 were probably underestimates because of the 
high mortality after 1 year, when the nephritis was unsually seen. 
Hemorrhagic and distended urinary bladders were usually associated 
with severe nephritis and were only seen in males that died. Reuber 
also found several cases of acute renal necrosis, especially in females, 
hyperplasia of the renal tubules, and one hyperplastic nodule.
2.2.4 Central Nervous System and Peripheral Motor Effects
As discussed in Section 2.1.3, the effects of aldrin and 
dieldrin on the central nervous system are not completely understood. 
Experiments involving long-term dietary exposure have demonstrated a 
variety of effects, including nonspecific neural lesions, impairment 
of learning, increased chronaxy, and impairment of muscular performance.
Harr et al (1970b) administered purified dieldrin at concentrations 
between 0.08 and 40 ppm in the diet to Wistar rats for up to 2 years.
They reported nonspecific neural lesions, cranial edema, dieldrin residues 
in the brain, and convulsions in most exposed rats. No functional effects 
were observed at dietary concertrations below 2.1 ppm dieldrin, although 
cranial edema was observed at 0.63 ppm, and cerebral, cerebellar, brain­
stem, and vascular lesions were at all dietary levels down to 0.08 ppm. 
Dieldrin residue levels of 9-11 ppm in the brain were associated with 
convulsions.
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Smith et al (1976) exposed two groups of seven squirrel monkeys to 
technical dieldrin at two oral dose levels, 0.1 and 0.01 mg/kg/day.
Two zero-dose controls were included. After 55 days the higher dose 
group was shifted to zero exposure and the lower dose group was shifted 
to exposure at the high dose; controls continued at zero exposure. The 
new regimens were continued for 54 days. The monkeys were presented 
with a visual nonspatial successive discrimination reversal task. During 
the first 55 days, before the change in regimen, control and low-dose 
monkeys learned the task, whereas high-dose monkeys did not (P<0.001). 
During the subsequent 54 days, the performance of each group remained 
approximately at the level achieved before the change in regimen. It 
was concluded that the high dose disrupted learning without affecting 
retention of the learned task. The authors suggested that this effect 
could be attributed to disruption of hippocampal activity. The low 
dose had no effect on task acquisition or retention.
Al-Hachim (1971) reported apparent effects of prenatal exposure to 
aldrin on the central nervous system of mice. The 38-day-old offspring 
of mice given aldrin at 2 or 4 mg/kg/day orally for 7 days during the 
third stage of gestation showed a significant reduction in body weight 
and a significant increase in electroshock seizure threshold compared 
to controls.
London and Pallade (1964) exposed rats to aldrin at 3 mg/kg/day 
in the diet for 6 months and then at 4.5 mg/kg/day for 7 months. They 
measured chronaxy by applying an electric current to the tails of the
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rats and measuring the duration of the voltage pulse required to elicit a 
withdrawal response. They found that chronaxy was longer in the rats 
exposed to aldrin than in controls.
Khairy (1960) studied the effects of dieldrin exposure on the 
muscular performance of rats given diets containing the substance at 
25 or 50 ppm for 60 days. The criterion for muscular performance 
was the time taken to pull a weight along a 250-cm runway. He 
observed a progressive deterioration of performance related to the 
amount of dieldrin administered. Jager (1970) reported that the 
gastrocnemius muscle of rats receiving dieldrin at 50 ppm in the 
diet for 7 months failed to maintain a tetanus comparable to that 
of control rats.
I
Medved et al (1964) reported that, in cats, feeding of aldrin 
at 1 mg/kg/day or inhalation of aldrin at 0.1 mg/m for an unspecified 
period caused marked lowering of conditioned reflexes and of unconditioned 
orientation reflexes. These reflexes required as much as 6-8 days to 
return to normal after exposure.
2.2.5 Effects in Other Organs
In 39- to 140-day-old female Wistar rats fed dieldrin at 2.5-
10.0 ppm in the diet, Harr et al (1970a) found proliferation of 
reticuloendothelial components and pancreatic ductal cells. Fibrinoid 
degeneration, arteritis, endothelial proliferation, and perivascular 
edema were seen in small to medium sized arteries.
Although no data were found on dieldrin's effects on the 
mammalian thyroid, Jefferies and French (1972) reported that dieldrin
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at 1, 2, and 4 mg/kg/day produced hyperplastic goiters m  the thyroids 
of pigeons. In a visual examination, they observed that the thyroids 
were significantly enlarged and had small follicles with decreased 
amounts of colloid, epithelial hyperplasia, and vascular congestion.
2. 3 Effects on Reproduction
2.3.1 In Mice
Good and Ware (1969) studied the effects of technical dieldrin 
on reproduction m  101 pairs of CFW mice, with a similar number of 
controls. At a dietary level of 5 ppm, dieldrin did not affect 
maternal mortality, fertility (defined as the percentage of pairs 
producing young), or fecundity (defined as the number of young per 
producing pair) but significantly reduced the average size of litters.
Virgo and Bellward (1975 a,b) studied the effects of technical 
dieldrin at dietary levels of 0, 2.5, 5, 10, 15, 20, and 25 ppm m  
SWV mice. Virgin and diparous females were studied. Dietary levels 
of 20 and 25 ppm caused maternal mortality. At levels up to 15 ppm, 
dieldrin had no effect on the incidence of breeding in parous females, 
nor did it affect fetal survival, the duration of gestation, 
or parturition. Levels of 10-15 ppm reduced fertility by 18% and 
there was a dose-related reduction (maximum 17%) in litter size. The 
reductions in fertility and litter size resulted from a lesion or 
lesions preceding implantation. Dieldrin exposure resulted in 
preweaning losses of entire litters in 100% of litters from dams 
exposed to dieldrin at 10 ppm or higher, 80% of litters from dams exposed
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at 5 ppm, and 47% at 2.5 |>pm, versus 31% in controls. Maternal 
cannibalism and neglect of pups were responsible for deaths m  
litters of dams fed dieldrin at 15 ppm or more, although it was 
considered that most of these pups would have died from toxic effects 
of dieldrin anyway.
In a six-generation study using Swiss mice exposed either to 
aldnn (3, 5, 10, and 25 ppm) or to dieldrin (3, 10, and 25 ppm), the 
principal adverse effects were on lactation indices and the viability of 
pups. Dieldrin at 10 ppm did not affect fertility in the mice in the 
first mating but decreased it by 31% in the second mating. This dose 
did not reduce litter size, and reproduction was not substantially 
affected at 3 ppm. The authors suggested that the adverse effects may 
have been mediated through hormonal imbalance rather than direct 
toxicity (Deichmann and Keplinger 1966, Keplinger et al 1970, Deichmann 
and MacDonald 1971).
2.3.2 In Rats
Results of a three-generation reproduction study m  Carworth 
rats have been reported in summary form only (Treon and Cleveland 
1955, Cleveland 1966). Aldrin or dieldrin was fed to rats at dietary 
levels of 0, 2.5, 12.5, and 25 ppm, and two sets of offspring were 
obtained from each generation. There was no reported effect on the 
number of pups per litter nor on the weight of the young rats at 
weaning. "Initially aldrin in the diet at levels of 12.5 ppm or 
higher and dieldrin at 2.5 ppm or higher appeared to reduce the
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number of pregnancies in these rats. However, this^effect tended to 
diminish to the point of disappearance when the feeding of aldrin at
12.5 ppm or lower was maintained over several generations." Incorporation 
of aldrin or dieldrin into the diet of parent rats during the period of 
suckling increased mortality among the offspring, the effect being "slight 
to moderate" at 2.5 ppm but higher at 12.5 or 25 ppm.
In a factonally designed experiment, Wistar rats weaned at 28 
days were placed on diets containing dieldrm at a concentration of 
0.08, 0.16, 0.31, 0.63, 1.25, 2.5, 5, 10, 20, or 40 ppm (Harr et al 
1970a). Twenty males and 20 females were included in each of the 10 
exposure groups and in a control group. The animals were killed 
at various intervals ranging up to 750 days. Values for dam 
survival, conception rate, pup survival, and weaned litter size 
were normal in rats fed dieldrm at 0.08 and 0.16 ppm. In rats fed 
0.31-1.25 ppm, there was a slight reduction m  the survival of 
litters and a marked reduction in conception rates (to 73% m  the 
first mating and 33% m  the second mating). At dietary levels of 
2.5-10 ppm, females survived to breeding age, but nursing pups 
either died in convulsions or starved. The calculated maximum 
dietary concentration of dieldrin consistent with normal reproduction 
was 0.26 ppm in the first breeding and 0.09 ppm m  the second 
breeding. Computed dietary levels of dieldrin associated with 
various effects are shown in Table 2.3.1.
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TABLE 2.3.1
DIETARY LEVELS OF DIELDRIN ASSOCIATED WITH VARIOUS LEVELS 
OF REPRODUCTIVE PERFORMANCE IN RATS
Measure of Repro­
ductive Performance Calculated Dietary Levels (ppm)
1st Breeding 2nd Breeding
(146-day-old rats) (336-day-old rats)
50% dam survival 27.0 16.0
80% dam survival 21.0 9.0
*100% dam survival 10.0 5.0
30% conception rate 13.75 2.88
70% conception rate 2.50 0.24
*90% conception rate 0.36 0.09
3 pups of litter weaned 6.36 2.34
7 pups of litter weaned 1.39 0.50
*9 pups of litter weaned 0.26 0.26
*Normal
Adapted from Harr et al (1970a)
2.3.3 In Dogs
Kitselman (1953) exposed 9 male and 11 female dogs to 
recrystallized aldrin or dieldrin in food at doses of 0.2, 0.6, 
and 2.0 mg/kg/day in the diet for up to 1 year. Of the 11 exposed 
females, 9 became pregnant and came to term, but only 7 pups 
survived (4/4 from a bitch given dieldrin at 0.2 mg/kg, 2/5 from 
a bitch given aldrin at 0.2 mg/kg, and 1/5 from a bitch given 
aldrin at 0.6 mg/kg). The other 32 pups were either stillborn or 
died within 3 days after birth.
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Deichmann and MacDonald (1971) and Deichmann et al (1971) 
exposed beagle dogs by capsule to technical aldrin at 0.15 mg/kg 
(four females), aldrin at 0.3 mg/kg (four males and three females), 
or a mixture of aldrin at 0.15 mg/kg plus 6 mg/kg recrystallized 
p ,p 1-DDT at 6 mg/kg (four males and four females). Capsules were 
given 5 days/week for 14 months, and then the dogs were maintained 
for up to 9 months on uncontaminated diets. Reproduction was 
severely affected in all three treatment groups, as evidenced by 
reduced fertility, reduced mammary development, and impaired 
lactation in the females, and stillbirths and increased mortality 
of pups. Only 26 pups were raised to weaning in 17 breeding 
attempts, compared to 78 pups from 18 control females.
2.3.4 In Raccoons
Frederickson (1973) reported on a study of the effects of chronic 
exposure to dieldrin on reproduction in raccoons. At 2.2 ppm in the 
diet (wet weight, corresponding to 6 ppm dry weight) most of the 
females died "under the stress of breeding." At 0.73 ppm in the diet 
statistically significant adverse effects on the estrous cycle and on 
the incidence of pregnancy were reported. Fetal death, resorption of 
embryos, and reduced litter size were also reported. The exposed 
females produced only 20% of the number of young produced by unexposed 
females. Seven of 15 exposed females failed to respond normally to the 
sexual behavior of males. Adverse effects were also noted in males, 
on the production of sperm, the quality of sperm, and total fertility.
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2.3.5 In Rabbits
Wild-trapped cottontail rabbits were confined in 1-acre pens and 
exposed to granular dieldrin applied at 0.5 or 2.0 lb/acre (Malecki 
et al 1974) . No significant effects were recorded on testis weight, 
date of breeding, ovulation rates, preimplantation losses, resorption 
of embryos, or embryonic litter size. No adequate measures of post­
natal mortality were obtained. Precise exposure levels were not 
determined, but food plants contained dieldrin at 0.07-0.25 ppm, and
4
brain residues of dieldrin in the rabbits were in the range 0.11- 
0.66 ppm.
2.3.6 In Sheep
Thirty-six ewes were fed dieldrin at 0, 1, 5, or 25 ppm during 
40 months, which included two gestation periods (FAO/WHO 1971). 
Reproductive success was apparently normal at exposure concentrations 
up to 5 ppm. However, at 25 ppm the lambs died shortly after birth.
2.3.7 In Deer
Murphy and Korschgen (1970) studied reproduction in white-tailed 
deer exposed to dieldrin at dietary levels of 0 (controls), 5, and 
25 ppm for 3 years. Ten females (five yearlings, five fawns) were 
included in each exposure group. No effects on conception rates or 
on mortality in utero were reported. Fawns from does fed dieldrin 
at 25 ppm were smaller at birth, and the number of postpartum 
deaths was increased in the 5 and 25 ppm exposure groups. The 
fertility of male progeny was not affected. Weight gains of fawns 
born to does exposed to dieldrin were significantly reduced.
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2.3.8 Effects on Steroid Hormones
In a number of experiments dieldrin induced hepatic microsomal 
enzymes that can enhance the metabolism of steroid hormones such as 
testosterone and progesterone. Such effects have been reported even 
at dietary levels as low as 2 ppm (Conney et al 1967, Thomas and 
Lloyd 1973). Schein and Thomas (1975) showed that administration of 
dieldrin m  five daily doses of 2.5 mg/kg or in one dose of 10 mg/kg 
increased hepatic microsomal protein and cytochome P450 concentration, 
increased testosterone hydroxylase activity, and altered the metabolism 
of testosterone in the liver and prostate of mice. These effects were 
enhanced by simultaneous or subsequent exposure to parathion Schein 
and Thomas 1976). Similar enhancement of dieldrin effects on the 
metabolism of testosterone by exposure to carbaryl was reported by 
Schein et al (1976).
Exposure to dieldrin reduced the ability of the prostate gland of 
rats to assimilate testosterone both in vivo and in vitro (Blend and 
Schmidt 1971, Thomas et al 1973, 1975). Wakeling et al (1972) reported 
that dieldrin interfered with the binding of dihydrotestosterone to 
male sex hormone receptors m  the nuclear and cytosol fractions of the 
rat prostate. Further studies by Wakeling and Visek (1973) suggested 
that the dieldrin interferes with the in vitro binding of 5-alpha- 
dihydrotestosterone to its androphilic molecule by a mechanism involving 
noncompetitive inhibition. Schein and Thomas (1975) showed that dieldrin 
at 1.25, 2.5, or 5 mg/kg/day for 5 days significantly reduced the total
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uptake and subsequent metabolism of androgens in the anterior prostate 
of the mouse. Dieldrin at concentrations as low as 4 x 10-7M in vitro 
effectively decreased the formation of dehydrotestosterone in the mouse 
anterior prostate and of androstanediol in the rat ventral prostate.
In addition to the actions of dieldrin upon the prostate glands 
of rodents, it apparently produces changes in the levels of serum 
luteinizing hormone (LH) (Blend and Lehnert 1973) . Levels of LH were 
not affected when the rats were fed dieldrin at 0.7 ppm. At 6.2 ppm, 
dieldrin produced significant elevations in serum LH. Even in 
castrated rats, dieldrin (6.2 ppm) caused an increase in the serum 
levels of this gonadotropin. Dieldrin also caused a slight decrease 
in the ratio of body weight to pituitary gland weight and a sma:il 
increase in the ratio of body weight to prostate gland weight. Blend 
and Lehnert (1973) suggested that the smaller prostate glands observed 
in the treated (0.7 ppm) rats were possibly caused by an action of 
dieldrin on hepatic microsomal enzymes that effectively lowered the 
levels of circulating androgens. These lowered androgen levels in 
the blood might account for the observed decreases in accessory sex 
organ weights.
2.4 Te ratogene sis
Ottolenghi et al (1974) administered aldrin and dieldrin at 
approximately one-half the lethal dose to pregnant Syrian golden hamsters 
and to pregnant CD1 mice. Hamsters given aldrin at 50 mg/kq or dieldrin 
at 30 mg/kg by oral intubation on day 7, 8, or 9 of gestation showed
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a high incidence of-fetal death, growth retardation, and congenital 
abnormalities. The most frequent abnormalities were open eyes, webbed 
feet, cleft palate, cleft lip, and fused ribs. Dieldrin also induced 
a smaller number of other defects including exencephaly, platycrania, 
micrognathia, and ectrodactyly. Hamster pups exposed on day 8 of 
intrauterine development showed a much higher incidence of abnormalities 
(22% for aldrin, 33% for dieldrin) than those exposed on day 7 or 9.
The same type of defects were induced in mice given aldrin at 25 mg/kg 
or dieldrin at 15 mg/kg by oral intubation on day 9 of gestation.
The percentages were 33% for aldrin and 17% for dieldrin, versus zero 
in controls.
Chernoff et al (1975) administered dieldrin at doses of 1.5,
3.0, and 6.0 mg/kg to pregnant CD1 mice and CD rats by gastric intubation 
on days 7-16 of gestation. The highest dose caused maternal death and 
weight loss in rats but did not cause fetal mortality or anomalies.
In mice, all three doses induced an increase in the number of super­
numerary ribs in one of two experiments; the increase was statistically 
significant at 3 and 6 mg/kg. The 6 mg/kg dose also induced a decrease 
in the number of caudal ossification centers. The authors did not 
regard these as teratogenic effects. Photodieldrin administered at 
0.15, 0.30, and 0.60 mg/kg induced no fetal toxicity or anomalies in 
rats and mice.
Boucard et al (1970) reported that dieldrin was teratogenic in 
rats and mice, but the incidence of anomalies was low in all exposed
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groups. When data from three dosage regimens (day 6, days 6-14, and 
days 1-14) are pooled, the incidences in rats were: control, 1/1,336;
2.5 ug/kg/day, 4/655; 3.4 mg/kg/day, 5/617. In mice, the incidences 
were: control, 2/1,123; 2.5 jjg/kg/day, 4/475; 3.4 mg/kg/day, 4/510.
These results suggest that dieldrin has a weak teratogenic effect, 
but the effect was not statistically significant in any one treatment 
group. The malformations observed in the exposed animals included 
hydrocephaly (5), hydronephrosis (2), cleft palate (2), and miscellaneous 
abnormalities (10).
2.5 Carcinogenesis
The carcinogenicity of dieldrin was the principal focus of 
public hearings held in 1973-74 before the U.S. Environmental 
Protection Agency (EPA) on the cancellation of registrations of 
aldrin/dieldrin, and a large volume of expert testimony and exhibits 
on this subject was introduced into the public record (USEPA 1973-74).
The most extensive published review is by Epstein (1975) , but it was 
limited to material introduced by witnesses for parties arguing for 
cancellation and subsequent to its preparation additional material, 
including new data, revised diagnoses, and extended statistical 
analysis, was introduced by witnesses called by Shell Chemical Company 
(Thorpe 1974, Stevenson 1974, Hunt 1974, Sternberg 1974; see also 
Stevenson et al 197 6).
Epstein (1975) concluded that aldrin/dieldrin has been shown to 
be carcinogenic in the liver in at least five independent experiments
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with mice and in other sites, as well as in the liver, in at least 
one experiment with rats. The reported positive findings in rats 
were disputed on both pathologic and statistical grounds (Thorpe 
1974, Stevenson 1974, Hunt 1974, Sternberg 1974) . Dieldnn was also 
reported to be carcinogenic in the lung and other sites in several 
experiments with mice (Gross 1974), but this also was disputed on 
statistical grounds (Stevenson 1974, Hunt 1974) . On reviewing the 
record, the Administrator of EPA concluded that dieldrin has been 
shown to be carcinogenic in the liver and lung of mice in several 
experiments and that "there is a strong probability that aldnn/dieldrin 
is a carcinogen in rats as well ?s mice" (Train 1974). The 
following is a brief summary of the experiments and reported findings, 
including the results of experiments recently reported by the National 
Cancer Institute (NCI 1977, 1978a,b).
2.5.1 FDA Studies 2 and 3 in C3H Mice
Following an earlier inconclusive experiment, two long-term 
feeding studies in C3HeB/Fe strain mice were carried out at the U.S.
Food and Drug Administration and were reported by Davis and Fitzhugh 
(1962) and Davis (1965). In Study 2, groups of 215-218 mice, with 
about equal numbers of males and females, were fed diets containing 
aldrin or dieldrin at 10 ppm. A similar group of 217 unexposed mice 
was a control group. Average survival times were 51.6 weeks in 
exposed mice and 59.8 weeks in the controls. Liver tumors, described 
as "extending from very benign lesions to borderline carcinomas," were
found in 38/151 (23%) aldrin-exposed, 38/148 (24%) dieldrin-exposed, 
and 9/134 (7%) control mice. Hepatic tumors developed in mice exposed 
to aldrin in an average of 80 weeks, in dieldrin-exposed mice in 77 
weeks, and in control mice in 89 weeks (Davis and Fitzhugh 1962) .
In Study 3, groups of 200 mice, with equal numbers of each sex, 
were fed diets containing aldrin at 10 ppm, dieldrin at 10 ppm, or no 
added material. Exposed mice survived less well than controls but 
showed a markedly increased incidence of liver tumors diagnosed as 
"benign hepatomas" (Davis 1965: see Table 2.5.1).
TABLE 2.5.1 
RESULTS OF FDA STUDY 3 WITH C3H MICE
Dietary
Exposure
No. of 
Survivors
No. of Mice 
with Lesions* 
When Killed
No. of Mice 
with Tumor
52 wk 78 wk 104 wk Hy H HC Benign Malignanl
Control (0) 188 150 64 48 27 4 30 21
Aldrin 
(10 ppm)
152 121 31 72 65 3 61 9
Dieldrin 
(10 ppm)
169 117 39 71 69 5 71 9
*Hy = hyperplasia, H = "benign hepatoma," HC = hepatic carcinoma 
Adapted by Davis 1965
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Histologic material from both studies (excluding dieldrin-exposed 
mice from Study 3) was examined by Reuber (1974), with the results 
shown in Table 2.5.2. There were marked and highly statistically 
significant increases in hepatocellular carinomas in all four 
treated groups. The carcinomas and other hepatic lesions have been 
fully described and illustrated by'Reuber (1974, 1975, 1976). Carcinomas 
in controls were generally small and single, in contrast with those in 
treated animals, which were larger and sometimes multiple. Metastases 
to the lungs were found in 4% of the males exposed to aldrin and 5% of 
the females exposed to dieldrin, although no serial sections were made. 
Hepatic vein thrombosis, causing massive liver necrosis and death, was 
diagnosed in about 5% of the treated mice. Carcinomas from 7/8 control 
mice, 9/10 mice exposed to aldrin, and 8/9 dieldrin-exposed mice were 
successfully transplanted into isologous hosts. The behavior of the 
transplants correlated well with the degree of malignancy as diagnosed 
histologically, the more highly malignant tumors growing more rapidly 
than those judged to be less malignant (Reuber 1974, 1975, 1976;
Epstein 1975).
2.5.2 Tunstall Experiment 1 in CF1 Mice
This is the largest-scale experiment on the carcinogenicity of 
dieldrin. Because of the unusually large numbers of mice involved, 
the data have been analyzed extensively (Walker et al 1972, Gross 
1974, Epstein 1975, Stevenson 1974, Hunt 1974, Thorpe 1974, IARC 1974).
In addition to positive controls, the experiment included a total of
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1,500 mice segregated into groups containing the following numbers of 
mice of each sex: 0.01 ppm dieldrin ("control"), 300; 0.1 ppm, 125;
1 ppm, 125; 10 ppm, 200 (Table 2.5.3).
From the 9th month onwards, palpable abdominal masses were 
detected in mice fed 10 ppm. These mice were killed when the enlarge­
ment was considered to be detrimental to their health. Thus, 50% of 
the mice fed dieldrin at 10 ppm were dead at 15 months and 50% in the 
other groups were at 20 months (Walker et al 1972).
There was a statistically significant and dose-related increase 
in liver tumors in dieldrin-exposed mice, in both sexes independently. 
The increase was significant in female mice even at 0.1 ppm (Table
2.5.3). Liver tumors also appeared earlier in the mice fed dieldrin 
than in control mice (Gross 1974). The liver tumors were classified 
into two types, "a" and "b," on the basis of their morphology (Walker 
et at 1972, Thorpe 1974). Type a tumors were described as nodular 
growths of solid cords of parenchymal cells, whereas type b tumors 
were papilliform and adenpid growths with cells proliferating in 
confluent sheets with necrosis and increased mitoses. Reuber (1974,
1976) pointed out that this morphologic classification does not 
correspond to the morphologic and biologic behavior of lesions of the 
liver in mice and rats. Whereas type b tumors were clearly malignant 
on biologic and morphologic criteria, type a tumors ranged from 
histologically well-differentiated hepatocellular carcinomas to 
hyperplastic nodules (Reuber 1974, 1976; Epstein 1975). Lung metastases 
were observed from 12/138 type b tumors (Walker et al 1972). Successful
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TABLE 2.5.2 
LIVER TUMORS IN MICE IN FDA STUDIES 2 AND 3
Group No. Examined Av. Survival % Incidence of Liver Lesions*
(and sex) (weeks) NH H N SC LC TC
Control (M) 73 89 40 12 18 18 12 30
Control (F) 53 93 72 11 13 2 2 4
Aldrin (M) 91 86 1 3 13 21 62 82
Aldrin (F) 85 80 1 6 8 29 55 85
Dieldrin (M) 71 91 0 3 10 17 70 87
Dieldrin (F) 71 81 0 4 8 21 66 87
*NH = no hyperplasia, H = hyperplasia, N = nodules, SC = small 
carcinomas (less than 5 mm), LC = large carcinomas, TC = total 
carcinomas
Adapted from Reuber 1974, Epstein 1975
transplantation of tumor tissue to unrelated mice provided further 
confirmation of malignancy (Thorpe 1974).
In Tunstall experiment 1 the incidences of pulmonary adenomas and 
pulmonary carcinomas in males and females exposed to dieldrin at 0.1 and 
1 ppm were increased above those in controls (Table 2.5.3). The 
differences were statistically significant in females (Gross 1974, 
Epstein 1975). Although Stevenson (1974) presented revised data listing 
more females without tumors, the increased incidence of lung tumors 
remained statistically significant in both sexes combined (Gross 1974). 
The increased incidence of lung tumors was also significant in the
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RESULTS OF TUNSTALL EXPERIMENT 1 IN CF1 MICE
TABLE 2.5.3
Dose
(ppm)
No. of 
Mice % with 
(Type
Liver Tumors 
a/Type b)
% with 
Lung 
Metastases
% with Lung 
Tumors*
A C
% with 
Lymphoid 
Tumors
% with 
Other 
Tumors
Males
0 288 20 (16/4) 0.7 33 8 35 6
0.1 124 26 (22/4) 0.8 38 11 21 3
1.0 111 31 (23/8) 0.4 38 12 20 5
10.0 176 94 (37/57) 0.6 18 1 24 2
Females
0 297 13 (13/0) 0 16 6 40 7
0.1 90 27 (23/4) 0 26 13 50 9
1.0 87 37 (31/6) 1.1 34 14 54 17
10.0 148 92 (37/55) 4.5 10 0 5 1
*A = adenomas, C = carcinomas
Adapted from Walker et al 1972, Epstein 1975
subsample of mice without liver tumors (Gross 1974). These statistical 
comparisons omitted the mice fed the diet containing dieldrin at 10 
ppm, because many died or were killed early in the experiment (Gross 1974). 
However, a "relative risk" analysis incorporating data on age at death 
showed a highly significant dose-related increase of lung tumors in 
both sexes independently (Table 2.5.4, Hunt 1974). There were also 
statistically significant increases in lymphoid tumors and in "other" 
tumors in females in the data as originally published (Gross 1974), but 
the differences were not significant according to the revised data 
(Hunt 1974).
2.5.3 Tunstall Experimental Series 2 in CF1 Mice
The Tunstall experimental series 2 (Walker et al 1972) comprised 
six independent tests, each with its own controls but involving smaller 
numbers of animals (10-33 mice per treated group) than experiment 1.
Study 2.1 was a dose-response experiment in which mice were exposed to 
dieldrin at dietary concentrations of 1.25, 2.5, 5, 10, and 20 ppm.
Study 2.2 involved three groups exposed to dieldrin at 10 ppm, two of 
which were fed diets sterilized with gamma rays or ethylene oxide.
Study 2.3 compared tumor incidences in groups of mice fed DDT at 50 ppm, 
DDT at 100 ppm, and a mixture of dieldrin at 5 ppm and DDT at 50 ppm.
Study 2.4 compared tumor incidences in mice exposed to dieldrin, beginning 
early in life, for 2, 4, 8, 16, 32, and 64 weeks.
The incidence of liver tumors was significantly increased in both 
males and females independently in each of the six experiments (Tables
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TABLE 2.5.4
SUMMARY OF CHI-SQUARE VALUES FROM RELATIVE RISK 
ANALYSIS OF TUMOR INCIDENCE IN TUNSTALL EXPERIMENTS
Tumors Experiment
1 2.1 2.2a 2.2b 2.2c 4
(df=3) (df=5) (df=l) (df=l) (df=l) (df=l)
Male Mice
Liver, type a 210* 90.2* 18.4* 9.4* 9.0* 3.1*
Liver, type b 535* 93.5* 6.2* 6.0* 5.1* 29.7*
Liver, total 725* 143* 28.3* 19.5* 16.1* 37.3*
Lung, benign 31.8* 4.89 3.8* 0.1 0.7 0.1
Lung, malignant 6.83 - — - - 0.0
Lung, total 30. 2* 3.03 3.8* 0.1 0.8 0.0
Female Mice
Liver, type a 261* 113* 11.0* 22.3* 18.2* 0.3
Liver, type b 547* 45.1* 9.8* 2.1 7.1* 66. 0*
Liver, total 807* 165* 24.5* 26.9* 28.5* 56.5*
Lung, benign 27.5* 5.37 1.8 - 4.6* 1.7
Lung, malignant 2.82 - - - - 0.0
Lung, total 21.2* 6.38 1.1 1.0 4.6* 0.9
*Statistically significant (P less than 0.05); df = degrees of freedom
Note: Data for experiment 3 not included, because the statistical
analysis included data on other chemicals
Adapted from Hunt 1974
2.5.4 and 2.5.5, Walker et al 1972, Epstein 1975). In study 2.1, the 
increase was uniformly dose-related in both sexes when allowance was 
made for age at death (Hunt 1974). In study 2.3, there was evidence for 
synergistic action of dieldrin and DDT (Table 2.5.5). In study 2.4, 
liver tumor incidence was increased even in animals exposed for only 8, 
4, or 2 weeks (Table 2.5.6). In addition, the age-adjusted incidence of
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lung tumors was increased in 10 of 12 groups exposed to dieldrin, the 
increase being statistically significant in males in Study 2.2a and in 
females in Studies 2.2c and 3 (Table 2.5.4). The age-adjusted incidence of 
other tumors was statistically significantly increased in females m  
Study 2.4 (Hunt 1974).
TABLE 2.5.5
LIVER LESIONS* IN MICE IN TUNSTALL EXPERIMENT 2.3
Dietary No. and Sex of
Exposure Mice Examined % Incidence of Liver Lesions**
NH H N SC LC TC
Control 45 M 62 29 9 0 0 0
Control 32 F 47 44 9 0 0 0
DDT at 50 ppm 31 M 31 34 28 6 0 6
DDT at 50 ppm 31 F 32 16 35 13 3 16
DDT at 50 ppm and
Dieldrin at 5 ppm 33 M 3 18 21 15 42 58
DDT at 50 ppm and
Dieldrin at 5 ppm 31 F 0 0 6 29 65 94
* Diagnosed by Reuber (1974)
** NH = no hyperplasia, H = hyperplasia, N = nodules, SC = small 
carcinomas (less than 5 mm), LC = large carcinomas, TC = total 
carcinomas
Adapted from Epstein 1975
2.5.4 Tunstall Experiment 3 in CF1 Mice
In Tunstall experiment 3, CF1 mice were exposed, beginning at 
4 weeks, to dieldrin in the diet at one concentration, 10 ppm. Relatively 
few mice were used. Mice were not killed when abdominal masses became 
large, but were if they became moribund. Mice surviving to 110 weeks 
were killed then (Thorpe and Walker 1973).
TABLE 2.5.6
INCIDENCE OF LIVER TUMORS IN MICE EXPOSED TO 
DIELDRIN FOR DURATIONS OF 2-64 WEEKS
Duration No. of Mice with
of Feeding No. of Mice Liver Tumors
(weeks) (Type a/Type b)
M F M F
0 18 16 2/0 1/0
2 13 9 2/0 2/0
4 10 12 0/1 3/1
8 10 12 3/1 4/0
16 11 8 4/0 3/0
32 10 10 4/0 4/0
64 13 9 6/7 6/2
Adapted from Walker et al 1972, Epstein 1975
The incidence of liver tumors was increased significantly in treated 
mice of both sexes (Table 2.5.7), and the tumors occurred significantly 
earlier in treated mice than in controls (Thorpe and Walker 1973, Epstein 
1975). The incidence of pulmonary metastases was much higher than in 
Studies 1 and 2 (Table 2.5.7), presumably because the animals were not 
killed prematurely (Epstein 1975) . The age-adjusted incidence of lung 
tumors was increased in females, but not significantly (Hunt 1974).
2.5.5 Tunstall Experiment 4 in Three Strains of Mice
In Tunstall experiment 4, the effects of exposure to dieldrin at 
10 ppm were compared m  CF1 mice, in LACG mice, and in hybrids of the 
two strains (Stevenson 1974, Thorpe 1974, Hunt 1974) . Forty mice of 
each sex were used in each treatment group, with groups of 60 controls.
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The age-adjusted incidence of liver tumors was highly significantly 
increased in all six treated groups (Table 2.5.4, Hunt 1974). The 
incidence of lung tumors was also increased in all six treated groups, 
although not significantly so in any one considered alone (Hunt 1974) . 
However, the incidence of other tumors was significantly increased in 
treated female CF1 mice (Hunt 1974).
TABLE 2.5.7
INCIDENCE OF LIVER TUMORS IN MICE IN TUNSTALL 
EXPERIMENT 3
No. of % with Liver % with Lung
Group Mice Tumors Metastases
(Type a/Type b)
Males
Control 45 24 (20/4) 0
10 ppm 30 100 (47/53) 3
Females
Control 44 23 (23/0) 0
10 ppm 30 87 (40/47) 17
Adapted from Thorpe and Walker 1973
2.5.6 University of Miami Study with Swiss-Webster Mice
Four hundred Swiss-Webster mice were exposed to dieldrin at 3 or 
10 ppm in the diet, with appropriate controls (MacDonald et al 1972). 
The death rate was high because of fighting and amyloidosis, and the 
mean lifespan of the males was only 12-13 months. There was a marked 
increase m  liver lesions in the treated groups. The lesions were 
originally reported as "nodulation or restorative hyperplasia," but a
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number of these diagnoses were later amended to hepatocellular 
carcinomas (MacDonald et al 1973 addendum). Diagnoses as carcinomas 
were confirmed on representative slides by Reuber (1974) and other 
pathologists, as reviewed by Epstein (1975).
2.5.7 NCI Study with B6C3F1 Mice
The National Cancer Institute recently reported the results of 
a bioassay of technical aldrin and technical dieldrin for carcinogenicity 
in B6C3F1 mice (NCI 1978a). Groups of 50 mice of each sex were fed diets 
containing aldrin or dieldrin for 80 weeks, then observed for 10-13 weeks. 
The time-weighted average dietary concentrations of aldrin were 4 and 8 
ppm for males and 3 and 6 ppm for females; dieldrin was fed at 2.5 and 
5 ppm. Untreated matched controls were groups of 20 untreated male and 
10 female mice. Pooled control groups, used for statistical evaluation, 
consisted of the matched controls combined with 92 untreated male and 
79 untreated female mice from similar bioassays of other chemicals.
All surviving mice were killed at 90-93 weeks.
The mice fed aldrin or dieldrin and the control mice had similar 
mean body weights. Hyperexcitability was observed in all treated groups 
with increasing frequency during the 2nd year of the study. Female 
mice fed aldrin showed a dose-related increase in mortality.
There was a significant dose-related increase in the incidence 
of hepatocellular carcinomas in male mice fed either chemical (matched 
controls 3/20, pooled controls 17/92, low-dose aldrin 16/49, high- 
dose aldrin 25/45, low-dose dieldrin 12/50, high-dose dieldrin 16/45).
The incidence of hepatocellular carcinomas in females was higher in
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all the exposed groups than in controls, but the differences were 
not statistically significant. No other tumors appeared at a 
significantly higher frequency in the exposed groups than in the 
controls.
2.5.8 NCI Study of B6C3F1 Mice Exposed to Photodieldrin
The National Cancer Institute has also reported the results of a 
bioassay of photodieldrin (recrystallized and without detectable residual 
dieldrin) for carcinogenicity in B6C3F1 mice (NCI 1977) . Groups of 50 
mice of each sex were fed diets containing photodieldrin at concentrations 
of 0.32 and 0.64 ppm for 80 weeks, then observed for 10-13 weeks.
Matched controls were 10 untreated mice of each sex at each dose; pooled 
controls groups consisted of 60 untreated mice of each sex.
Convulsions and hyperactivity were noted in exposed male mice, 
but body weights and mortality were unaffected by exposure to photo­
dieldrin. Exposed mice and controls showed no statistically significant 
differences in tumor incidence.
2.5.9 FDA Experiment 1 and 2 with Osborne-Mendel Rats
In the FDA experiment 1, initiated at the U.S. Food and Drug 
Administration (FDA) in 1952 but not published until 1964, 12 groups 
of 12 male and 12 female Osborne-Mendel rats were fed diets containing 
aldrin or dieldrin at 6 concentrations, from 0.5 to 150 ppm (Fitzhugh 
et al 1964). Exposure began at 3 weeks and continued until mice 
surviving after 2 years were killed. Twelve rats of each sex were 
controls. Only 68% (227/336) of the animals, including only 17/24
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controls, were examined histologically. The many small groups of 
animals makes the experiment difficult to analyze with statistical 
rigor.
The exposed rats could be classified into two groups (Table 
2.5.8). Those exposed to aldrin or dieldrin at high dietary con­
centrations (50-150 ppm) showed a dose-related decrease in survival, 
acute renal necrosis, chronic nephritis, and a high incidence of liver 
lesions (Fitzhugh et al 1964, Reuber 1974, Epstein 1975). Rats exposed 
to aldrin or dieldrin at lower concentrations (0.5-10 ppm) survived 
well and had a low incidence of liver and kidney lesions but a higher 
incidence than controls of tumors in other organs, primarily the 
lymphatic system and mammary glands (Fitzhugh et al 1964, Reuber 1974, 
Epstein 1975, Thorpe 1974). The increase in tumor incidence in the 
rats exposed at low concentrations is statistically significant if groups 
are pooled (Gross 1974, Hunt 1974). The increase m  liver lesions is also 
statistically significant (Gross 1974, Epstein 1975), but the pathologic 
diagnoses have been disputed vigorously. Reuber (1974) diagnosed 18 
hepatocellular carcinomas in exposed animals, whereas other 
pathologists diagnosed most of the lesions as hyperplastic nodules 
or even milder lesions (Thorpe 1974, Sternberg 1974). In the 
terminology of the Liver Cancer Workshop (Squire and Levitt 1975) most 
of the lesions would be classified as neoplastic nodules.
In a second experiment conducted at FDA m  1963, 43 Osborne-Mendel 
rats were exposed to dieldrin at 1 ppm for 2 years. There were 39 controls. 
The results were similar to those for the groups at the lower concentrations
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TABLE 2.5.8
GROSS AND MICROSCOPIC PATHOLOGY OF SOME RATS IN FDA EXPERIMENT 1
Dietary Number Urinary
Exposure Sectioned Nephritis* Bladder** No. of Rats with Tumors***
(ppm) 0 <S M&S >M Dis Hem A B C D E F Total
Control (0) 17 5 5 6 1 0 0 1 1 0 0 0 1 3
Aldrin
0.5 19 3 10 4 2 0 0 5 3 2 3 0 1 10
2 19 4 8 4 3 0 0 2 3 2 0 0 0 7
10 22 3 10 8 1 0 0 2 3 0 0 2 2 8
50 18 8 7 1 2 2 1 2 3 0 0 0 0 5
100 11 1 2 4 5 3 2 4 0 0 1 0 0 5
150 9 1 3 3 2 4 2 1 0 0 0 0 0 1
Dieldrin
0.5 22 5 9 5 3 1 0 4 1 1 1 0 2 8
2 23 9 8 6 0 1 0 2 4 0 0 1 2 8
10 18 5 6 6 1 1 0 2 0 1 0 1 0 4
50 20 5 6 6 3 0 0 1 2 0 0 0 1 4
100 18 5 3 2 8 2 1 0 0 0 1 0 2 3
150 11 1 2 7 1 2 2 0 0 0 0 0 0 0
*S = slight, M = moderate; based on microscopic sections except one markedly damaged kidney 
based on gross appearance only in the 100 ppm aldrin group 
**Dis = distended, Hem = hemorrhagic
***A = pulmonary lymphosarcoma, B = fibroadenoma of breast, C = carcinoma of breast, D = 
lymphoid except lung, E = fibrosarcoma, F = other
Adapted from Fitzhugh et al 1964
in experiment 1, in that there was a statistically significant increase in 
lung and other tumors in males and a small incidence of liver lesions of 
disputed significance (Reuber 1974, Epstein 1975, Thorpe 1974).
2.5.10 Tunstall Experiment with CFE Rats
Groups of 25 male and 25 female CFE strain rats were fed diets 
containing recrystallized dieldrin added at concentrations of 0.1, 1, 
and 10 ppm. Exposure began at 5 weeks of age and continued for 2 years.
A control group of 45 animals of each sex was fed a diet containing 
dieldrin at 0.026 ppm. The results of the experiment as originally 
reported (Walker et al 1969) are summarized in Table 2.5.9. Subsequently, 
revised data have been reported (Stevenson et al 1976) . There was an 
increase in tumor incidence, primarily in the thyroid and mammary glands, 
in the females exposed at 0.1 and 1 ppm. This increase was of marginal 
statistical significance in the pooled groups (Gross 1974, Epstein 1975).
With the revised data the difference was statistically significant in a 
conventional analysis but not in an actuarial analysis (Stevenson et al 1975). 
There was no increase in tumor incidence in rats of either sex fed diets 
containing dieldrin at 10 ppm.
2.5.11 NCI Experiment with Aldrin and Dieldrin in Osborne-Mendel Rats 
The National Cancer Institute recently reported the results of a
bioassay of technical aldrin and technical dieldrin for carcinogenicity 
in Osborne-Mendel rats (NCI 1978a). Groups of 50 rats of each sex were 
fed diets containing aldrin or dieldrin at one of two concentrations for 
59-80 weeks and were then observed for an additional 30-52 weeks. The 
dietary concentrations of aldrin were 30 and 60 ppm, and the time-
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TABLE 2.5.9 
TUMORS IN RATS FED DIELDRIN FOR 2 YEARS
Dietary No. of No. of Rats % Tumor
Concentration Rats  Tumors______________ with Tumors Incidence
(ppm) Thyroid Pituitary Mammary Other
Males
0.026 43 3 2 1 6 12 28
0.1 23 2 2 - 2 6 26
1.0 23 2 1 - 3 5 22
10.0 23 4 2 2 8 35
Females
0.026 43 3 2 13 3 19 44
0.1 23 6 1 11 2 15 . 65
1.0 23 4 1 10 4 14 61
10.0 23 3 2 8 - 12 52
Adapted from Walker et al 1969
weighted average dietary concentrations of dieldrin were 29 and 65 ppm. 
Matched control groups were 10 untreated rats of each sex; pooled controls, 
used for statistical evaluation, consisted of the matched-control groups 
combined with 58 untreated males and 60 untreated females from similar 
bioassays of other chemicals. All surviving rats were killed at 111- 
113 weeks.
Hyperexcitability was observed in all exposed groups with increasing 
frequency and severity during the 2nd year. Rats fed dieldrin had a 
higher death rate than controls during the first 90 weeks of the experiment. 
During the 2nd year, the mean body weights of rats fed either aldrin or 
dieldrin were lower than those of the controls. Rats fed aldrin had an 
increased incidence of thyroid tumors, including follicular-cell adenoma 
and carcinoma. In males, the incidences were 4/48 for pooled controls,
14/38 at the low dose, and 8/38 at the high dose; in females, they were 
3/52 for pooled controls, 10/39 at the low dose, and 7/46 at the high 
dose. The increases were statistically significant in the males (P=0.001) 
and the females (P=0.009) at the low dose but not in either high dose 
group. There was also an increased incidence of adrenal cortical adenomas 
in exposed females (pooled controls 0/55, low dose 8/45, high dose 
1/48), which was also statistically significant in the rats at the 
low dose (P=0.001) but not in those at the high dose. In the males, a 
significant increase in pancreatic islet tumors occurred at the low dose 
(P=0.043) but not at the high dose.
Female rats fed dieldrin had an increased incidence of adrenal 
cortical tumors (adenoma or carcinoma). The incidences were 0/55 in
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pooled controls, 6/45 at the low dose, and 2/40 at the high dose.
As in rats fed aldrin, this increase was statistically significant 
in the rats at the low dose (P=0.007) but not in those at the high 
dose. There was also a statistically significant (P=0.030) dose-related 
increase in incidence of thyroid tumors in females.
2.5.12 NCI Experiment with Dieldrin in Fischer Rats
The National Cancer Institute also reported the results of a 
bioassay of recrystallized dieldrin for carcinogenicity in Fisher 344 
rats (NCI 1978b). Groups of 24 rats of each sex were fed diets 
containing dieldrin at concentrations of 2, 10, and 50 ppm for 104- 
105 weeks. Matched control groups consisted of 24 untreated rats of 
each sex. All surviving rats were killed at 104-105 weeks.
The body weights of the exposed rats were essentially unaffected, 
but hyperexcitability, tremors, and coma were observed beginning in the 76th 
week in males at the high dose and in the 80th week in females at the 
high dose. Survival was not adversely affected by exposure.
There was no statistically significant differences in the tumor 
incidences in exposed rats and the controls; however, the thyroid and 
adrenal glands of the exposed rats were not examined histopathologically 
in this study.
2.5.13 NCI Experiment with Osborne-Mendel Rats Exposed to Photodieldrin 
The National Cancer Institute also reported the results of a
bioassay of photodieldrin for carcinogenicity in Osborne-Mendel rats 
(NCI 1977). The photodieldrin was recrystallized and contained no 
detectable residual dieldrin. Groups of 50 rats of each sex were fed
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diets containing photodieldrin for 80 weeks and then observed for an 
additional 31-32 weeks. Male rats received photodieldrin at 5 and 
10 ppm; the time-weighted average dietary concentrations for females 
were 3.4 and 7.5 ppm. Matched control groups were 10 untreated rats 
of each sex; pooled control groups, used for statistical evaluation, 
consisted of the matched controls combined with 65 untreated rats of 
each sex from other similarly conducted bioassays.
Convulsions and hyperactivity were noted in exposed rats of both 
sexes, but mortality and body weights were unaffected. The incidence of 
tumors of several types (mammary tumors and thyroid tumors in females 
and multiple-site hemangiomas in males) was higher in exposed rats than 
in controls. However, these increases were only marginally statistically 
significant and were considered not clearly associated with exposure to 
photodieldrin (NCI 1977).
2.5.14 Other Experiments
Several other long-term feeding experiments in mammals have been 
reported but are of little value as carcinogenicity tests because of 
defects in methodology or reporting (Epstein 1975, IARC 1974). Song 
and Harville (1964) reported neoplastic effects in mice and rats 
exposed to aldrin and dieldrin at high doses for short periods, but 
did not provide details. Treon and Cleveland (1955) and Cleveland 
(1966) referred to tests with aldrin and dieldrin in rats, but the 
data published were somewhat conflicting and were insufficient for 
evaluation. Deichmann et al (1967) reported a study with aldrin in 
rats exposed at 5 ppm. Deichmann et al (1970) fed rats aldrin and
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dieldrin at 20, 30, and 50 ppm in the diet and reported a significant 
reduction in tumor incidence, but the lifespan in the exposed groups 
was markedly reduced and the data given were insufficent for 
estimating relative risks. Epstein (1975) also reviewed three studies 
with dogs exposed to aldrin and dieldrin for up to 2 years and one 
study with rhesus monkeys exposed to dieldrin for up to 6 years, but 
these studies are too short in relation to the lifespan of the animals 
to be acceptable carcinogenicity tests (IARC 1974) .
2.6 Mutagenesis and Related Cytotoxic Effects
Bidwell et al (1975) conducted a comprehensive evaluation of the 
mutagenic potential of dieldrin, but the results have been reported 
only in abstract form. They used direct bacterial tests with and 
without microsomal activation, a host-mediated assay, analyses of 
blood and urine for active metabolites, a micronuclei test, metaphase 
analysis, a dominant lethal assay, and a heritable translocation test. 
In most of the tests with mammals, dieldrin was administered by gavage 
on a "sub-acute basis " at 0.08, 0.8, and 8 mg/kg in corn oil. The 
authors' overall evaluation of the data from mice was that dieldrin 
was negative for mutagenicity in all tests. Dieldrin did not increase 
the number of mutants in five tests with Salmonella, including excision 
repair-deficient mutants and frame-shift and base-analogue detection 
strains.
Dean et al (1975) repor-*-"^  the results of three tests of the 
mutagenic potential of recrystallized dieldrin. In a dominant lethal 
assay with mice, dieldrin gave marginally positive results in one
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experiment, in that the number of fetal implantations in female mice 
mated with males given dieldrin at 12.5 or 25 mg/kg was significantly 
reduced in the lst-3rd weeks after dosing, although the number of 
early fetal deaths was not increased. These results were not dupli­
cated in a second experiment, in which the number of fetal implantations 
was increased in all three treatment groups. The test system seems 
to have been insensitive, because a positive control substance 
(cyclophosphamide) produced small effects even at 100 mg/kg. Dieldrin 
at 30 or 60 mg/kg caused a nonsignificant decrease in polyploidy in 
bone marrow cells from Chinese hamsters and no increase in chromatid 
gaps. In a host-mediated assay, dieldrin induced no changes in the 
rate of mitotic gene conversion in Saccharomyces cerevisiae (strain 
D4) when it was administered to mice in single doses of 25 and 50 mg/kg 
or repeated doses of 0.2, 5, and 10 mg/kg/day. However, the positive 
control (ethyl methanesulfonate of 400 mg/kg) produced only a slight 
increase in the rate of gene conversion.
McCann et al (1975) and McCann and Ames (1976) reported that 
dieldrin gave negative results for mutagenicity in the reversion bio­
assay with Salmonella typhimurium strains TA 1535, TA 1536, TA 98, and 
TA 100, both with and without activation by rat liver microsomal pre­
parations (S-9). Van Dijck and van de Voorde (1976) similarly reported 
that aldrin and dieldrin were negative in this bioassay with activation 
by mouse liver microsomes. Marshall et al (1976) reported that dieldrin 
was not mutagenic in the S typhimurium bioassay, with or without 
rat liver microsomal homogenates. They used four strains of
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S typhimurium: TA 1535, TA 1536, TA 1537, and TA 1538. They did not use
the more sensitive strains, TA 98 and TA 100. Shirasu et al (1976) also 
reported that aldrin and dieldrin were negative for mutagenicity in the 
four strains of S typhimurium used by Marshall et al and in two 
tryptophaneless strains of E coli, but they did not use microsomal 
activation. They also reported that aldrin and dieldrin were negative 
for mutagenicity m  recombination assays with Bacillus subtilis strains 
HI7 Rec+ and M45 Rec-.
Swenberg et al (1976) found negative results for dieldrin m  
an in vitro alkaline elution assay for DNA damage in Chinese hamster 
(V79) cell culture with rat liver microsomal activation. Both McCann 
and Ames (1976) and Swenberg et al (1976) interpreted the results with 
dieldrin as "false negatives," because the systems used m  their ex­
periments otherwise usually give positive results with carcinogens.
In contrast to the negative results summarized above, a number 
of investigators have reported positive results for aldrin and dieldrin 
m  other bioassay systems. Majumdar et al (1976) reported that recrys­
tallized dieldrin caused chromosome damage in bone marrow cells of mice 
in vivo and in human embryonic lung cells in vitro. Single mtraperitoneal 
injections of dieldrin at 1, 30, and 50 mg/kg into STS mice caused pronounced 
mitotic inhibition and produced twofold to sixfold increases in chromosome 
abnormalities, primarily breaks and fragments, in bone marrow cells; these 
changes were statistically significant even at the lowest dose. At 1, 10, 
and 30 yg/ml, dieldrin caused similar effects in human lung cell cultures 
(WI-38) m  vitro. The chemical also produced chromosomal interchanges
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and rings. Cytotoxic studies using the WI-38 cell line revealed dose- 
response and time-response reactions to dieldrin.
Ahmed (1975) and Ahmed et al (1977) reported that aldrin and 
dieldrin, with rat liver microsomal activation, induced unscheduled DNA 
repair in human fibroblasts (VA-4) transformed by the SV-40 virus. The 
kinetics of dieldrin-induced damage and repair were studied through 
incorporation of bromodeoxyuridine into the damaged regions. Dieldrin also 
increased the mutation frequency in vitro of spontaneously transformed 
Chinese hamster cells (V79) to ouabain-resistant mutants.
Georgian (1975) found that aldrin induced chromosome aberrations 
in human lymphocyte cultures in vitro and in bone marrow cells of rats 
and mice exposed in vivo. Dose-response relationships were observed 
m  both bioassays. In the lymphocyte bioassay, aldrin showed a narrow 
range of doses causing chromosomal changes, between 19 and 38 pg/ml, 
close to the cytotoxic concentrations. In the m  vivo rodent bioassays 
the minimal dose inducing chromosomal aberrations was 19 mg/kg (single 
dose ip). No effects were observed at 9.6 mg/kg.
Markaryan (1966) reported that dieldrin administered to mice 
caused mitotic inhibition and a variety of chromosomal aberrations, 
including significant increases in the incidence of breaks, fragments, 
chromosome and chromatid bridges, and stickiness, but not of trans­
locations or dicentrics. Guerzoni et al (1976) detected mutagenic 
activity on S cerevisiae by aldrin at 5 and 50 ppm.
Bunch and Low (1973) fed technical dieldrin at dietary concentra­
tions of 4, 10, and 30 ppm to mallard ducks for 60 days and examined
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bone marrow cell cultures from the ducks' offspring. No significant 
increase in chromosomal aberrations was observed, but dieldrin at 30 
ppm caused a significant reduction in the rate of mitosis. Duck 
lymphocyte cultures exposed to dieldrin at 100 ppm showed a significant 
increase in the incidence of chromosomal aberrations, including gaps 
and breaks. Mitotic indices were significantly reduced at all dieldrin 
concentrations down to 0.1 ppm.
Walker et al (1977) reported that recrystallized dieldrin markedly 
inhibited incorporation of amino acid precursors of DNA, RNA, and protein 
into Ehrlich ascites tumor cells in vitro. Effects on incorporation 
of thymidine and uridine were marked at concentrations as low as 
10”%  (0.4 ppm). Daily injections of dieldrin at 1.5 mg/kg for 5 days 
into mice inhibited the growth of Ehrlich ascites tumor cells in vivo. 
Chung et al (1967) had earlier reported inconsistent effects of 
dieldrin on the synthesis of DNA, RNA, and protein in HeLa cells.
Sheinman and Yannai (1974) reported that dieldrin, at concentrations 
as low as 25 pg/ml, was toxic to rat fetal liver primary culture 
cells and human kidney cell line B in vitro. Observed morphologic 
changes included granulation and shrinkage of the cytoplasm, formation 
of long and narrow cytoplasmic projections, and the appearance of 
giant cells.
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3. Human Effects
3.1 Clinical and Case Reports
Aldrin and dieldrin, particularly in oil solution, are readily 
absorbed through the skin, the respiratory mucosa, and the gastrointestinal 
tract (Hayes 1963) . Untoward symptoms in humans are known to result from 
oral doses as small as 10 mg/kg (Committee on Toxicology 1960, Hayes 1963, 
Jager 1970) . The acute median lethal dose by the oral route lies between 
20 and 95 mg/kg in various mammals (Table 2.1.1) and presumably lies in 
the same range in humans (Committee on Toxicology 1960, Hodge et al 1967). 
Several human deaths have been ascribed to ingestion of dieldrin, but no 
reliable information about doses is available (Committee on Toxicology 
1960, Hayes 1963, Pribilla 1963, Weinig et al 1966, Preda et al 1963,
Jager 1970, Symanski 1970, Gupta 1975). When a toxic dose of aldrin or 
dieldrin has been ingested or has contaminated the skin, a more or less 
typical syndrome appeared from 20 minutes to 24 hours afterwards. In 
all cases the principal site of action was the central nervous system, 
and the principal sign was a series of convulsions. The convulsions were 
self-remitting but recurred with increasing severity, characteristically 
alternating with periods of severe depression (Princi 1957; Hayes 1957, 
1963; Bell 1960; Hoogendam et al 1962, 1965; Kazantzis et al 1964; Jager 
1970).
Convulsions induced by the cyclodiene insecticides may be preceded 
by subjective complaints, but frequently they occurred with no forewarning 
or prodromal signs or symptoms (Hoogendam et al 1962). Abnormalities of 
the EEG, such as bilateral synchronous theta wave activity and occasional
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bilateral synchronous spike and wave complexes, have been seen in patients 
without clinical illness both before and after convulsion (Kazantzis et 
at 1964). Myoclonia indicates that a convulsive episode is imminent. 
Prodromal signs that have been reported include headache, visual 
disturbances, dizziness, sweating, insomnia, nausea, and malaise. 
Convulsions are accompanied by loss of consciousness and "frothing at 
the mouth" but not incontinence (Hayes 1957, Patel and Rao 1958).
Death may result from anoxemia (Princi 1957; Hayes 1963; Hoogendam 
et al 1962, 1965). The interval between oral intake or skin contact 
and the onset of symptoms, as well as the clinical picture, depend 
on the dose absorbed.
Many cases of aldrin and dieldrin poisoning have been described 
in the medical literature. In 1951, Spiotta described a case of acute 
convulsive aldrin poisoning in a 23-year-old man who ingested an aldrin 
emulsifiable concentrate in an attempted suicide. The man had convulsions 
accompanied by typical EEG changes but completely recovered.
Other investigators also reported epileptiform convulsions and 
EEG abnormalities. Drowsiness, lack of appetite, headache, and "prickly 
sensation of the skin" were reported in a man who had been previously 
exposed to dieldrin and became ill when his reducing diet resulted in 
mobilization of fat and release of the pesticide into the blood (Paul 
1959). Disturbed sleep rhythm and manic and irrational behavior have 
been reported as sequelae (Fry 1964). Other autonomic manifestations 
have also been described (Gowdey and Stavraky 1955).
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Garrettson and Curley (1969) reported that in a 4-year-old child 
accidentally poisoned via oral ingestion EEG abnormalities declined 
gradually over a 6-month period, paralleling the decline of dieldrin 
concentrations in serum. However, dieldrin residues in fat remained 
high for .at least 8 months despite treatment with anticonvulsants.
In contrast to the phenomena observed after acute poisonings, 
after repeated exposures several spraymen developed a syndrome 
indistinguishable from idiopathic epilepsy, except that it ceased 
when the exposure was terminated (Hayes 1957). Myoclonic jerks and 
major motor seizures were reported in humans and animals exposed for 
6-12 months to aldrin and BHC in contaminated flour; two persons died 
(Gupta 1975). A motor polyneuropathy resembling the Guillain-Barre 
syndrome is a rare complication of exposure (Jenkins and Toole 1964) .
In the usual acute intoxication, recovery is complete or well advanced 
within 24 hours, but animal experiments and clinical experience (Hayes 
1957, Patel and Rao 1958) indicate the possibility of seizures for many 
days after a single dose or repeated doses. EEG anomalies may persist 
for days after apparent clinical recovery (Hoogendam et al 1962).
Transient kidney damage has been reported in some acute poisoning 
cases (Spiotta 1951, Jacobs and Lurie 1967, Nelson 1953, Committee on 
Toxicology 1960). Liver damage has also been reported, in one case 
persisting for more than 1 year (Committee on Toxicology I960, Garrettson 
and Curley 1969).
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In animals the percutaneous toxicity of dieldrin is almost as high 
as its oral toxicity (see Section 2.1.2). Dermal exposure usually results 
in systemic poisoning, without skin irritation or local sensitization 
except secondary to the solvent or vehicle, which is usually kerosene 
or xylene (Bundren et al 1952). However, Ross (1964) reported an incident 
of nonspecific dermatitis occurring on the legs of 288 police officers who 
wore wool socks impregnated with dieldrin as a mothproofing agent.
Nelson (1953) and D'Eramo and Croce (1960) also reported contact 
dermatitis caused by aldrin. In addition, skin diseases such as 
scleroderma may facilitate cutaneous absorption of dieldrin, resulting 
in systemic poisoning (Starr and Clifford 1971).
One case of suicide by intravenous injection has been reported 
(Schwar 1965).
3.2 Studies in Volunteers
A 2-year study of volunteers with measured exposure to dieldrin 
was conducted with the primary purpose of studying the pharmacokinetics 
of dieldrin in men (Hunter et al 1967, 1969). The subjects were 13 
healthy men, aged 21-52 years, with no history of recent occupational 
exposure to pesticides. Four groups of three or four men were given 
recrystallized dieldrin (99% HEOD) in gelatin capsules daily for 2 
years at doses of 0, 10, 50 and 211 pg dieldrin/day. Added to the 
normal dietary intake from background contamination, this increased 
the daily intakes to approximately 14, 24, 64, and 225 pg/day, respec­
tively. In addition to measurements of dieldrin concentrations in 
blood and fat, which were summarized in Section 1.5.4, urinalysis,
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EEG studies, polygraphic recording of cardiorespiratory function, 
electromyographic studies, and blood chemistry, including estimation 
of blood plasma protein and urea, activity of plasma alkaline 
phosphatase, SGPT, and SGOT, and cholinesterase activities in 
erythrocytes and plasma, were performed. Full clinical examinations 
were made after 3, 9, 15, 18, and 24 months of exposure. The subjects 
were observed for 8 months after exposure was discontinued.
No changes were observed in any of the measured parameters, and 
no clinical or subjective symptoms attributable to exposure were 
recorded (Hunter et al 1967, 1969) . A preliminary examination of 
the concentrations of p,p'-DDE in the blood of the volunteers (resulting 
from general environmental exposure) did not show any significant decrease 
relative to that of the control group (Jager 1970); such a decrease might 
have occurred if the exposure to dieldrin had significantly increased 
microsomal enzyme activity.
3.3 Studies of Occupationally Exposed Workers
The most extensive studies of occupationally exposed workers are 
those conducted at a manufacturing plant in the Netherlands and summarized 
by Jager (1970). Some followup studies of more highly exposed workers 
were reported by Versteeg and Jager (1973). A total of 826 men worked 
full-time in the plant for various periods between 1955 and 1968. 
Maintenance workers, plant cleaners, and formulators were included in 
this count, as well as operators. The workers were divided as follows:
Group A: 277 workers with exposure shorter than 1 year;
Group B: 316 workers with exposures of 1-4 years;
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Group C: 223 workers with exposures of 4-13.25 years.
Group C was subdivided as follows:
Group C-l: 52 workers who left the company and could not be
contacted for followup;
Group C-2: 75 workers transferred to other plants but still
under medical surveillance;
Group C-3: 106 workers still working in the insecticide plant
and having periodic medical examinations.
Within groups C-2 and C-3 three "extreme exposure" groups were identified: 
Group C-2a: 17 workers transferred because insecticide levels
in their blood exceeded intoxication thresholds;
Group C-2b: 9 workers who had had an episode of insecticide 
intoxication;
Group C-3a: 35 operators with an insecticide exposure of more
than 10 years (through January 1, 1968). Their 
average length of exposure at that time was 11.1 
years.
A number of workers with pre-existing medical disorders, primarily EEG 
changes, skin diseases, mental disturbances, or neurologic diseases, 
were rejected or preventively transferred from insecticide work (Jager
1970).
Although most or all of the workers in the extreme exposure 
group were exposed to aldrin and dieldrin, most were also exposed at 
times to endrin, Telodrin, or to organophosphate insecticides. The
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mean dieldrin level in the blood of the "extreme exposure" group was 
0.039 yg/ml. Those in aldrin/dieldrin workers at the time of exposure 
were in the range 0.022-0.078 pg/ml (Jager 1970).
Of 54 episodes of intoxication in the plant, 23 were attributed 
to aldrin or dieldrin, 15 of which involved convulsive seizures. Only 
a few of these episodes involved Group C workers (Jager 1970) . With 
one exception, aldrin/dieldrin intoxications were not peracute but 
were preceded by prodromi or, in some cases, by a gradual increase of 
dieldrin levels in the blood. The threshold level of dieldrin in 
the blood for overt intoxication was determined to be 0.15-0.20 pg/ml, 
and that for induction of convulsions was about 0.30 ug/ml (Jager 1970).
Except for signs and symptoms of intercurrent diseases not related 
to insecticides and the clear specific signs and symptoms, in some 
cases, of overt poisoning, no abnormalities were observed in the long­
term exposure groups (Jager 1970). Specifically, no increases in liver 
size or enzyme activity (alkaline phosphatase, SGOT, SGPT, LDH) were 
recorded in the extreme exposure groups. EEG patterns generally 
returned to normal after intoxication episodes. Absenteeism due to 
sickness or accident was higher in insecticide workers than in other 
workers in the same plant, but no single type of disease or accident 
was associated with exposure. Through 1973, when a few workers had 
worked in the plant for up to 18 years, two cases of cancer and one 
death had been reported in groups C-2 and C-3 (Jager 1970, Versteeg 
and Jager 1973); this compares with an expected number of three or
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four in a group from the general population with the same age dis­
tribution (Seidman 1974).
In a statistical study, serum alkaline phosphatase and SGOT 
levels were found to increase with insecticide levels in the blood.
This was attributed to "adaptation" of the liver to the chemicals. 
However, it was not established whether the correlation was with 
levels of dieldrin, Telodrin, or both (Jager 1970).
Workers exposed to endrin exhibited a marked increase in 
excretion of 6-beta-hydroxycortisol and a marked decrease in tissue 
storage levels of p,p'-DDE resulting from general environmental 
exposure. Both of these changes are indicative of stimulation of 
liver microsomal enzymes. However, workers exposed to aldrin/dieldrin 
showed no significant changes (Jager 1970). In a subsequent study,
14 aldrin/dieldrin workers showed a statistically significant 
increase over controls in urinary excretion of D-glutaric acid 
(another indirect measure of microsomal enzyme activity); endrin 
workers showed a larger increase (Hunter et al 1972). Dieldrin levels 
in the blood of the workers involved averaged 0.026 pg/ml but were 
not significantly correlated with D-glutaric acid excretion.
Other studies of workers occupationally exposed to aldrin/ 
dieldrin have been considerably less detailed. Fletcher et al (1959) 
observed no clinical poisoning symptoms in spraymen in East Africa 
dermally exposed to dieldrin at 1.8 mg/kg/day. A 2-year study of 
256 spraymen in Arakan, Burma, (dosage not reported) also failed to 
reveal any symptoms of toxicity in workers or household animals exposed
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to the spray (U Than Pe and Venkat Rao 1960). Six workers at a pesti­
cide formulating and packaging plant had aldrin and dieldrin in their 
blood at levels of 10-125 ppb and 100-312 ppb, respectively (Mick et 
at 1971). Although these levels exceed the threshold for intoxication 
identified by Jager (1970), the workers reported no complaints or 
health problems to the company physician. Hayes and Curley (1968) 
studied workers in a manufacturing plant whose exposure (estimated 
from levels in plasma and fat) was estimated to be in the range 0.72 
mg/man/day. They were unable to find a relationship between dieldrin 
exposure and use of sick leave.
According to the AMA's Committee on Toxicology (1960), the 
proportion of workers poisoned in public health spraying programs 
involving the use of dieldrin around the world varied from 2 to 40 
percent, with the proportion of cases involving convulsions ranging 
from 47 to 100 percent. Patel and Rao (1958) reported 20 cases of 
intoxication in 297 workers spraying dieldrin in India. Bllizquez and 
Bianchini (1956) reported 22 cases in workers spraying dieldrin in 
Venezuela. Subsequently 51 cases of poisoning were reported in 285 
workers spraying dieldrin in Venezuela (Committee on Toxicology 1960, 
Hayes 1957; Table 3.3.1). Hayes (1957) listed 13 cases of intoxication, 
including 1 fatality, in 92 spraymen in Ecuador, and 8 cases in 40 spray- 
men in Nigeria. Zavon and Hamman (1961) stated that nine countries 
had reported cases of dieldrin intoxication in spraymen, due pre­
dominantly to gross and continued exposure over a prolonged time 
period. Incidents usually occurred 3-8 months after a sprayman had
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TABLE 3.3.1 
POISONING IN SPRAYMEN EXPOSED TO DIELDRIN*
Duration of
Exposure
(months)
Spraymen Exposed for 
the Specified Duration
Cases of 
No. Poisoning
Total No. of Spraymen 
Exposed for the Specified 
Duration or Longer
Percentage of 
Poisoning in Total 
No. Exposed
0-3.9 69 0 285 0
4-7.9 38 5 216 2
8-11.9 26 9 178 5
12-15.9 54 14 152 9
16-19.9 41 13 98 13
20-23.9 45 4 57 7
21-27.9 7 6 12 50
28-31.9 1 0 5 0
32-35.9 0 0 4 0
36-39.9 4 0 4 0
0-39.9 285 51 285 18
*Under practical working conditions in Venezuela
Adapted from Hayes 1957
started regular use of the pesticide- The spray programs involved
applications of solutions of 0.68-2.5 percent dieldrin to surfaces
at rates of 0.27-1.0 g/m (Hayes 1957). Symptoms reported in studies
of workmen exposed to dieldrin and aldrin for prolonged periods
include dizziness, insomnia, muscle twitching, increased blood pressure,
and electroencephalography (EEG) abnormalities consisting of bilateral
synchronous theta-wave activity and occasional bilateral synchronous
spike and wave complexes (Hayes 1957, Zavon and Hamman 1961, Committee on
*
Toxicology 1960, Blazquez and Bianchini 1956). Removal from exposure 
was followed by reduction or complete loss of EEG abnormalities and 
convulsions, generally within a few months (Hoogendam et al 1962,
1965; Kazantzis et al 1964; Avar and Czegledi-Janko 1970). Hayes 
(1957) also listed the following signs and symptoms in spraymen 
exposed for 30 or more weeks: blurred vision, diplopia, tinnitis,
sweating, difficulty in sleeping and bad dreams, nausea, alteration 
of reflexes, incoordination, nystagmus, and change in personality. 
Blazquez and Bianchini (1956) reported hepatomegaly m  10 of 22 
dieldrin-exposed sparymen, in addition to the symptoms listed by 
Hayes (1957) . In one survey, EEG abnormalities were found in about 
one-third of spraymen not clinically ill (Hayes 1957). Avar and 
Cz£gledi-Janko (1970) reported preconvulsive changes and EEG 
abnormalities in one worker with a concentration of HEOD in the blood 
as low as 0.05 ppm. Prior and Deacon (1969) noted spontaneous sleep in 
otherwise healthy subjects. Nelson (1953) reported contact dematitis
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in workers exposed to 25% aldrin dust, together with "transient bronchial 
complications due to inhalation of concentrated fumes."
Takahashi et al (1976) reported significantly higher C-reactive 
protein levels in the sera of workers chronically exposed to dieldrin 
and pentachlorophenol than in controls. Serum levels of gamma2- 
globulm were significantly associated with concentrations of dieldrin 
in serum. Elevated C-reactive protein levels were considered to indicate 
the presence of tissue inflammation.
In a study of five male farmworkers exposed to a mixture of 
herbicides and pesticides, including dieldrin, four were found to have 
suffered impotence after chronic exposure; sexual function was recovered 
after exposure was terminated (Espir et al 1970). Peck (1970) suggested 
that their exposure to dieldrin might have induced an increased 
metabolism of testosterone that led to a deficiency of this hormone.
Dean et al (1975) found no significant increase in the frequency 
of chromosome abnormalities in lymphocytes from 22 workers occupationally 
exposed to aldrin and dieldrin.
3.4 Epidemiologic Studies in the General Population
A number of epidemiologic searches for health effects associated 
with general uses of aldrin/dieldrin have been conducted in various 
parts of the United States, with generally negative results (USDHEW 
1969). However, such studies are difficult to conduct in the general 
population, ie, m  nonoccupationally exposed persons, because 
residues of dieldrin are widespread in the environment. Virtually 
everyone is exposed to traces of dieldrin in food, and residues of
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dieldrin have been found in the tissues of almost every person 
examined (Train 1974). Accordingly it is impossible to identify 
unexposed groups for rigorous comparison with exposed groups.
However, since residues of dieldrin are retained in tissues for 
months or years after exposure, it is possible to use these residues 
as indirect measures of the intensity of past exposure. A number of 
epidemiologic studies have been published in which correlations have 
been sought between various pathologic conditions and tissue levels 
of dieldrin.
In a study of 38 autopsy cases, there was an association between 
high residues of organochlorme compounds and malignant tumors. The 
highest residues of organochlorine compounds were associated with 
carcinomas, cachexia, and a variety of focal or generalized abnormalities 
of the liver. However, these reported associations were with total 
organochlorine residues, not specifically with dieldrin (Casarett et 
al 1968).
In another investigation of various pesticides in fat samples 
taken at autopsy, the average concentration (in ppm) of dieldrin was 
0.55 ± 0.34 in 40 cases of carcinoma, 0.47+ 0.22 in 5 cases of leukemia, 
0.51±0.18 in 5 cases of Hodgkin's disease and 0.21±0.15 in 42 "control" 
cases. Each of the differences from the control level was statistically 
significant (Radomski et al 1968). The data from this study suggested 
a relationship between dieldrin levels in adipose tissues and cases of 
portal cirrhosis and hypertension.
Davies et al (1975) compared levels of dieldrin in the adipose
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tissues of 122 cancer victims with those in 122 matched controls. The 
average dieldrin level was 0.3 ppm in each group. There were no 
significant differences between dieldrin residue levels m  cancer 
patients and controls, either when the patients were grouped together 
or divided according to the primary site of cancer. Robinson et al 
(1965) found no significant differences between dieldrin levels in the 
fat of 7 cancer victims, 29 victims of cardiovascular diseases, and 7 
accident victims sampled at autopsy.
Dacre and Jennings (1970) reported that dieldrin levels were 
significantly higher in the lung tissues of 26 persons who died of 
lung canger than in persons who died of other causes. Dieldrin 
concentrations were significantly higher in cirrhotic than m  noncirrhotic 
livers in an autopsy study of Oloffs et al (1974). However, when 
expressed on a lipid basis, the dieldrin levels were similar in 
the two groups.
D'Ercole et al (1976) detected no correlation between dieldrin 
residues in the blood of newborn infants and maternal age, sex of 
newborn, birth weight, or incidence of congenital anomalies. Residues 
were found in premature infants but were not significantly different 
from those in full-term infants.
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4. Correlation of Exposure and Effect
4.1 Effects on Humans
Aldrin is converted to dieldrin both in the environment and 
by metabolism in mammals. Exposure of mammals to either is re­
flected by storage of dieldrin in the tissues, including the 
blood and fat. Where comparative data are available, toxic effects 
resulting from exposure to aldrin are similar, both qualitatively 
and quantitatively, to those resulting from exposure to dieldrin. 
Accordingly the two chemicals are treated together in this section 
correlating exposure with effect.
Table 4.1.1 summarizes the clinical and case reports of the 
effects of aldrin/dieldrin on humans and the studies with volun­
teers, which were cited in Sections 3.1 and 3.2, respectively.
There are many reports of human poisonings, including a number of 
deaths, resulting from accidents or suicides. However, little 
quantitative information on the doses of aldrin/dieldrin responsible 
for the poisonings is available, and in some cases even the route 
of exposure is not clearly established. Many of the poisonings 
involved exposure to dust or spray formulations, and in these cases 
exposure may have been by dermal, respiratory, or oral routes. A 
few accidental poisonings resulted from ingestion, and there was 
one reported case of suicide by injection.
The AMA Committee on Toxicology (1960) suggested that the 
median lethal dose by ingestion in humans is probably about 65 mg/kg 
and "untoward symptoms" will result from a single dose of 10 mg/kg
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or more. For long-term exposure, the concentration of HEOD in the 
blood or fat provides an indirect measure of cumulative exposure 
(Hunter et al 1969, Jager 1970). Jager (1970) summarized evidence 
suggesting that a concentration of HEOD in the blood of 0.15-0.20 
ppm is the approximate threshold for clinical intoxication and a 
blood concentration of 0.30 ppm is the approximate threshold for 
convulsive seizures. According to the pharmacokinetic data 
summarized in Section 1.5.4, these blood concentrations correspond 
to about 30-40 ppm of HEOD in fat and to a continuous intake of 
about 15-20 pg/kg/day. Although a number of factors complicate 
these pharmacokinetic relationships, including intermittent 
exposures and interactions with other chemicals, these figures are 
a rough guide to the tissue levels and exposure that present toxic 
hazards.
The data in Table 4.1.1 are consistent with these figures but 
provide little additional quantitative information. One individual 
who survived a convulsive intoxication had 40 ppm HEOD in his fat 
2 weeks after exposure (Bell 1960). A 4-year-old child who survived 
a severe intoxication had 0.27 ppm HEOD m  blood serum and 47 ppm 
in fat 3 days after exposure (Garrettson and Curley 1969). One 
individual survived a single dose of 44 mg/kg (Hayes 1963) , and 
another survived a single dose of 25.6 mg/kg (Spiotta 1951). The 
only report found of accidental long-term exposure was one by 
Gupta (1975) about two children who died after 6-12 months of 
exposure to contaminated food. Their average daily intake is
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likely to have been less than 1 mg. However, in a study with 
volunteers, daily intake of 211 yg/day for 2 years by middle-aged 
men led to no measurable adverse effects (Hunter et al 1969).
Table 4.1.2 summarizes the results of studies of workers 
occupationally exposed to aldrin/dieldrin. These studies are 
described more fully in Section 3.3. Incidents of clinical 
intoxication, including convulsive seizures and at least one death, 
were frequently recorded in public health programs involving the 
spraying of liquid formulations containing 0.5-2.5% dieldrin (Hayes 
1957, Blrfzquez and Bianchini 1956, Zavon et al 1961). In contrast, 
poisonings associated with the use of dust formulations have been 
much less frequent and have involved observation of inadequate 
safety precautions (Nelson 1953, Bell 1960). Little quantitative 
information from these incidents is available, except for an estimate 
by Fletcher et al (1959) that spraymen came into dermal contact with 
as much as 1.8 mg/kg/day of dieldrin without showing clinical 
symptoms. This figure is about 100 times the estimated threshold 
intake for clinical intoxication derived from the data of Jager (1970).
A few studies listed in Table 4.1.2 included data on tissue 
levels of HEOD. Blood concentrations as high as 0.14, 0.25, or 
0.31 ppm were reported in individual workers with no overt symptoms 
(Hayes and Curley 1968, Avar and Czegledi-Janko 1970, Mick et al
1971). However, one worker with a blood concentration of HEOD 
as low as 0.05 ppm showed clinical symptoms of intoxication and 
characteristic EEG changes (Avar and Czegledi-Janko 1970).
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In most of the studies summarized in Tables 4.1.1 and 4.1.2, 
the symptoms of aldrin/dieldrin intoxication involved the central 
nervous system, including headache, muscular jerking, convulsive 
seizures, and EEG changes. Other symptoms occasionally reported 
included dermatitis, enlarged liver, hematuria, transient 
bronchial complications, and elevated levels of serum enzymes 
(Avar and Czegledi-Janko 1970, Blazquez and Bianchini 1956, Nelson 
1953, Jager 1970).
In two cases, biochemical changes occurred in association 
with low blood levels of HEOD. Hunter et al (1972) reported 
measurements of D-glutaric acid excretion that indicated 
significantly elevated microsomal enzyme activity in workers whose 
mean blood level of HEOD was only 0.026 ppm. Takahashi et al (1976) 
found elevated serum levels of C-reactive proteins and a correlation 
between alpha globulin and HEOD levels in workers whose mean 
blood level of HEOD was only 0.012 ppm. These results suggest 
functional biochemical changes at exposure levels one order of 
magnitude lower than the threshold for overt intoxication.
Few data were found which can be used to assess the 
possibility that aldrin/dieldrin has carcinogenic, teratogenic, 
or mutagenic effects on the human population, or affects human 
reproduction. In two studies, cancer victims were shown to have 
higher tissue levels of HEOD than persons without cancer (see 
Section 3.4). However, these findings do not prove a cause-and- 
effect relationship. No evidence of chromosome abnormalities was
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found in one study of 22 exposed workers (Dean et al 1975).
Workers exposed for up to 19 years had no excess incidence of 
cancer (Jager 1970, Versteeg and Jager 1973), but the number of 
workers who were "highly exposed" was small and even thexr 
exposure appears to have been comparatively modest (see Section
3.3). No studies of female workers or of the reproductxve 
performance of male workers were found.
4.2 Effects on Experimental Animals
Table 4.2.1 summarizes the reported effects of oral exposure 
to aldrin/dieldrin on experxmental animals. Teratogenic, car­
cinogenic, and mutagenic effects are listed in Tables 4.3.1, 4.3.2, 
and 4.3.3, respectively. No studies of the effects of dermal 
exposure of animals to aldrin/dieldrin were found. The only 
study of the effects of respiratory exposure of animals to aldrin/
I
dieldrin is that of Medved et al (1964), who reported that
3
exposure of cats to aldrin at a concentration of 0.1 mg/m for an 
unspecified period caused marked lowering of conditioned and 
unconditioned reflexes.
At high dietary levels (10-150 ppm), the most striking effects 
of aldrin/dieldrin were on the central nervous system, the liver, 
and the kidney. Dose-response relationships for these effects 
appear to have comparatively small slopes. For example, although 
rats developed kidney and liver lesions and occasional convulsions 
at a dietary level of 10 ppm, some rats have survived for up to 
2 years at dietary levels of 50, 100, and even 150 ppm (Fitzhugh 
et al 1964).
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At dietary levels between 1 and 10 ppm, the most pronounced 
effects of aldrin/dieldrin were on the liver and the reproductive 
system. At a dietary level of 1 ppm dieldrin, reported effects 
included liver enlargement, liver lesions, and induction of 
hepatic microsomal enzymes in rats and mice, enzyme induction in 
rhesus monkeys, and liver enlargement in dogs (Street et al 1969; 
Wright 1974; Jager 1970; Walker et al 1969, 1972; Treon et al 1955). 
Adverse effects on reproduction were reported in rats and mice 
exposed at 2.5 ppm (Cleveland 1966, Virgo and Bellward 1975) and 
in dogs exposed at about 3 ppm (Deichmann et al 1971, Kitselman 
1953). The importance of these observations is that dietary 
exposure to dieldrin at 1 ppm led to blood levels of HEOD in the 
range 0.017-0.086 ppm in these species (Table 1.5.4). These blood 
concentrations are in the lower part of the range observed in 
occupationally exposed workers (Table 4.1.2).
Several experiments showed effects of aldrin/dieldrin at 
dietary levels even below 1 ppm. Raccoons exposed at 0.73 ppm in 
the diet suffered severe adverse effects on reproduction 
(Frederickson 1973). Rats exposed at 0.5 ppm had increased 
liver weights and liver lesions (Fitzhugh et al 1964). In 
another study, rats exposed at 0.31, 0.16, and 0.08 ppm developed 
brain and vascular lesions, and those exposed at 0.31 and 0.16 
suffered impaired reproduction (Harr et al 1970a,b). Mice 
exposed at 0.1 ppm had an increased incidence of liver tumors 
(Walker et al 1972).
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4.3 Teratogenic, Carcinogenic, and Mutagenic Effects
Table 4.3.1 summarizes the experiments on teratogenesis, 
which are cited in Section 3.4. Aldrin and dieldrin were terato­
genic in mice and Syrian golden hamsters when administered at 
about one-half the median lethal doses (Ottolenghi et al 1974). 
However, dieldrin had no effects on mice (other than minor effects 
on ossification) and no effects in rats exposed at lower doses 
(Chernoff et al 1975). A third experiment with dieldrin was 
inconclusive (Boucard et al 1970).
Table 4.3.2 summarizes the experiments on carcinogenesis, 
which are cited in Section 3.5. Aldrin and dieldrin were carcino­
genic in mice, having produced increased incidence of tumors in 20 
experiments, usually in males and females independently. The 
principal site of action is the liver, although treatment with 
dieldrin was associated with an increase in tumors of the lung 
and other sites in several experiments for which age-adjusted 
statistical analysis of tumor incidence was reported. In most of 
the experiments, dietary levels were 2.5-10 ppm, but in the most 
extensive experiment dietary exposure to dieldrin at 1 and 0.1 
ppm led to significant increases in incidence of liver and lung 
tumors.
The results of carcinogenicity tests with rats are more 
equivocal. If several inadequately reported experiments are 
discounted, aldrin/dieldrin has been tested for carcinogenicity 
in rats in eight experiments. In six of these experiments, there
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was a statistically (P<0.01) or marginally significant (P<0.05) increase in 
tumor incidence at one or more of the lower doses (0.1-30 ppm).
However, the sites at which these increases were observed were 
inconsistent (thyroid, lung, adrenal, pancreas, lymphatic system, 
mammary gland, and liver), and in five cases tumor incidence was 
reduced at higher doses (10-150 ppm). The only statistically 
significant effects at these higher doses were liver lesions of 
disputed biologic significance. If only the data from the higher 
dose levels were available, the results would be accepted as 
consistently negative. On the other hand, if only the data from 
the lower dose levels were available, aldrin and dieldrin would 
be accepted as strongly carcinogenic, at least on the basis of 
the NCI experiments. The reasons for the apparent reversal m  
dose-response relationships are not clear, although the results of 
one experiment suggested that the pathways of metabolism of dieldrin 
may be different at low and high dose levels (Mueller et al 1975a,b).
Table 4.3.3 summarizes the experiments on mutagenesis, which 
are cited in Section 3.6. Several studies indicated that aldrin 
and dieldrin can damage chromosomes, primarily by causing breaks 
and gaps, in mammalian cells, both in vitro and in vivo (Ahmed 
1975, Majumdar 1976, Georgian 1975). Aldrin and dieldrin yielded 
consistently negative results m  bacterial reversion bioassays, with 
or without metabolic activation. In other mutagenicity tests, 
including dominant lethal and host-mediated assays, aldrin and
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dieldrin generally gave negative results, although the sensitivity 
of some of the systems used is questionable. Dieldrin caused 
unscheduled DNA repair in human fibroblast cultures (Ahmed et al
1977).
Most of the positive results of damage to chromosomes were 
obtained at high concentrations, close to cytotoxic levels both 
in vitro and in vivo. However, Majumdar et al (1976) reported 
statistically significant increases in chromosome aberrations at 
the lowest doses tested (1 mg/kg in mice exposed in vivo and 1 
ppm in human embryonic lung cell cultures).
4.4 Summary
Aldrin is converted to dieldrin in the environment and in 
mammalian tissues. The toxic effects of the two chemicals are 
similar, qualitatively and quantitatively.
When mammals are exposed to either aldrin or dieldrin, 
dieldrin is circulated in their blood and is stored in their 
tissues, primarily in the fat. After ingestion, humans store 
dieldrin in their tissues at much higher concentrations than those 
measured in experimental animals exposed at comparable levels. 
Consequently, target tissues in humans are exposed to dieldrin 
at concentrations proportionately higher than in experimental 
animals that ingest comparable quantities.
Aldrin/dieldrin is neurotoxic, and many cases of poisoning, 
including a few deaths, caused by accidental or imprudent overexposure 
have been reported. In a study conducted in a manufacturing plant,
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concentrations of dieldrin in the blood were reported to be in­
dicative of toxic hazard. A concentration of 0.15-0.20 ppm in the 
blood was considered the threshold for EEG changes and other CNS 
effects, whereas 0.30 ppm was considered the threshold for con­
vulsive seizures. Corresponding average daily intakes were about 
15-22 yg/kg and 30 yg/kg, respectively. Only minor biochemical 
changes (induction of hepatic microsomal enzymes and elevated 
levels of C-reactive protein in serum) were reported m  workers 
with lower blood concentrations of dieldrin (0.012-0.026 ppm). 
Although a few workers who were exposed to aldrin/dieldrin for up 
to 19 years have been studied, the available reports are 
inadequate for determining whether aldrin/dieldrin may have car­
cinogenic, mutagenic, or teratogenic effects in humans, or may 
affect reproduction.
In experimental animals, the most conspicuous effects of 
aldrin/dieldrin are on the liver and on the CNS. A concentration 
of 1 ppm in the diet has been reported to be the approximate 
threshold for induction of hepatic microsomal enzymes in rats and 
mice. Rats exposed at a dietary concentration of 0.08-0.31 ppm 
have had brain and vascular lesions and impaired reproduction.
Aldrin/dieldrin is carcinogenic in mice, increasing the 
incidence of tumors primarily in the liver but also m  the lung 
and perhaps other sites. In one experiment, carcinogenic effects 
occurred even at 0.1 ppm, the lowest dietary concentration tested. 
In rats, aldrin/dieldrin appeared to increase the incidence of
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tumors at a variety of sites when administered at low dietary con­
centrations (0.1-30 ppm) but consistently failed to do so when 
administered at higher concentrations (10-150 ppm). The reasons 
for this apparent reversal in dose-response relationships are not 
clear.
Aldrin/dieldrin administered at about one-half the median 
lethal dose was teratogenic in mice and hamsters, but lower doses 
had no teratogenic effects in mice and rats. Aldrin/dieldrin has 
yielded consistently negative results in bacterial mutagenesis 
bioassays. However, aldrin/dieldrin has repeatedly caused 
chromosome damage in mammalian cells, even at low exposure levels 
(1 mg/kg in mice exposed in vivo and 1 ppm in human embryonic 
lung cultures). Dieldrin caused unscheduled DNA repair in human 
fibroblast cultures.
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TABLE 4.1.1
SUMMARY OF EFFECTS OF ALDRIN/DIELDRIN EXPOSURE ON HUMANS (CLINICAL AND CASE REPORTS)
Duration
and Route Concentration Tissue Levels
Substance of Exposure or Dose of Dieldrin* Reported Effects Reference
Dieldrin
(aerosol)
Dieldrin
Aldrin
(dust)
Dieldrin
Aldrin
(field
residues)
84-214 hr 
respiratory
Unknown 
dermal and 
perhaps oral
2 working days 
dermal, 
respiratory 
(packaging)
18 hr
dermal (dusting 
sheep)
6 wk
1-2 mo 
dermal
176 mg/m^ 
"per day"
4% powder
No detectable effect
3% solution
0.4% solution
Hodge et al 
1967
Convulsions, fever, cy- Committee on 
anosis, death in 20 hr Toxicology 
(9-mo-old girl)
40 ppm in fat 
after 2 wk
Convulsions, EEG 
changes
5-7 ppm in fat Twitching of arms and 
after 1 mo legs
1 ppm in fat 
after 8 mo
"Symptoms of dieldrin 
poisoning"
Myoclonic jerks, par­
esthesia, muscle 
weakness, tachycardia, 
motor polyneuropathy
1960 
Bell 1960
Jenkins and 
Toole 1964
10
8
TABLE 4.1.1 (continued)
SUMMARY OF EFFECTS OF ALDRIN/DIELDRIN EXPOSURE ON HUMANS (CLINICAL AND CASE REPORTS)
Duration
and Route Concentration Tissue Levels
Substance of Exposure or Dose of Dieldrin* Reported Effects Reference
Dieldrin Unknown
(impregnated dermal 
wool)
Nonspecific dermatitis Ross 1964
0.1-0.5% m  
wool
No sensitization of 
skin
Hodge et al 
1967
Dieldrin Single dose 
oral
5% solution 0.27 ppm in 
serum, 47 ppm 
in fat (3 d 
after 
ingestion)
Convulsions, death in 
2-yr-old girl; con­
vulsions , cyanosis, 
EEG changes, elevated 
serum alkaline phos­
phatase after 6 mo in 
4-yr-old boy
Garrettson 
and Curley 
1969
Aldrin Single dose 
oral (in food)
20% powder Nausea, vomiting, 
hyperirritability, 
convulsions, death in 
4/9 cases
Preda et 
at 1963
Aldrin or 
dieldrin
Single dose 
oral
65 mg/kg Estimated median lethal 
dose
Committee on 
Toxicology 
1960
TABLE 4.1.1 (continued)
SUMMARY OF EFFECTS OF ALDRIN/DIELDRIN EXPOSURE ON HUMANS (CLINICAL AND CASE REPORTS)
Duration
and Route Concentration Tissue Levels
Substance of Exposure or Dose of Dieldrin* Reported Effects Reference
Dieldrin Single dose 
oral
44 mg/kg Convulsions Hayes 1963
Aldrin Single dose 
oral (attempted 
suicide)
0.279 ppm 
in plasma
Survived Hayes and 
Curley 1968
Aldrin
(liquid
mixture)
Single dose 
oral
25.6 mg/kg Convulsions within 20 
min, EEG changes, 
generalized cerebral 
dysrhythmia, hematuria, 
albuminuria; treatment 
with barbiturates, EEG 
normal within 5 mo
Spiotta 1951
Dieldrin Convulsions after 30 
min, hematuria, am­
nesia; no EEG abnor­
malities , normal kidney 
and liver function
Jacobs 1967
TABLE 4.1.1 (continued)
SUMMARY OF EFFECTS OF ALDRIN/DIELDRIN EXPOSURE ON HUMANS (CLINICAL AND CASE REPORTS)
Substance
Duration 
and Route 
of Exposure
Concentration 
or Dose
Tissue Levels 
of Dieldrin* Reported Effects Reference
Aldrin 6-12 mo 
oral
About 0.5% dust 
(mixture of aldrin 
and HCH) in flour
Myoclonic jerks, con­
vulsions , EEG changes, 
death in 2/12
Gupta 1975
Dieldrin Single dose 
oral
10 mg/kg "Untoward symptoms" Committee on 
Toxicology 
1960
Dieldrin 
(99% HEOD 
m  gelatin 
capsules)
2 year 
oral
50 or 211 ug 
daily
0.005-0.025 
ppm in blood, 
0.4-4.9 ppm m  
fat
None Hunter et al 
1967, 1969
Dieldrin in 
hydrocarbon 
solvent
Single dose 
iv injection 
(suicide)
5 ml of 
solution 
(unspecified 
concentration)
50 ppm in 
blood
Convulsions, frothing 
at the mouth, death 
within 3 min
Schwar 1965
*Aldnn is converted to dieldrxn m  the body, and the presence of dieldrin in tissues reflects 
exposure to either.
TABLE 4-1.2
SUMMARY OF EFFECTS OF OCCUPATIONAL EXPOSURE TO ALDRIN/DIELDRIN
Duration
and Route Concentration Tissue Levels
Substance of Exposure or Dose of Dieldrin* Reported Effects Reference
Aldrin 1-5 yr 
unknown
0.024-Q.4 ppm 
m  blood
Muscular jerking, my- 
ocloni a, convuls ions, 
psychic disturbances,
EEG changes; clinical 
symptoms and EEG changes 
associated with blood 
levels of HEOD as low as 
0.05 ppm; no symptoms in 
one worker with HEOD 
blood level of 0.25 ppm
Avar and 
Czegledi- 
Janko 1970
Dieldrin Unknown 
dermal, 
respiratory
2.5% spray ap­
plied to surfaces 
at 0.5 g/m2
Muscle jerking, con­
vulsions , one death
Hayes 1957
1-18 mo 
dermal, 
respiratory
1.25-2.5% emulsion 
applied to surfaces 
at 1 g/m2
Vertigo, nausea, my­
oclonia , convulsions, 
tremors, dermatitis, 
enlarged liver
Blazquez and 
Bianchini 
1956
TABLE 4.1.2 (continued)
SUMMARY OF EFFECTS OF OCCUPATIONAL EXPOSURE TO ALDRIN/DIELDRIN
Duration
and Route Concentration Tissue Levels
Substance of Exposure or Dose of Dieldrin* Reported Effects Reference
Dieldrin 14-154 d 
respiratory, 
dermal
1.25 or 2.5% 
spary
Giddiness, headache, 
muscle twitching, con­
vulsions, loss of 
consciousness
Patel and 
Rao 1958
Aldrin 
("empty 
drums")
Aldrin and 
dieldrin 
(technical 
product and 
various for­
mulations ; 
also expo­
sure to 
Telodrin and 
Endrin in 
some cases)
1-13 yr
respiratory,
dermal
0.022-0.078 
ppm in blood 
in most work­
ers ; occasion­
ally up to 
0.23 ppm in 
blood in high­
ly exposed 
workers
Nausea, vomiting, mal- Nelson 1953 
aise, headache, faint­
ing, convulsions, 
hematuria, EEG changes
No significant effects Hoogendam et 
in most workers, adverse al 1962, 1965 
effects associated with Jager 1970; 
blood levels of dieldrin Hunter et al 
0.05-0.20 ppm: con- 1972
vulsions in 15; head­
ache, dizziness, drowsi­
ness, hyperirritability, 
malaise in 8 others; EEG 
abnormalities; elevated 
serum alkaline phosphatase 
and SGOT levels, increased 
urinary excretion of D- 
glutaric acid
1
13
TABLE 4.1.2 (continued)
SUMMARY OF EFFECTS OF OCCUPATIONAL EXPOSURE TO ALDRIN/DIELDRIN
Substance
Duration 
and Route 
of Exposure
Concentration 
or Dose
Tissue Levels 
of Dieldrin* Reported Effects Reference
Aldrin or 
dieldrin
Long-term
respiratory,
dermal
30 yg/kg/d 
(estimated)
0.30 ppm in 
blood
Threshold for convul­
sive seizures
Jager 1970
11 If 15-20 u g / k g / d  
(estimated)
0.15-0.20 ppm 
in blood
Threshold for EEG 
changes and other CNS 
effects
Brown et al 
1964, Jager 
1970
Aldrin 1-2 yr
respiratory,
dermal
25% dust Contact dermatitis, 
furunculi, "transient 
bronchial complications"
Nelson 1953
Aldrin and
dieldrin
(manufacture)
“ No significant increase 
in chromosome 
abnormalities
Dean et al 
1974
Dieldrin 180 d dermal 
(estimated as 
1.8 mg/kg/d)
0.55-1.1% emul­
sions, sprayed 
on surfaces at 
0.5-1.0 g/m2
No clinical symptoms Fletcher et 
al 1959
TABLE 4.1.2 (continued)
SUMMARY OF EFFECTS OF OCCUPATIONAL EXPOSURE TO ALDRIN/DIELDRIN
Duration
and Route Concentration Tissue Levels
Substance of Exposure or Dose of Dieldrin* Reported Effects Reference
Aldrin 
technical 
(formulat­
ing plant)
5 wk 
dermal, 
respiratory
0.100-0.312 ppm 
in plasma
No complaints or health Mick et al 
problems reported to the 1971 
company physician
Aldrin and 
dieldrin 
(manufac­
ture)
1-19 yr 
dermal, 
respiratory
0.0012-0.137 ppm 
(mean Q.Q25 ppm) 
in plasma; 0.60- 
32 ppm (mean 6.1 
ppm) in fat; 
0.0014-0.066 ppm 
(mean 0.028 ppm) 
in urine
No meaningful associa­
tion of tissue levels 
with history of sick 
leave
Hayes and 
Curley 1968
Dieldrin 
(also expo­
sure to pen- 
tachloro- 
phenol)
Long-term
unknown
Mean 0.012 ppm 
in blood
Elevated levels of C- 
reactiye protein in 
serum; significant 
correlation between 
alpha-2-globulin and 
dieldrin levels in 
serum
Takahashi 
et al 1976
TABLE 4.1.2 (continued)
SUMMARY OF EFFECTS OF OCCUPATIONAL EXPOSURE TO ALDRIN/DIELDRIN
Substance
Duration 
and Route 
of Exposure
Concentration Tissue Levels 
or Dose of Dieldrin* Reported Effects Reference
Dieldrin 1-8 yr 0.001-0.009 ppm No symptoms Morgan and
(spray) dermal, in blood Hickin 1966
respiratory
*Aldrin is converted to dieldrin in the body, and the presence of dieldrin in tissues reflects 
exposure to either.
TABLE 4.2.1
SUMMARY OF EFFECTS OF ORAL ADMINISTRATION OF ALDRIN/DIELDRIN TO ANIMALS
Substance Species
Dietary 
Concentration 
or Oral Dose 
and Duration
Tissue 
Levels of 
Dieldrin* Reported Effects Reference
Aldrin or 
dieldrin 
(99% pure)
Rat 50, 100, or 
150 ppm 
2 yr
Dieldrin 75 ppm 
396-440 d
Dieldrin
(technical)
50 or 100 ppm 
8 wk
Dieldrin 40 ppm 
2 yr
25 or 50 ppm 
60 d
Dose-related reduction in sur­
vival, increased liver weight, 
liver lesions, nephritis, 
renal necrosis, distended and 
hemorrhagic urinary bladders
Fitzhugh et 
al 1964, 
Reuber 1974
Increased liver weight, liver Ferrigan 
cell changes, nephritis et al 1965
Increase in smooth endoplasmic 
reticulum, atypical mitochon­
dria
Kimbrough et 
al 1971
Reduced survival, convulsions, Harr et al 
reproductive failure, brain 1970a,b
and vascular lesions
Reduced muscular performance 
(as measured by speed of pull­
ing a weight along a runway)
Khairy 1960
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TABLE 4.2.1 (continued)
SUMMARY OF EFFECTS OF ORAL ADMINISTRATION OF ALDRIN/DIELDRIN TO ANIMALS
Substance Species
Dietary 
Concentration 
or Oral Dose 
and Duration
Tissue 
Levels of 
Dieldrin* Reported Effects Reference
Aldrin or 
dieldrin
Rat 25 ppm 
2 yr
- Increased liver weight, liver 
lesions
Treon et al 
1955
I f 1» 12.5 or 25 ppm 
3 generations
Inconsistent effects on preg­
nancy rates, severe reduction 
in survival of offspring
Treon and 
Cleveland 
1955, Cleve­
land 1966
Aldrin II 3-4.5 mg/kg/day 
13 mo
- Increased chronaxy London and 
Pallade 1964
Dieldrin I I 20 ppm 
2 yr
Reduced survival, convulsions, 
reproductive failure, brain 
and vascular lesions
Harr et al 
1970a,b
Aldrin or 
dieldrin
I I 12.5 ppm 
2 yr
- Increased liver weight, liver 
lesions
Treon et al 
1955
Dieldrin 
(99% pure)
I I 10 ppm 
2 yr
0.03-0.11 ppm 
in blood, 8-50 
ppm in fat
Increased liver weight in fe­
males, lesions, irritability, 
convulsions
Walker et al 
1969
TABLE 4.2.1 (continued)
SUMMARY OF EFFECTS OF ORAL ADMINISTRATION OF ALDRIN/DIELDRIN TO ANIMALS
Substance Species
Dietary 
Concentration 
or Oral Dose 
and Duration
Tissue 
Levels of 
Dieldrin* Reported Effects Reference
Aldrin or 
dieldrin 
(99% pure)
Rat 10 ppm 
2 yr
Dieldrin
6.2 ppm 
5 d
5 ppm 
2 yr
Aldrin or 
dieldrin
2.5 ppm 
2 yr
2.5 ppm 
3 generations
Increased liver weight, liver 
lesions, nephritis
Fitzhugh et 
al 1964
Neural spasms, severely im- Harr et al
paired reproduction, brain 1970a,b
and vascular lesions
Increased level of serum 
luteinizing hormone, de­
creased prostate weight
Blend and 
Lehnert 1973
Severely impaired reproduction, Harr et al
brain and vascular lesions 1970a,b
Increased liver weight, liver Treon et al 
lesions 1955
Slightly decreased pregnancy Treon and
rate, slightly to moderately Cleveland
decreased survival of offspring 1955, Cleve­
land 1966
1
1
9
TABLE 4.2.1 (continued)
SUMMAFY OF EFFECTS OF ORAL ADMINISTRATION OF ALDRIN/DIELDRIN TO ANIMALS
Substance Species
Dietary 
Concentration 
or Oral Dose 
and Duration
Tissue 
Levels of 
Dieldrin* Reported Effects Reference
Aldrin or 
dieldrin 
(99% pure)
Dieldrin 
(99% pure)
Rat 2 ppm 
2 yr
1 ppm
2 yr
0.009-0.069 
ppm in blood, 
1.3-16 ppm in 
fat
Increased liver weight, liver 
lesions
Increased liver weight in 
females
Fitzhugh et 
al 1964, 
Reuber 1974
Walker et al 
1969
Dieldrin 1 ppm
2 wk
0.7 ppm 
5 d
"Threshold" level for induction Street et al
of hepatic microsomal enzymes 
Decreased prostate weight
1969
Blend and 
Lehnert 1973
0.31, 0.63, 
1.25, or 2.5 
ppm 
2 yr
4-50 ppm in 
fat
Impaired reproduction; brain Harr et al 
and vascular lesions 1970a,b
TABLE 4.2.1 (continued)
SUMMARY OF EFFECTS OF ORAL ADMINISTRATION OF ALDRIN/DIELDRIN IN ANIMALS
Substance Species
Dietary 
Concentration 
or Oral Dose 
and Duration
Tissues 
Levels of 
Dieldrin* Reported Effects Reference
Dieldrin 
(99% pure)
Dieldrin
Rat 0.1 ppm 
2 yr
0.08 or 0.16 
ppm 
2 yr
0.003-0.013 ppm 
in blood, 0.17- 
3.1 ppm in fat
1-2 ppm in fat
No significant effects
Impaired reproduction in 
second breeding, brain and 
vascular lesions
Walker et al 
1969
Harr et al 
1970a,b
Aldrin or 
dieldrin 
(99% pure)
Dieldrin 
(99% pure)
Aldrin
0.5 ppm 
2 yr
1 ppm
Mouse 2 or 4 mg/kg/d
7 d late 
in pregnancy
Increased liver weight, liver 
lesions
Increased hepatic microsomal 
enzyme activity
Significant reduction in body 
weight and significant in­
crease in electroshock seizure 
threshold in offspring tested 
at 38 d
Fitzhugh et 
al 1974, 
Reuber 1974
Wright 1974
Al-Hachim
1971
TABLE 4.2.1 (continued)
SUMMARY OF EFFECTS OF ORAL ADMINISTRATION OF ALDRIN/DIELDRIN TO ANIMALS
Substance Species
Dietary 
Concentration 
or Oral Dose 
and Duration
Tissue 
Levels of 
Dieldrin* Reported Effects Reference
Dieldrin Mouse 1.25, 2.5, 
5 mg/kg/d 
5 d
or Increased hepatic microsomal 
protein and cytochrome P-450, 
alteration in uptake and meta­
bolism of testosterone
Schein and 
Thomas 1975
Dieldrin
(technical)
10 or 15 ppm 
76 d
Reduced fertility and litter Virgo and
size, 1QQ% mortality of off- Bellward
spring 1975
Aldrin or 
dieldrin
10 or 25 ppm 
6 generations
Reductions in fertility, 
lactation indices, and 
viability of pups
Deichmann 
and Mac­
Donald 1971, 
Keplinger 
et al 1966, 
1968
Dieldrin
(99% pure)
10 ppm 
2 yr
0.42-0.52 in 
blood, 11-12 
ppm in fat
Reduced survival, enlarged 
livers, liver lesions
Walker et al 
1972, Thorpe 
and Walker 
1973
TABLE 4.2.1 (continued)
SUMMARY OF EFFECTS OF ORAL ADMINISTRATION OF ALDRIN/DIELDRIN TO ANIMALS
Substance Species
Dietary 
Concentration 
or Oral Dose 
and Duration
Tissue 
Levels of 
Dieldrin* Reported Effects Reference
Dieldriu 
(99% pure)
Dieldrin
(technical)
Mouse 5 ppm 
2 yr
5 ppm 
90 d
Reduced survival, enlarged 
livers, liver lesions
Reduced litter size
Walter et al 
1972
Good and 
Ware 1969
Aldrin or 
dieldrin
Dieldrin
(technical)
Dieldrin
(99% pure)
1 mg/kg 
single dose
3 ppm
6 generations
2.5 or 5 ppm 
76 d
2.5 ppm 
2 yr
1.25 ppm 
2 yr
Reduced toxic reaction to 
parathion and paraoxon 
1-12 days later
No significant effect on 
reproduction
Increased mortality of off­
spring
Reduced survival in females, 
enlarged livers, liver lesions
Enlarged livers, liver lesions
Triolo and 
Coon 1966a,b
Deichmann and 
MacDonald 1971
Virgo and 
Bellward 1975
Walker et al 
1972
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TABLE 4.2.1 (continued)
SUMMARY OF EFFECTS OF ORAL ADMINISTRATION OF ALDRIN/DIELDRIN TO ANIMALS
Substance Species
Dietary 
Concentration 
or Oral Dose 
and Duration
Tissue 
Levels of 
Dieldrin* Reported Effects Reference
Dieldrin Mouse 1.0 ppm
(99% pure) 2 yr
0.044 ppm in 
blood, 1.27- 
1.55 ppm in 
fat
Enlarged livers, liver lesions Walker et al
1972
Dieldrin 1 ppm Increased hepatic microsomal 
enzyme activity
Wright 1974
Dieldrin 
(99% pure)
0.1 ppm 
2 yr
0.0026-0.0039 
ppm in blood, 
1.27-1.55 ppm 
in fat
Enlarged livers, liver lesions Walker et al
1972
Aldrin or 
dieldrin
Dog 2-10 mg/kg/d 
2-5 wk
Fatty changes in liver and 
renal tubules; death in 9/10
Fitzhugh et 
al 1964
Dieldrin
(99% pure)
2 mg/kg/d 
1 wk
Proliferation of smooth endo­
plasmic reticulum, increased 
hepatic microsomal enzyme 
activity
Wright 1974
TABLE 4.2.1 (continued)
SUMMARY OF EFFECTS OF ORAL ADMINISTRATION OF ALDRIN/DIELDRIN TO ANIMALS
Substance Species
Dietary 
Concentration 
or Oral Dose 
and Duration
Tissue 
Levels of 
Dieldrin* Reported Effects Reference
Aldrin or 
dieldrin
Dog 1 mg/kg/d 
12-49 wk
Aldrin or 
dieldrin 
(recrystal­
lized)
0.6 or 2.0 
mg/kg/d 
1 yr
Aldrin 0.5 mg/kg/d 
up to 2 yr
Dieldrin
0.2 mg/kg/d 
6 yr
Fatty change in liver and Fitzhugh
renal tubules; reduced number et al 1964
of erythrocytes in bone 
marrow; death in 4/4
36/37 pups stillborn or died Kitselman
within 3 d of birth 1953
Convulsions; death Fitzhugh et 
al 1964
Convulsions; survival for 
2 yr in 3 of 4
Increased serum alkaline 
phosphatase activity, in­
creased bromosulphthalein 
clearance
Jager 1970
TABLE 4.2.1 (continued)
SUMMARY OF EFFECTS OF ORAL ADMINISTRATION OF ALDRIN/DIELDRIN TO ANIMALS
Substance Species
Dietary 
Concentration 
or Oral Dose 
and Duration
Tissue 
Levels of 
Dieldrin* Reported Effects Reference
Aldrin or 
dieldrin
Aldrin or 
dieldrin 
(recrystal­
lized)
Aldrin
(technical)
Aldrin
Dieldrin
Aldrin
Dog 0.2 mg/kg/d 
2 yr
0.2 mg/kg/d 
1 yr
0.15 or 0-3 
mg/kg/d 
14 mo
3 ppm 
15 mo
1 ppm
15 mo
0.012-0.14 ppm 
in blood, 11- 
150 ppm in fat
No clinical effects
10/16 pups stillborn or died 
within 3 d of birth
Reduced fertility, mammary 
development, and lactation; 
stillbirths and increased pup 
mortality
Fitzhugh et 
al 1964
Kitselman
1953
Deichmann et 
al 1971
Increased liver weight; liver Treon et al 
cell changes 1955
Increased liver weight "
No reported effects "
TABLE 4.2.1 (continued)
SUMMARY OF EFFECTS OF ORAL ADMINISTRATION OF ALDRIN/DIELDRIN TO ANIMALS
Substance
Dieldrin
Species
Dog
Dietary 
Concentration 
or Oral Dose 
and Duration
Tissue 
Levels of 
Dieldrin* Reported Effects
1 ppm 
15 mo
Increased liver weight
Reference
Treon et al 
1955
Dieldrin
(recrystal­
lized)
0.05 mg/kg/d 
2 yr
0.03-0.087 ppm 
in blood
Increased serum alkaline 
phosphatase activity, in­
creased liver weight in 
females
Walker et al 
1969
Dieldrin Rhesus
monkey
0.005 mg/kg/d 
2 yr
5 ppm
6 yr
1.75 ppm 
6 yr
0.005-0.024 ppm 
in blood
0.075 ppm in 
blood, 19 ppm 
in fat
No reported effects
Increased hepatic microsomal Jager 1970, 
enzyme activity; death in 2/5 Wright 1974
Increased hepatic microsomal "
enzyme activity
1 ppm 
6 yr
0.033 ppm in 
blood, 8.3 ppm 
in fat
Increased hepatic microsomal 
enzyme activity, marginal in­
crease in microsomal protein
TABLE 4.2.1 (continued)
SUMMARY OF EFFECTS OF ORAL ADMINISTRATION OF ALDRIN/DIELDRIN TO ANIMALS
Substance Species
Dietary 
Concentration 
or Oral Dose 
and Duration
Tissue 
Levels of 
Dieldrin* Reported Effects Reference
Dieldrin
Dieldrin
(technical)
Dieldrin
Rhesus
monkey
Squirrel
monkey
0.01, 0.10, or 0.004-0.022 ppm No reported effects
Sheep
0.50 ppm 
6 yr
0.1 mg/kg/d 
55-109 d
0.Q1 mg/kg/d 
55-109 d
10 mg/kg/d 
30 d
in blood, 0.39-
5.0 ppm in fat
Impaired learning of a dis­
crimination reversal task
Np measurable effect on 
learning
Inpaired learning
Jager 1970, 
Wright 1974
Smith et al 
1976
Van Gelder 
et al 1970
25 ppm 
40 mo
Death of all lambs shortly 
after birth
Harris and
Greenwood
1963
1 or 5 ppm 
40 mo
No measurable effects on 
reproduction
TABLE 4.2.1 (continued)
SUMMARY OF EFFECTS OF DIETARY ADMINISTRATION OF ALDRIN/DIELDRIN TO ANIMALS
Substance Species
Dietary 
Concentration 
or Oral Dose 
and Duration
Tissue 
Levels of 
Dieldrin* Reported Effects Reference
Dieldrin White­
tailed
deer
25 ppm 
3 yr
Reported growth, increased 
liver weight, reduced pi­
tuitary weight, increased 
thyroid size, reduced size 
of fawns at birth, increased 
postpartum mortality
Murphy and
Korschgen
1970
M I 5 ppm 
3 yr
- Increased postpartum 
mortality in offspring
I
I Raccoon 2.2 ppm 
2 yr
- Death of most females under 
the stress of breeding
Frederickson
1973
I I 0.73 ppm 
2 yr
Reduced pregnancy rate and " 
litter size, fetal deaths and 
resorption of embryos ; adverse 
effects on sperm production and 
fertility in males
I Cottontail
rabbit
0.07-0.25 ppm 
1 yr
0.11-0.66 ppm in 
brain
No measurable effect on 
reproduction
Malecki et 
al 1974
*Aldrin is converted to dieldrin in the body, and the presence of dieldrin in tissues reflects 
exposure to either.
TABLE 4.3.1
TERATOGENIC EFFECTS OF ALDRIN/DIELDRIN ADMINISTERED TO ANIMALS BY ORAL INTUBATION
Dose and Time of
Substance Specie^ Administration* Reported Effects Reference
Aldrin 
{recrystal­
lized)
Rat 25 mg/kg 
d 9
Anomalies in 33%: open eye,
webbed foot, cleft palate
Ottolenghi et al 
1974
Dieldrin
(recrystal­
lized)
15 mg/kg 
d 9
Anomalies in 17%: 
cleft palate
webbed foot,
Dieldrin
(technical)
6 mg/kg/d 
d 7-16
Maternal deaths and weight loss ; 
no anomalies in offspring
Chernoff et al 1975
1.5 or 3.0 mg/kg/d None 
d 7-16
Dieldrin 3.4 mg/kg/d 
d 6, 6-14, or 1-14
Nonsignificant increase in 
anomalies
Boucard et al 1970
2.5 ug/kg/d 
d 6, 6-14, or 1-14
Photo-
dieldrin
0.15, 0.3, or 0.6 
mg/kg/d 
d 7-16
15% maternal mortality at 0.6 
mg/kg/d, no increase in anomalies 
in offspring
Chernoff et al 1975
1
3
0
TABLE 4.3.1 (continued)
TERATOGENIC EFFECTS OF ALDRIN/DIELDRIN ADMINISTERED TO ANIMALS BY ORAL INTUBATION
Dose and Time of
Substance Species Administration* Reported Effects Reference
Dieldrin Mouse
(technical)
3.0 or 6.0 mg/kg/d 
d 7-16
Increased maternal liver weight; Chernoff et al 1975 
increase in supernumerary ribs 
and decrease in caudal ossi­
fication centers in offspring
1.5 mg/kg/d 
d 7-16
No significant effects
Dieldrin 3.4 mg/kg/d 
d 6, 6-14, or 1-14
Nonsignificant increase in 
anomalies
Boucard et al 1970
2.5 yg/kg/d 
d 6, 6-14, or 1-14
Photo-
dieldrin
0.15, 0.30, or 
0.60 mg/kg/d 
d 7-16
No significant effects Chernoff et al 1975
Aldrin
(recrystal­
lized)
Hamster 50 mg/kg 
d 7, 8, or 9
Anomalies in 11-22%: open eye, Ottolenghi et al
webbed foot, cleft palate, 1974
cleft lip, others
TABLE 4.3.1 (continued)
TERATOGENIC EFFECTS OF ALDRIN/DIELDRIN ADMINISTERED TO ANIMALS BY ORAL INTUBATION
Substance Species
Dose and Time of 
Administration* Reported Effects Reference
Dieldrin
(recrystal­
lized)
Hamster 30 mg/kg 
d 7, 8, or 9
Anomalies in 4-33%: open eye, 
cleft lip, cleft palate, 
exencephaly, platycrania, 
micrognathia, ectrodactyly
Ottolenghi et al 1974
*Day of pregnancy
TABLE 4.3.2
CARCINOGENIC EFFECTS OF DIETARY ADMINISTRATION OF ALDRIN/DIELDRIN TO ANIMALS
Concentration
Substance Species and Duration Reported Effects Reference
Aldnn Rat 30 or 60 ppm
(technical) 74 wk followed by
37-38 wk observation 
for females,
80 wk followed by 
32-33 wk observation 
for males
At 60 ppm, no significant increases in NCI 1978a 
tumor incidence; at 30 ppm, signif­
icant increases (compared to pooled 
controls) in three types of tumor: 
thyroid follicular cell tumors and 
adrenal cortical adenomas in both 
sexes, pancreatic islet tumors in 
males
Dieldrin
(technical)
Significant dose-related increase in 
thyroid follicular cell tumors in 
females; at 30 ppm, significant in­
crease (compared to pooled controls) 
in incidence of adrenal cortical 
adenomas and carcinomas in females
Aldrin 5 ppm 
25 mo
No significant increase in tumor 
incidence
Deichmann et 
al 1967
Dieldrin
(recrystal­
lized)
2, 10, or 50 ppm 
104-105 wk
NCI 1978b
TABLE 4.3.2 (continued)
CARCINOGENIC EFFECTS OF DIETARY ADMINISTRATION OF ALDRIN/DIELDRIN TO ANIMALS
Concentration
Substance Species and Duration Reported Effects Reference
Dieldrin Rat 1 ppm Significant increase in lung and other 
tumors in males; nonsignificant in­
cidence of liver lesions of disputed 
significance
Reuber 1974, 
Epstein 1975
Aldrin
(recrystal­
lized)
0.5, 2, 10, 50, 100, Reduced survival at 50, 100, and 150 Fitzhugh et al
or 150 ppm 
2 yr
Dieldrin
(recrystal­
lized)
ppm; significant increase in lymphatic 
and mammary tumors at 0.5, 2, and 10 
ppm (25/60 in pooled groups vs 2/17 in 
controls) but not at higher doses, 
significant increase in liver lesions 
of disputed significance (probably 
neoplastic or preneoplastic)
Reduced survival at 50, 100, and 150 
ppm; marginally significant increase in 
lymphatic and mammary tumors at 0.5, 2, 
and 10 ppm (16/63 in pooled groups vs 
2/17 in controls) but not at higher 
doses; significant increase in 
liver lesions of disputed significance 
(probably neoplastic or preneoplastic)
1964, Reuber
1974, Epstein
1975, Thorpe 
1974
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TABLE 4.3.2 (continued)
CARCINOGENIC EFFECTS OF DIETARY ADMINISTRATION OF ALDRIN/DIELDRIN TO ANIMALS
Substance Species
Concentration 
and Duration Reported Effects Reference
Dieldrin
(recrystal­
lized)
Photo-
dieldrin
(recrystal­
lized)
Rat 0.1, 1.0, or 10 ppm 
2 yr
Marginally significant increase in 
thyroid and mammary tumors in females 
exposed at 1.0 and 0.1 ppm (15/23 and 
14/23 vs 19/43 in controls) but not 
at 10 ppm; liver lesions at 10 ppm
5 or 10 ppm (males); No significant increases in tumor 
3.4 or 7.5 ppm time- incidence 
weighted average
(females)
80 wk followed by 
30 wk observation
Walker et al 
1969, Gross 
1974, Stevenson 
et al 1975
NCI 1977
Dieldrin Mouse 10 ppm
(recrystal- 2 yr
lized) (series of nine
experiments)
Increased incidence of liver tumors in 
males and females m  nine independent 
experiments; lung métastasés from 0- 
17% of tumors; some tumors successfully 
transplanted; significant increase in 
age-adjusted incidence of lung tumors 
in three experiments ; increase m  
lymphoid and other tumors in two 
experiments
Walker et al
1972, Thorpe 
and Walker
1973, Hunt
1974, Epstein
1975, Gross 
1974
TABLE 4.3.2 (continued)
CARCINOGENIC EFFECTS OF DIETARY ADMINISTRATION OF ALDRIN/DIELDRIN TO ANIMALS
Concentration
Substance Species and Duration Reported Effects Reference
Dieldrin Mouse 10 ppm 
2 yr
Mean survival time 51 wk vs 59.8 wk 
in controls, 24% incidence of liver 
tumors vs 7% in controls
Davis and 
Fitzhugh 1962
Dieldrin
(recrystal­
lized)
Aldrin
10 ppm
2, 4, 8, 16, 32, or 
64 wk
sacrifice at 104 wk
10 ppm 
2 yr
Increased incidence of liver tumors, 
which was statistically significant 
in 64-wk group; malignant tumors in 
64-, 8-, and 4-wk groups
Mean survival time 51.6 wk vs 59.8 wk 
in controls, 23% incidence of liver 
tumors vs 7% in controls
Walker et al 
1972
Davis and 
Fitzhugh 1962
Dieldrin 10 ppm 
2 yr
Reduced survival, 39% vs 64% in con­
trols at 2 yr; increased incidence of 
liver tumors, 87% in males and 87% in 
females vs 30% in male and 4% in fe­
male controls; lung metastases in 5% 
of exposed females; 8/9 tumors trans­
planted successfully
Davis 1965, 
Reuber 1974, 
Epstein 1975
TABLE 4.3.2 (continued)
CARCINOGENIC EFFECTS OF DIETARY ADMINISTRATION OF ALDRIN/DIELDRIN TO ANIMALS
Substance Species
Aldrin
Dieldrin
(x'ecrys~al-
lized)
Concentration 
and Duration
Mouse 10 ppm 
2 yr
5 ppm (with 50 ppm 
DDT)
2 yr
Reported Effects Reference
Reduced survival, 31% at 2 yr vs 64% 
in controls, increased incidence of 
liver tumors, 82% in males and 85% in 
females vs 30% in male and 4% in fe­
male controls; lung métastasés in 4% 
of exposed males; 9/10 tumors trans­
planted successfully
Incidence of liver tumors 58% in males 
and 94% in females vs 0 in controls,
6% in males exposed to DDT only, and 
16% in females exposed to DDT only
Davis 1965, 
Reuber 1974, 
Epstein 1975
Walker et al 
1972, Reuber 
1974, Epstein 
1975
Aldrin 
(techni il)
4 or 8 ppm (males)
3 or 6 ppm (females)
time-weighted
average
80 wk followed 
by 10“13 week 
observation
Hepatocellular carcinomas in 56% of 
males at 8 ppm, -33% of males at 4 ppm, 
and 18% of pooled control males; non­
significant increase in females
NCI 1978a
TABLE 4.3.2 (continued)
CARCINOGENIC EFFECTS OF DIETARY ADMINISTRATION OF ALDRIN/DIELDRIN TO ANIMALS
Concentration
Substance Species and Duration Reported Effects Reference
Dieldrin Mouse 3 or IQ ppm
lifetime
Marked increase in liver lesions, in­
cluding some diagnosed as hepato­
cellular carcinomas
MacDonald et al 
1972, 1973; 
Reuber 1974; 
Epstein 1975
Dieldrin
(technical)
2.5 or 5 ppm time- Hepatocellular carcinomas in 36% of NCI 1978a
weighted average males at 5 ppm, 24% of males at 2.5 ppm,
80 wk followed by and 18% of pooled control males; non-
10-13 wk observation significant increase in females
Dieldrin
(recrystal­
lized)
1.25, 2.5, or 5 ppm 
2 yr
Increased incidence of liver tumors in 
both sexes in all exposed groups; lung 
metastases from 3 tumors in exposed 
mice; significant dosc-related increase
Walker et al 
1972, Hunt 1974
m -adjusted ■« "i ^  c of lung ;umoj
0.1 or 1 ppm 
2 yr
Increased incidence of liver tumors in 
both sexes at both dose levels indepen­
dently; lung metastases from 3 tumors 
in exposed mice; increased incidence of 
pulmonary adenomas and carcinomas in 
males and females
Walker et al 
1973, Gross 1974, 
Epstein 1975
TABLE 4.3.2 (continued)
CARCINOGENIC EFFECTS OF DIETARY ADMINISTRATION OF ALDRIN/DIELDRIN TO ANIMALS
Concentration
Substance Species and Duration Reported Effects Reference
Photo- Mouse 0.32 or 0.64 ppm No statistically significant increases NCI 1977
dieldrin 80 wk followed by in tumor incidence
10-13 wk observa­
tion
TABLE 4.3.3
SUMMARY OF MUTAGENIC EFFECTS OF ALDRIN/DIELDRIN
Species
Substance or System Strain Dose Reported Effects Reference
Aldrin or Salmonella
dieldrin typhimurium
(technical)
TA 1535 
TA 1536 
TA 1537 
TA 1538
20 yg No increase in number of re­
in DMSO vertants without microsomal
activation
Shirasu et al 
1976
Dieldrin 1,000 yg No increase in number of re- 
vertants with and without rat 
liver microsomal activation
Marshall et 
al 1976
Aldrin or 
dieldrin
No increase in number of re- 
vertants with mouse liver 
microsomal activation
Van Dijck and 
Van de Voorde 
1976
Dieldrin TA 1535 
TA 1536 
TA 98 
TA 100
10 mg No increase in number of re-
vertants with and without rat 
liver microsomal activation
McCann et al 
1975
5 unspe­
cified 
strains
No increase in number of re- 
vertants with and without micro­
somal activation (no details 
given in abstract)
Bidwell et al 
1975
TABLE 4.3.3 (continued)
SUMMARY OF MUTAGENIC EFFECTS OF ALDRIN/DIELDRIN
Species
Substance or System Strain Dose Reported Effects Reference
Aldrin or
dieldrin
(technical)
Aldrin or 
dieldrin
Aldrin
Dieldrin
Bacillus H17 Rec+ 20 yg in
subtilis M45 Ree” DMSO
Escherichia
coli
Saccharomyces
cerevisiae
Chinese hamster V79 
cells
B/r try WP2 20 yg in 
WP2 try her DMSO
5 and 50 
yg/ml
0.1, 0.3, 
1.0, or 
3.0 mM
Negative results in recombination 
assays
No increase in number of mutants 
without microsomal activation
Significant mutagenic activity
Negative results in vitro in 
alkaline elution assay for DNA 
damage, with rat liver microsom­
al activation
Shirasu et al 
1976
Guerzoni et al 
1976
Swenberg et al 
1976
Significant increase in ouabain 
resistant mutants
Ahmed 1975
Dieldrin Chinese hamster
(recrystal­
lized)
30 or 60 
mg/kg 
single 
dose in 
DMSO
Nonsignificant decrease in poly- Dean et al
ploidy in bone marrow cells, no 1975
increase in chromatid gaps
TABLE 4.3.3 (continued)
SUMMARY OF MUTAGENIC EFFECTS OF ALDRIN/DIELDRIN
Species
Substance or System Strain Dose Reported Effects Reference
Aldrin Human lym­
phocytes
19 or 38 Increase in chromosome aberrations :
yg/ml gaps, breaks, deletions, fragments,
and interchanges
Georgian 1975
Aldrin or 
dieldrin
Human fi­
broblasts
VA-4 1, 10, 100, Induction of unscheduled DNA repair Ahmed et al 
or 1,000 in VA-4 cells transformed by SV-40 1977
yM virus, with and without rat liver
microsomal activation
Dieldrin Human lung
(purified) cells
Dieldrin Duck lym- 
(technical) phocvtes
WI-38
Dieldrin
(recrystal­
lized)
Saccharomyces D4 
cerevisiae 
(host-mediated 
assay in CF1 
mice)
1, 10, or Significant dose-related increases Majumdar et 
30 yg/ml in chromosome abnormalities: breaks, al 1976 
fragments, interchanges, and rings
0.1, 1, Significant increase in chromosomal Bunch and Low
10, or 100 aberrations, including gaps and 1973
yg/ml breaks, at 100 yg/ml; mitotic
indices reduced at all concentrations
25 or 50 No changes in rate of mitotic gene Dean et al
mg/kg sin- conversion 1975
gle dose or
repeated
doses of
0.2, 3, or
10 mg/kg/d
TABLE 4.3.3 (continued)
SUMMARY OF MUTAGENIC EFFECTS OF ALDRIN/DIELDRIN
Species
Substance or System Strain Dose Reported Effects Reference
Dieldrin
(purified)
Mouse STS 1, 30, or 50 
mg/kg single 
ip injection
Pronounced mitotic inhibition and 
significant 2- to 6-fold in­
creases in chromosome abnormal- 
ilities in bone marrow cells
Majumdar et 
1976
Aldrin or 
dieldrin
Dieldrin
(recrystal­
lized)
Mouse
(dominant
lethal
assay)
CF1
1.2 or 2 mg/ 
kg single 
dose
12.5, 24, or 
5Q mg/kg 
single dose 
in DMSO
Mitotic inhibition, chromosome 
aberrations including breaks, 
fragments, chromosome and 
chromatid bridges, and stickiness
Negative results in one assay, 
reduced number of fetal implan­
tations in another
Markaryan
1966
Dean et al 
1975
Aldrin Mouse 9.6, 19, or 
38 mg/kg 
single ip 
injection
Dose-related increase in chromo­
some and chromatid aberrations; 
no effect at 9.6 mg/kg
Georgian 1975
Rat Significant increase in chromosome 
and chromatid aberrations at 19 
mg/kg; inconclusive results at 38 
mg/kg
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TABLE 4.3.3 (continued)
SUMMARY OF MUTAGENIC EFFECTS OF ALDRIN/DIELDRIN
Substance
Species 
or System Strain Dose Reported Effects Reference
Dieldrin Mammal
(unspecified)
0.08, 0.8, or 
8 mg/kg by
Negative for mutagenicity in 4 
tests (unspecified)
Bidwell et al 
1975
Dieldrin
(technical)
Mallard
duck
4, 10, or 30 
ppm in diet 
for 60 days
No significant increase in chro­
mosome aberrations
Bunch and Low 
1973
1
4
4
I
TABLE 5.1 
VON BAEYER/IUPAC NAMES OF DIELDRIN
Abbreviated Chemical Names
and Other Designations Von Baeyer/IUPAC Name
Aldrin
HHDN 
SD 2794
1,8,9,10,11,11-Hexachloro-2,3-
7,6-endo-2,l-7,8-exo-tetracyclo- 
(u.2 .1 .1^' .0^'^)dodfc;ca-‘i,9-aiene
Dieldrin
HEOD 
SD 3417
l,8 ,9,10,ll,ll-Hexachloro-4 ,5-exo- 
epoxy-2,3-7 ,6-endo-2,1-7,8-exo- 
tetracyclo(6 .2.1 .13 < 6.02 < 7)dodec- 
9-ene
cis-4,5-Dihydroxy-dihydroaldrin
“Aldrin cis-diol"
WL 43020
l,8,9,10,ll,ll-Hexachloro-4,5- 
(exo)cis-dihydroxy-2,3-7,6-endo
2,1-7,8-exo-tetracyclo- 
(6.2.1.13 '®.02,7)dodec-9-ene
trans-4,5-Dihydroxy-dihydro­
aldrin
"trans-6,7-Dihydroxy-dihydro-
aldrin"
"Aldrin trans-diol"
WL 40549
1,8,9,10, ll,ll-Hexacliloro-4,5- 
trans-dihydroxy-2,3-7,6-endo
2,1-7,8-exo-tetracyclo- 
(6.2.1.I3'6 .0^'^)Jodec-9-ene
4,5-Dih ydroaldrin l,8,9,10,ll,ll-Hexachloro-2,3-7,6-
endo-2,l-7,8-exo-tetracyclo- 
(6. 2. 1, l3 f6.02 /7)dodec-9-ene
4-Ketodihydroaldrin l,8,9,10,ll,ll-Hexachloro-2,3-7,6- 
endo-2,1-7,8-exo-tetracyclo- 
ifi 5.1.13 <6 .02,7)dodec-9-en-4-one
(HEOD) AND RELATED COMPOUNDS
CAS No.*
Molecular
Weight
Molecular
Formula Structure
3 0 9 - 0 0 - 2 3 6 4  . 9 C 12II8C 1 6 Cl Cl
6 0 - 5 7 - 1  3 8 0 . 9  C 1 2 H8 C 1 6 0
3 0 4 6 0 - 7 4 - 3  3 9 8 . 9  C1 2 H1 0 C 1 6 ° 2
3 1 0 6 - 2 9 - 4  3 9 8 . 9 C 12H 10CX6°2 s-
1 0 0 5 9 - 6 5 - 1  3 6 6 , 9  C1 2 H1 0 C 1 6
3 4 0 2 2 - 7 7 - 0  3 8 0 . 9  C1 2 H8 C 1 6 0
TABLES
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TABLE 5,1 (continued)
V O N  B A E Y E R / I U P A C  N A M E S  OF’ D I E L D R I N  ( 1 I E O D )  A N D  R E L A T E D  C O M P O U N D S
Abbreviated Chemical Names 
and Other Designations
Photoslielur in
" P h o t o i s o m e i  of d i e l d r i n "  
" Photo - H E O ü "
BL 66 2 3
Von Baeyer/IUPAC Name CAS N o .*
Molecular 
Wei g h t
3, exo-4, 5,6,6, 7-II cxach loro-11, 12- 
exo-epoxy-pentacyclo-v  
( 6 . 4 . 0 . 0 ' . U3 ' ' . O 5 ' ,J) ilodc.
INCORRECT JAI1E: 1 , 9 , 1 0 , 1 Ü , 11 - O XO -
12-!lexachloro-4 , 5-exo-epoxy-8 , 3- 
7,6-e ndo-8¿9-7,11-exo-pentacyclo-
iecane
/  b a o,y / li e 
(7.3.0.02 '^.03 '8 .07 »H) d o d c
133 6 6-73 - 3 0 Ü . 9
Molecular
Formula
ci2W
Structure
4-Ke to-4-dechloro-photodieldr in 3,5 ,6,6,7-Pentachloro-ll,12-exo-
epoxy-pentacyclo;
(6 .4.0.0¿"lo.OJ' . 0:>' J) dodecan-
21030-31-3 360 . 5 C 12n7C15°2
"HEOD Pentachloroketone" 
"Ketophotodieldrin" 
"Klein's me tabolite"
4-one
INCORRECT NAME: 1,9,10,10,11-
Pentachloro-4 ,5-exo-epoxy-8 ,9-7 , 11- 
exo-pentacyclo-
(7.3.0 .0^*6 .0^*8 .o7,H)dodecan- 
12-one
4, 5-seco-Aldrin-4, 5- 
dicarboxylic acid (seco-ADA)
"Aldrin dicarboxy1ic acid” 
"Dihydrochlordene dicarboxy­
lic acid"
"Aldrin-derived acid"
"ADA"
SD 2878
1,7 ,8 , 9, 10, 10, llexach loro-2, 3-6 ,5- 5103-66-2
endo-tricyclo{5.2.1 .02'6)dec-8-ene- 
3 ,5-exo,exo-diearboxy1ic acid
4 28.9 C12H8C16°4
11,12-seco-Photoaldrin-ll, 12- 
dicarboxylic acid
"Acid ftom oxidation of 
photoaldrin"
1,7,8,exo-9,10.10-Hexachlorotetra- 
cyclo(5.2.1.02 , 6 .04 «8 )d ecane-3 , 5 - 
e x o ,e x o-dicarboxy1 ic acid
420 . 9
C 12!,aC 1 6°4
Adapted from Bedford 1974
tI
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T A B LU 5.1 (continued)
V O N  R A E Y E R / TU l ?AC N A M E S  OK D t E L D R l N  ( H E O D )  A N U  R E L A T E D  C O M P O U N D S
Abbrevia f. od Chemical Names 
and Other Designations’
s y n - 12-Hydroxy-dieldrin
"9-Hydroxy HEOU"
WL 40231
Von li a c y e r / 1U P A C Name CAS No.*
M o 1ecu lar 
W e i. y h t
Molecular
Formula
1,tí,y ,10,11,li-uexacnloro-4,3-exû- 
epoxy-12-(syn-epoxy)h y d roxy-2,3- 
7,b-endo-2,1 - 7 ,ö-exo-tetracycio- 
(6.2.1.1*.*.02.7 )dodec-9-ene
2e>y4ü-ui-u
C 12‘‘8C i 6°2
12-Ketodieldrin
"9-Kctü-llEOD" 
WL 4 2170
l , 8 , 9 , 1 0 , l l , l l - H e x a c h l o r o - 4 , 5 - e x o -  e p o x y - 2 ,  3 - 7 , 6 - e n d o - 2 , 1 - 7 , 8 - e x o -  t e t r a c y c l o { 6 .  2 .  1 .  1 ^ * 0 . 0  ^ r *7) <3o<3ec- 9 - e n - 1 2 - o n e
3 9 4  . 9 C 12H6C16°2
9-Dechloroaldrin
" P e n t a c l i l o r o  p l i o t o p r o d u c  t  o f  a l d r i n "
1 , 8 , 1 0 , 1 1 , l l - P e n t a c h l o r o - 2 , 3 - 7 , 6 -  e n d o - 2 , 1 - 7 , 8 - e x o - t e t r a c y c l o -  ( 6 . 2 . 1 . 1 3 ' 6 . 0 2 > 7 ) d o d e c a - 4 , 9 - d i e n e
21939-95-6 3 3 0 . 5
C 12U 9C 1 5
I
9-Dechlorodieldrin
"Pentachloro photoproduct 
of HEOU"
"pentachlorodieldrin"
1 , 8 , 1 0 , 1 1 , 1 1 - p e n  t a c h l o r o - 4 , 5 - e x o -  e p o x y -  2 , 3 - 7 , 6 - e n d o - 2 , 1 - 7 , 6 - e x o - 3 6 2  . 5 C1 2 H9 C 1 5 °t e t r a c y c l o ( 6 . 2 . 1 . 1 3 ' ^ . 0 2 7 ) d o d e c -9 - e n e
Pliotual drin
"Photuiaomer of aldrin" 
SD 18 103
1, oxo-4 , 5,6,6, 7-llcxachloropcatacyclo- 1 3366-64-8 
( 6 . 4 . 0 . 0 ' - 0 J ' ^ . O ^ ' ^ dodoc-il-enc
C12UÖC10
PHYSICAL AND CHEMICAL PROPERTIES OF ALDRIN
TABLE 5.2
Appearance 
Empirical formula 
bcructure
Molecular weight
Melting point
Vapor pressure
Octanol/water partition 
coefficient
Solubility
Stability
Brown to white crystalline solid
C 12H8C16
364.93
104-105.5 C
2.31 X 10  ^mm Hg at 20 C
5.00
Insoluble in water; very soluble m  most 
organic solvents
Stable in the presence of organic and 
inorganic alkalis; stable to the action 
of hydrated metal chlorides
From IARC 1974, Condensed Chemical Dictionary 1977, Merck 1976
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TABLE 5.3
PHYSICAL AND CHEMICAL PROPERTIES OF DIELDRIN
Appearance 
Empirical formula
Structure
Molecular weight
Melting point
Vapor presure
Octanol/water p^rtitiop 
coefficient
Solubility
Stability
Light tan, flaked solid
Cl
380.93
175 C
1.78 X 10"7 mpi Hg at 20 C
4.56
Practically insoluble in water (0.25 mg/liter); 
moderately soluble in common organic solvents 
except aliphatic petroleum solvents and methyl 
alcohol
Stable in organic and inorganic alkalis and 
acids commonly used in agriculture
From I ARC 1974, Condensed Chemical Dictionary 1977, Merck 1976
TABLE 5.4
SYNONYMS AND TRADE NAMES FOR ALDRIN AND DIELDRIN
Aldrin
1, 2,3,4,10,10-Hexachloro-l,4,4a,5,8,8a-hexahydro-l,4:5,8- 
dimethanonaphthalene
Compound 118
Octalene
HHDN
SD 2794
Dieldrin
3 ,4, 5,6,9,9-Hexachloro-la,2,2a,3,6,6a,7,7a-octahydro-2,7:3,6- 
dimethanonaphth[2,3-b]oxirene
1,2,3,4,10,10-Hexachloro-6,7-epoxy-l,4,4a,5,6,7,8,8a-octahydro-endo, 
exo-1,4:5,8-dimethanonaphthalene
Compound 497
Insecticide No. 497
HE OD
Octalox
SD 3417
From Condensed Chemical Dictionary 1977, Merck 1976
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